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Abstract 
Breathlessness is the dominant symptom that limits exercise tolerance in patients 
with COPD. Several ergogenic approaches have been employed to improve exercise 
tolerance in this population including bronchodilators, oxygen and heliox 
supplementation, intermittent exercise and non-invasive ventilation (NIV). Although 
application of NIV during exercise is beneficial for increasing exercise capacity in 
patients with COPD, there are several disadvantages that limit its wider application 
during exercise, including lack of compliance with the equipment, and the time required 
to set up and supervise the equipment in the setting of pulmonary rehabilitation.  
Recent advances in technology have facilitated the development of portable non-
invasive ventilation (pNIV) devices aiming to alleviate breathlessness during activities 
of daily living. The VitaBreath (Philips, Respironics) was developed in 2016 as a 
portable, handheld, battery powered, bi-level, NIV device, providing fixed positive 
inspiratory and expiratory airway pressure support (IPAP:18 and EPAP: 8 cmH2O, 
respectively). Accordingly, this dissertation aimed to investigate the physiological 
effects of pNIV application during controlled laboratory exercise conditions and 
activities of daily living, in patients with advanced COPD. As the VitaBreath device is 
no longer commercially available, but similar devices may come to market, the present 
dissertation provides proof of concept on how pNIV can be applied intermittently 
during exercise in patients with COPD, and how to select patients most likely to 
respond to pNIV. This in turn may encourage the development of more suitable devices. 
Intermittent exercise was chosen to evaluate the effects of pNIV in comparison to the 
commonly adopted pursed lip breathing (PLB) technique, as this type of exercise 
allowed regular application of the pNIV device or the PLB technique during recovery 
periods. Patients retained the device for 3 months to investigate the acceptability, 
comfort and usability of the device during activities of daily living.  
Twenty-four COPD patients were randomised to perform two intermittent exercise 
protocols sustained at different work intensities (60% WRpeak for 6-min and 80% 
WRpeak for 2-min) alternated with 2-min rest periods. Within each intermittent exercise 
modality, patients performed two identical exercise tests using either pNIV or the PLB 
technique in a balanced order sequence, during the recovery phases of intermittent 
exercise. The findings of this study showed that with both intermittent protocols average 
endurance time was greater when pNIV was applied compared to PLB. Improvements 
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in exercise tolerance were due to lower degrees of dynamic hyperinflation (DH) and 
breathlessness with pNIV compared to PLB.  
An important finding of the aforementioned study was that a subgroup of patients 
(8/24) failed to show a clinical important improvement in DH with pNIV compared to 
PLB and did not improve exercise tolerance. Analysis identified that these 8 patients 
experienced greater resting lung hyperinflation, greater exercise-induced DH and 
breathlessness, secondary to the adoption of a tachypnoeic breathing pattern with pNIV 
compared to PLB. Interestingly, these patients also reported less benefit from using the 
device at home, in terms of anxiety around breathlessness and recovery time from 
breathlessness. Considering the variation of response reported in the present thesis it is 
important that clinicians assess the response to pNIV on an individual basis. 
As with any new method, it was important to appreciate the physiological 
consequences of the acute application of pNIV on thoracoabdominal volume regulation 
and respiratory muscle recruitment (assessed by optoelectronic plethysmography), and 
central hemodynamic responses. Compared to PLB, acute application of pNIV was 
associated, in the majority of patients, with increased end-inspiratory and end-expiratory 
rib cage volumes and greater rib cage muscle recruitment, as well as decreased end-
expiratory abdominal volumes reflecting reduced expiratory abdominal recruitment. 
Measurement of cardiac output revealed no adverse circulatory responses with the 
application of positive airway pressures provided by pNIV during the recovery periods. 
However, the pattern of thoracoabdominal volume regulation and respiratory muscle 
kinematics confirmed the findings of the original studies, thereby identifying responders 
and non-responders to pNIV. Interestingly, responders to pNIV exhibited greater 
recruitment of the expiratory abdominal muscles compared to non-responders, thereby 
facilitating them to combat end-expiratory rib cage dynamic hyperinflation effectively. 
When patients used the VitaBreath device during their daily physical activities, the 
majority of patients felt less anxious about becoming breathless and felt that their 
breathlessness recovered faster when using the device at home for 3 months. Moreover, 
almost all patients used the device at least weekly and all patients rated the ease of 
VitaBreath use to be between good and excellent. Additionally, most patients felt that 
using the device had benefited them and that they would recommend the device to other 
patients. The main disadvantage of the device was reported to be the high cost and its 
portability. 
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The pNIV method provided fixed IPAP and EPAP. This represents a very important 
disadvantage of this particular pNIV device, which clearly mitigated the beneficial 
impact it had on some patients. Future research into pNIV devices should examine how 
best to identify patients who benefit from a pNIV method in everyday life. On-going 
development of auto-adjusted ventilators would facilitate a larger fraction of COPD 
patients to be physically active and experience a better quality of life.  
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1. General introduction 
1.1. Exercise intolerance in COPD 
Chronic Obstructive Pulmonary Disease (COPD) is characterized by a progressive 
reduction in pulmonary function (FEV1, FEV1/FVC), partially or not reversible (<12%) 
following bronchodilator medication and progressively deteriorating over time [1]. It 
includes two key components: chronic bronchitis which is partially reversible, and 
pulmonary emphysema which is irreversible [1]. According to the World Health 
Organisation (WHO) COPD is currently the fifth leading cause of death worldwide and 
will become the third leading cause of death by 2030 [2]. COPD may be asymptomatic 
in its early stages but causes severe symptoms such as dyspnoea, cough and sputum 
overproduction in later stages. As the disease severity progresses, a decline in forced 
expiratory flow at the first second (FEV1) occurs, due to decreased elastic properties of 
the lung and increased airway resistance, usually accompanied by  reduced arterial 
oxygen saturation indicating respiratory insufficiency [3]. 
Regarding the prevalence of COPD, a number of studies in Europe showed that 4% 
to 10% of the adult population suffers from COPD [4]. A recent systematic review and 
meta-analysis suggested that 66 million people in Europe live with COPD [5], whilst 
4.8% of people in the entire world are diagnosed with COPD [6]. However, this finding 
may only partially represent the burden of the disease as a significant proportion of 
patients are undiagnosed or misdiagnosed [7, 8]. 
The major risk factor for COPD is tobacco smoke, as 85% of all cases are attributed 
to smoking [9, 10], whilst air pollution is also an important risk factor especially in the 
developing world [1, 11]. Although smokers are 5 times more likely  to develop COPD 
[10], less than 50% of smokers develop COPD during their life [12, 13]. Furthermore, 
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passive smoking can also contribute to the development of COPD due to the inhalation 
of toxic gases and particles [14]. Finally, COPD can develop due to genetic disorders, 
abnormal lung development and aging [1]. In fact, low levels of a protein called alpha-1 
antitrypsin caused by a genetic abnormality and respiratory infections during childhood 
are responsible for 1-5% of COPD development [15, 16]. 
Patients with COPD across different disease severity exhibit lower exercise tolerance 
compared to age matched individuals due to expiratory flow limitation (EFL) [17, 18]. 
EFL caused by airway collapsing leads to air trapping in the lungs resulting in a 
phenomenon known as dynamic hyperinflation (DH). Dynamic hyperinflation during 
exercise limits the normal increase in tidal volume, worsening breathlessness and 
reducing exercise capacity [19, 20]. In addition, DH and the concomitant high mean 
intrathoracic pressure swings are associated with adverse effects on central 
hemodynamic regulation, reducing the supply of oxygenated blood to deconditioned 
peripheral muscles [18, 20, 21]. This increases leg discomfort and further limits exercise 
tolerance. 
Different ergogenic strategies have been successfully employed to reduce exercise-
induced DH, breathlessness and leg discomfort, as well as increase exercise tolerance 
[20]. Bronchodilators, oxygen and heliox supplementation, non-invasive ventilation 
(NIV) and various intermittent exercise modalities have all been shown to induce 
clinically meaningful improvements in exercise tolerance in patients with COPD [20, 
22-25]. Bronchodilators and oxygen supplementation are commonly used during 
exercise in this population and increase exercise tolerance by an average of >100 
seconds, that represents the minimal clinical important difference (MCID) [26, 27]. 
Heliox supplementation is beneficial for increasing exercise tolerance by an average of 
approximately 200 seconds but is also impractical and expensive; therefore it has 
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primarily been used for research purposes [28]. Finally, intermittent exercise has been 
found to triple exercise endurance time in patients with COPD mainly due to lower 
ventilatory requirement and metabolic acidosis, thereby resulting in lower symptoms of 
breathlessness and leg discomfort [29]. 
Non-invasive ventilation (NIV), developed as a surrogate of invasive ventilation, is 
one of the most important developments in respiratory medicine over the past two 
decades [30, 31] and includes a variety of different ventilatory modes and settings to 
support ventilation [32]. The primary objective of NIV includes the support of 
ventilation in  Intensive Care Units (ICU) and nocturnal application at home mainly in 
patients with lung diseases [32]. However, during the last two decades technological 
advances have led to the availability of high-performance ventilators, allowing 
application of NIV during exercise [33] in patients with lung and heart diseases. 
Different ventilatory modes have been used during exercise to increase exercise 
tolerance. Application of Continuous Positive Airway Pressure (CPAP) reduces 
dyspnoea and increases exercise tolerance in patients with COPD [34-36]. In addition, 
when Inspiratory Pressure Support (IPS) was applied during exercise, work of breathing 
(WoB) was reduced resulting in lower dyspnoea and increased exercise capacity [37-
43]. Finally, application of Proportional Assist Ventilation (PAV) during exercise has 
been found to increase exercise tolerance in patients with COPD [44-48]. 
Although the application of NIV during exercise is beneficial for increasing exercise 
capacity, there are the following potential problems with the application of NIV during 
exercise: 
i) Non-invasive ventilation is provided by either full-face/nasal masks or a 
mouthpiece. However, breathing through a mask or a mouthpiece during 
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exercise may not be fully tolerable by the patients and can potentially reduce 
the compliance to the application of NIV [49]. 
ii) Presence of comorbidities, including ischaemic cardiac disease, is very 
common in patients with COPD. Although application of NIV might allow 
greater exercise loads, it is also associated with reduced cardiac output due to 
impaired venous return, secondary to increased intrathoracic pressures both in 
healthy and disease [50, 51], thus could potentially cause adverse central 
haemodynamic effects [49]. 
iii) Application of standard NIV methods is associated with practical problems 
such as lack of compliance with the equipment, time required to set up and 
supervise the use of the equipment during  exercise sessions [49]. 
Recent advances in technology have promoted the development of portable non-
invasive ventilation (pNIV) devices aiming to alleviate breathlessness during daily life 
physical activities. The VitaBreath (Philips, Respironics) is a portable, handheld, battery 
powered, non-invasive ventilation device (pNIV), intended to reduce activity-related 
shortness of breath. It delivers 18 cmH2O inspiratory and 8 cmH2O expiratory pressures 
(IPAP and EPAP, respectively) (Figure 1.1) [52]. However, when this dissertation 
begun, there was a lack of studies investigating the physiological effects of the 
application of pNIV either during controlled laboratory exercise conditions or during 
daily life physical activities. 
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Figure 1.1. The VitaBreath device 
1.2. Importance of the study 
The VitaBreath device was introduced by Philips in 2016 as a non-invasive support 
ventilation device indented to reduce activity-related shortness of breath in patients with 
COPD. However, at that time there was not any available evidence to support this 
intention. Accordingly, the original objective of this dissertation was to investigate the 
effect of application of the VitaBreath device on exercise tolerance, dynamic 
hyperinflation, and breathlessness during well-controlled laboratory conditions in 
patients with COPD. Furthermore, use of, and perceived benefit from the VitaBreath 
device was examined during daily life activities in patients with COPD. In addition, the 
acute physiological effect of pNIV application on thoracoabdominal volume regulation 
and central hemodynamic function was investigated in both healthy individuals (not 
presenting confounding factors due to lung disease) and in patients with COPD. As the 
VitaBreath device is no longer available in the market the present dissertation provides 
proof of concept on how pNIV can be applied intermittently during exercise and how to 
select patients most likely to respond.  
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1.3.Objectives 
These were the following: 
i) Τo investigate whether compared to the commonly adopted pursed lip 
breathing (PLB) technique, application of portable non-invasive ventilation 
(pNIV) support was more effective in terms of reducing breathlessness and 
enhancing exercise tolerance in patients with COPD. 
ii) To determine use of, and benefit from the pNIV device during activities of 
daily living in patients with COPD. 
iii) To appreciate the acute physiological effect of application of pNIV on 
thoracoabdominal volume and circulatory regulation during intermittent 
exercise in patients with COPD. 
1.4. Hypotheses 
i) Use of pNIV compared to PLB would increase exercise tolerance by reducing 
the magnitude of exercise-induced dynamic hyperinflation and thus the 
intensity of breathlessness during exercise in patients with COPD.  
ii) Use of pNIV during activities of daily life would reduce activity-related 
breathlessness, thereby increasing self-reported patient’s confidence to 
perform tasks of daily life in patients with COPD. 
iii) Acute application of fixed inspiratory and expiratory positive airway 
pressures by pNIV would be associated with increased end-inspiratory and 
end-expiratory thoracoabdominal volumes potentially causing adverse 
circulatory effects in patients with COPD. 
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1.5. Experimental approach 
The objectives of this dissertation were addressed by the following studies: 
1) A cross sectional study to identify patients experiencing profound exercise-
induced dynamic hyperinflation and breathlessness as the primary symptom 
limiting exercise tolerance (Chapter 4) in order to subsequently investigate the 
effect of pNIV on exercise-induced dynamic hyperinflation on these patients. 
2) A randomised, open label, cross over study comparing the effect of PNIV to 
PLB during recovery periods on exercise tolerance and dynamic hyperinflation 
across two different intermittent exercise protocols in patients with COPD 
(Chapter 5). 
3) An observational cross over study investigating the effect of pNIV on 
thoracoabdominal volumes and central hemodynamic responses during 
intermittent exercise in patients with COPD (Chapter 6). 
4) A survey research study to assess patient adherence with pNIV as well as the 
effects of pNIV on anxiety, symptom burden and ability to perform activities of 
daily living in patients with COPD (Chapter 7). 
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2. Literature review 
2.1. Factors limiting exercise tolerance in patients with COPD 
Exercise intolerance is defined as “a condition where the patient is unable to 
undertake physical activity at the level or for the duration that would be expected of 
someone in his or her age and general physical condition” [18]. Exercise capacity 
depends on the ability of in-series systems, including ventilation, gas exchange, 
circulation, O2 transport and utilisation to the locomotor muscles and CO2 elimination 
[18, 53] (Figure 2.1). 
 
Figure 2.1. In-series physiological systems participating in oxygen transport and 
utilisation [53]. 
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Figure 2.2. a) Limitation of energy supply [18], b) Effect of expiratory flow limitation 
(EFL) on cardiac function. DH: dynamic hyperinflation; ITP: intra-thoracic pressure; 
PVR: pulmonary vascular resistance; LV: left ventricular; RV: right ventricular; CO: 
cardiac output.  
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The lower exercise capacity in patients with COPD compared to aged matched 
healthy individuals has multifactorial background [54] including not only ventilatory 
constraints leading to excessive breathlessness [55], but also gas exchange 
abnormalities [56], central haemodynamic [57] and peripheral muscle dysfunction [58]. 
The aforementioned abnormalities collectively impede oxygen transport and utilisation, 
thus reducing exercise capacity (Figure 2.2a) [18]. In COPD exercise intolerance occurs 
due to the following mechanisms: a) mismatch between ventilatory capacity and 
ventilatory demand, b) mismatch between oxygen requirement and oxygen availability, 
secondary to impaired venous return and c) low aerobic capacity at the level of the 
peripheral muscles [18]. 
2.2.Imbalance between ventilatory capacity and demand 
Ventilatory capacity is reduced in patients with COPD mainly due to dynamic 
hyperinflation [55], secondary to expiratory flow limitation [18, 55]. Dynamic 
hyperinflation limits tidal volume expansion and increases end-expiratory lung volumes 
exacerbating dyspnoea [55]. Expiratory flow limitation is a common pathophysiological 
characteristic in this population [59] and is the result of the presence of emphysema and 
chronic bronchitis that collectively increase airway resistance [18]. Limited expiratory 
flow, impairs normal lung emptying [60], leading to increased end-expiratory lung 
volume both at rest (static hyperinflation) and during exercise (dynamic hyperinflation) 
[55]. 
The term static hyperinflation describes the situation when the respiratory muscles 
have been readjusted in a greater relaxation lung volume, due to the increase static lung 
compliance of emphysema [18] and is a typical pathophysiological characteristic of 
patients with COPD [55]. The increased lung volume during spontaneous breathing 
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increases airway conductance and limits patient’s ventilatory capacity when the 
circumstances demand increased ventilation (i.e. exercise) [55]. 
During conditions requiring increased ventilation such as exercise, air trapping 
further increases as inspiratory volume increases and time of expiration decreases [60, 
61]. Consequently, COPD patients do not have enough time to expire all the inspired 
amount of air when next inspiration begins. The phenomenon when additional air 
trapping in the lungs is added on the air which is already trapped in the lungs is called 
dynamic hyperinflation [55]. In fact, the greater the expiratory flow limitation and 
minute ventilation are, the greater the degree of dynamic hyperinflation is [19, 62]. 
Furthermore, dynamic hyperinflation increases the elastic loading of the respiratory 
muscles due to the increase of the end expiratory lung volume. As a result, work of 
breathing for a given amount of ventilation increases [19, 59, 63]. In addition, 
respiratory muscle operation is also affected by the degree of dynamic hyperinflation 
[18]. The greater the lung volume at the end of expiration the sorter the respiratory 
muscles become, affecting their contractility and reducing their ability to produce force, 
according to the length – tension relationship [64, 65], thus reducing the muscles ability 
to produce the required work to overcome the additional resistance caused by the 
expiratory flow limitation [66-68]. Another consequence of dynamic hyperinflation is 
the increased intrinsic positive alveolar end-expiratory pressure (PEEPi) [18]. Inhalation 
begins when alveolar pressure drops below atmospheric pressure. This is achieved by 
contracting the respiratory muscles and thus increasing lung volume above the 
relaxation volume. However, in COPD respiratory muscle length and ability to produce 
power is reduced due to the air trapped in the lungs, hence they should work harder to 
initiate inhalation as they have to overcome the increased inspiratory elastic load [69]. 
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On the other hand, ventilatory requirement during exercise is increased in patients 
with COPD due to abnormal ventilatory mechanics secondary to altered breathing 
pattern resulting in increased work of breathing [18]. Loss of the elastic recoil and 
obstruction of the airways increase the compliance of the lungs in COPD patients [18].  
Hence, adoption of a normal breathing pattern will require minimum energy making 
breathing easier due to lower pressures required to overcome the elastic recoil of the 
emphysematous lung [18]. In contrast, the fast and shallow breathing pattern that 
patients with COPD often adopt both at rest and during exercise [70, 71] has the 
opposite effect as the faster the breathing gets the less the compliance of the lung 
becomes [59] thus exacerbating breathlessness and limiting exercise tolerance [18]. 
In addition, compared to healthy age matched people, ventilatory requirement is 
greater in patients with COPD, due to the lower gas exchange capacity of the lung, 
increasing energy demands and workload of the respiratory muscles (Figure 2.3) [18]. 
The above is the consequence of a greater mismatch between alveolar ventilation and 
blood flow in the alveoli [18].  Taking into account that, in contrast to healthy people, 
lung dead space does not change during exercise in COPD [56, 72], minute ventilation 
has to increase in order to offset the absence of the additional space for gas exchange in 
the lungs and keep alveolar ventilation and blood gases in acceptable levels [18]. 
Another factor that increases ventilatory requirement in patients with COPD is the 
early metabolic acidosis which further stimulates ventilation [73, 74]. Early metabolic 
acidosis occurs mainly due to reduced oxygen delivery to locomotor muscles, low 
oxidative capacity of the peripheral muscles and abnormal regulation of the blood 
vessels [73-78]. This leads to greater minute ventilation during submaximal levels of 
exercise in patients with COPD compared to age matched healthy individuals as it is 
presented by the slope between minute ventilation and work rate [79-81]. 
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The imbalance between the decreased ventilatory capacity and the increased 
ventilatory requirement exacerbates breathlessness [82-84] which is associated with the 
magnitude of exercise-induced dynamic hyperinflation [62, 70]. In addition, a study 
performing a multiple regression analysis has shown that changes in end-inspiratory 
lung volume expressed as fraction of total lung capacity was the strongest predictor for 
breathlessness [62]. Additionally, in the same study tidal volume, breathing frequency 
and end-expiratory lung volume contributed more than 60% to exertional breathlessness 
[62]; these results are confirmed by another study from the same group [70]. Assuming 
that total lung capacity does not significantly change during exercise in COPD [85], 
inspiratory reserve volume decreases by 3-fold compared to healthy age-matched 
individuals [86] due to the higher end-inspiratory lung volumes, limiting tidal volume 
expansion and increasing dyspnoea [70]. Finally, there are a number of studies 
providing indirect evidence of contribution of the exercise-induced dynamic 
hyperinflation and the abnormal ventilatory mechanics during exercise on exertional 
dyspnoea, as interventions targeting to reduce either operational lung volumes (i.e. 
pharmacologically, surgically or by inhalation of oxygen or heliox mixtures) and the 
work of breathing (i.e. application of non-invasive ventilation) have shown to lessen the 
degree of dyspnoea [34-36, 63, 87-91]. 
2.3.Circulatory effects of dynamic hyperinflation 
It is well documented that resting and dynamic lung hyperinflation causes adverse 
circulatory effects including impaired diastolic function, intrathoracic hypovolemia [92-
96] and pulmonary arterial hypertension due to increased pulmonary vascular resistance 
[94, 97]. Furthermore, increased abdominal pressures that generated to overcome the 
expiratory flow limitation reduce venous return and thus cardiac output secondary to 
impaired blood volume return from the periphery due to compression of the inferior 
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vena cava [57, 94, 98-100]. Moreover, increased expiratory muscle recruitment 
increases alveolar pressures by compressing blood vessels in the alveolar walls, 
decreasing left ventricular preload secondary to further reduction in venous return [98]. 
Thus, generating expiratory pressure at a level seen during exercise in patients with 
COPD [101] can potentially compromise venous return and left ventricular preload and 
thus limit the normal increase in cardiac output with increasing exercise intensity [18]. 
In addition, left ventricular function can be potentially impaired during exercise in 
patients with COPD as left ventricular afterload increases due to the large negative 
intrathoracic pressure swings generated to overcome the increased inspiratory elastic 
and resistive loads [57, 99] (Figure 2.2). 
Likewise, increased lung volumes at rest and during exercise are associated with 
increased pulmonary arterial pressure and vascular resistance [57, 94, 99, 100, 102], 
leading to both increased right ventricular afterload [94, 96, 97, 102] and increased right 
ventricular end-diastolic pressure [57, 100], thereby reducing right ventricular ejection 
fraction [57, 100] (Figure 2.2a & b). The reduction in the right ventricular ejection 
fraction reduces left ventricular ejection fraction [96, 103], whilst left ventricular end-
diastolic and end-systolic volumes, as well as stroke volume are all decreased [104] 
(Figure 2.2a & b). 
When lung volume is close to normal functional residual capacity, the pulmonary 
vascular resistance is minimal. However, pulmonary vascular resistance increases 
progressively, along with the increase in lung volume as result of dynamic 
hyperinflation [57, 94, 99, 100, 102, 105-107]. In patients with COPD, the degree of 
dynamic hyperinflation is associated with the development of exercise pulmonary 
hypertension during exercise [100, 107-109], potentially contributing to increased right 
ventricular afterload [94, 96, 97, 102, 105-107, 109] (Figure 2.2a & b). Furthermore, 
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chronic lung diseases are associated with structural changes in pulmonary circulation, 
such as loss of vascularity, as well as changes in capillary structure, such as loss of 
alveolar wall structure and the associated capillaries, and thus with a reduction in the 
total cross-sectional area of the pulmonary capillary bed [105]. The latter, can further 
increase the mismatch between ventilation and perfusion with increased cardiac output 
during exercise [105]. These changes may result in reduced density of the pulmonary 
vascular bed, further contributing to increased vascular resistance, thus increasing right 
ventricular afterload [105] (Figure 2.2a & b). 
Although elevated right ventricular afterload appears to be the primary 
cardiovascular effect of chronic lung disease, a reduction in preload may also 
compromise right ventricle function. These conditions arise as a result of hyperinflation 
in patients with COPD, secondary to restriction of venous return by increased 
intrathoracic pressure. This may occur with dynamic hyperinflation during exercise, or 
in the setting of relative intravascular volume depletion [98] (Figure 2.2a & b).  
Moreover, in COPD patients, left ventricular diastolic function could be impaired, 
due to the ventricular interdependence in the distension of the right ventricle. This is 
because of increased pulmonary vascular resistance which may impede left ventricular 
diastolic filling [96, 103, 104, 106, 107, 109], thereby contributing to the decrease in 
left ventricular afterload (Figure 2.2a & b). The resulting increase in pulmonary venous 
pressure could contribute to overall pulmonary vascular resistance and/or to the 
development of dyspnoea during exercise [96, 103-107, 109]. 
2.4.Limited energy supply to the locomotor muscles 
In addition to the circulatory impairment dynamic hyperinflation also imposes 
adverse effects on oxygen transportation to the working muscles. In addition to 
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expiratory flow limitation, the increased airway resistance and the energetically 
wasteful breathing pattern increase work of breathing and thus, the energy requirements 
of the respiratory muscles [110, 111]. The increased energy requirement of the 
respirator muscles, achieved by applying expiratory load has been found to redistribute 
blood flow from the peripheral to respiratory muscles in healthy individuals during 
exercise [112-115].  
There is evidence that exercise performance is also limited as a result of inadequate 
energy supply to the working muscles as oxygen supplementation has been found to 
increase the maximum power generated by whole body and smaller muscles indicating 
that muscle capacity to produce power is limited by oxygen availability [116-118]. In 
fact the performance of the smaller muscles increased more compared to whole-body 
exercise indicating that more energy was available for those muscles due to lack of 
respiratory muscle competition for energy [116-118]. These findings are further 
supported by another study which reported that patients who did not reach their 
ventilatory ceiling leg blood flow, oxygen uptake and work capacity were all greater 
compared to those patients that reached their ventilatory ceiling and thus energy 
requirements of the respiratory muscles were greater [119]. In contrast, when exercise 
performed with heliox supplementation arterial oxygen content was increased whilst 
peripheral and respiratory muscle fatigue was reduced [119], suggesting a relationship 
between peripheral muscle fatigue and pulmonary limitation [18]. However, not all 
studies agree with this concept, as it is reported that blood flow of the intercostal 
muscles is limited at high levels of exercise, whilst quadriceps muscle perfusion was 
sustained during an incremental exercise test in COPD patients [120]. 
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2.5.Methods to assess dynamic hyperinflation 
There are two commonly used methods to assess dynamic hyperinflation during 
exercise, namely i) inspiratory capacity manoeuvres and ii) via optoelectronic 
plethysmography, both having advantages and disadvantages. Decrease in inspiratory 
capacity during exercise reflects an increase in end-expiratory lung volume. Studies that 
have used the flow through a pneumotachograph  to assess dynamic hyperinflation, 
consistently reported reduced inspiratory capacity by an average of 200 mL, during 
exercise in patients with COPD [19, 55, 62, 81, 90, 121, 122] (Figure 2.3). This method 
measures the amount of air inspired and it is simple to apply in patients who are familiar 
with the spirometry procedure. However, this method takes into account the assumption 
that total lung capacity remains stable during exercise [18]. Furthermore, this method 
relies on the effort of the subject when performing the inspiratory capacity manoeuvre 
and thus might underestimate the magnitude of dynamic hyperinflation during high 
levels of exercise when patients are perceived respiratory muscle discomfort and 
breathlessness. 
In contrast, when dynamic hyperinflation is assessed by breath-by-breath changes in 
end-expiratory chest wall volume using optoelectronic plethysmography either large 
increases [85, 86] at peak exercise (by 750 ml) in early hyperinflators or smaller 
increases in the range of 250 ml in late hyperinflators [86], or no changes in end-
expiratory chest wall volume [123, 124] have been reported. The main advantage of this 
method is the breath-by-breath recording of the dynamic changes of end-inspiratory and 
end-expiratory thoracoabdominal volumes. However, changes in thoracoabdominal 
volumes reflect changes in lung volumes, gas compression and decompression in the 
lungs and blood shifts between the periphery and the trunk [125]. 
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An additional advantage of utilising OEP during exercise is that it provides important 
information on compartmental end-inspiratory and end-expiratory volume regulation 
(ribcage and abdomen),during exercise in patients with COPD [126]. In fact, a number 
of studies highlight that late hyperinflators and evolumics offset rib cage dynamic 
hyperinflation by recruitment of expiratory abdominal muscles which is not the case in 
patients who demonstrate progressive dynamic hyperinflation during exercise.  
2.6.Ergogenic approaches to reduce dynamic hyperinflation  
Over the past two decades different approaches have been employed to reduce 
dynamic hyperinflation and increase exercise tolerance in patients with COPD namely 
bronchodilators [27], oxygen supplementation  [26] and heliox supplementation [28], 
interval exercise [127] and non-invasive ventilation [24, 128]. 
2.6.1. Effect of bronchodilators on dynamic hyperinflation and exercise tolerance 
 Use of inhaled bronchodilators have shown to increase tolerance [27, 87, 90, 122, 
129-135] to constant load exercise and peak incremental exercise assessed during a 
cardiopulmonary exercise test by reducing dynamic hyperinflation (eg. greater 
inspiratory capacity) and breathlessness in patients with moderate to severe COPD [27, 
87, 90, 122, 129-135]. 
Bronchodilators reduce dynamic hyperinflation by reducing inspiratory threshold 
loading οf the inspiratory muscles, allowing patients to achieve the required levels of 
minute ventilation with lower neural drive and work of breathing and thus, lower 
breathlessness [27, 70, 87, 136-138]. Furthermore, the lower end-expiratory lung 
volume with bronchodilators increases inspiratory reserve volume (IRV) and thus, 
allows tidal volume to increase more, before it reaches the critical respiratory 
mechanical constraints during exercise [27, 87, 134, 135, 137, 139]. Accordingly, the 
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mismatch between the inspiratory neural drive and the mechanical response of the 
respiratory system is reduced allowing greater tidal volume expansion with lower 
respiratory muscle effort [137]. 
A number of randomised clinical trials, reported varying evidence on the effect of 
use of bronchodilators on breathlessness and exercise tolerance in patients with 
moderate to severe COPD most likely due to the subjective nature of the method that is 
used to record breathlessness (Borg scale) and the small number of patients that 
participated in the studies [122, 129, 131-134, 140-143] (Figure 2.3) [27]. Moreover, 
the improvement of lung mechanics with the use of bronchodilators, as described above, 
is relative small and thus, patients with severe COPD are not greatly benefited during 
exercise [27, 137]. Finally, bronchodilators cannot affect other factors that limit exercise 
tolerance in patients with COPD such as circulatory factors [18, 27]. 
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Figure 2.3. Improvements in response to long-acting β2-agonists (LABA), long-acting muscarinic antagonists (LAMA) and LABA/LAMA 
combinations compared with placebo are shown for a) exercise measurements of IC at a standardised time during exercise (iso-time), b) constant-
WR cycle exercise endurance time, and c) dyspnoea intensity ratings at iso-time. Treatment differences in these randomised, placebo-controlled 
studies are statistically significant (p<0.05) unless indicated otherwise (not significant (NS)) [27].
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2.6.2. Effect of oxygen supplementation on dynamic hyperinflation and exercise 
tolerance 
A number of studies reported a clinically meaningful increase in exercise to tolerance 
in patients with COPD when oxygen supplementation was applied (Figure 2.4) [24, 26, 
52, 144-149]. Application of oxygen supplementation increases exercise tolerance 
mainly by reducing breathlessness. However, the mechanism by which breathlessness is 
reduced is different compared to that with bronchodilators. Likewise bronchodilators, 
ventilatory demand is lower with oxygen supplementation compared to room air 
breathing, resulting in lower operational lung volumes and thus, delaying the onset of 
ventilatory constraints that exacerbates breathlessness [26]. 
Furthermore, oxygen supplementation improves oxygen transport and utilisation in 
patients with COPD. In fact, arterial oxygen saturation increases with oxygen 
supplementation compared to room air breathing, resulting to greater oxygen 
availability in the peripheral working muscles [149], thereby  delaying metabolic 
acidosis [149]. Metabolic acidosis is associated with increased respiratory neural drive 
and ventilation due to the additional CO2 production secondary to the buffering of the 
hydrogen ions [150]. 
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Figure 2.4. a) Absolute changes in endurance time at the limit of tolerance (tLIM) during constant work-rate exercise with non-pharmacological 
interventions in chronic obstructive pulmonary disease patients. FEV1: forced expiratory volume in 1 second; WR: work-rate; NIV: non-invasive 
ventilation; MCID: minimum clinically important difference. #: suggested mean MCID thresholds 105 s (lower limit of 95% CI 60 s) [24]. 
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2.6.3. Effect of heliox supplementation on dynamic hyperinflation and exercise 
tolerance 
It is well documented that heliox administration also induces clinical meaningful 
increases in exercise tolerance in patients with moderate-to-severe COPD [24]. A 
number of studies reported that exercise tolerance is increased by an average of 
approximately 220 seconds compared to room air breathing [144, 146, 149, 151-155] 
(Figure 2.4). 
Patients with COPD experience greater turbulent flow within the large airways even 
during low breathing frequency [156] and as a result airflow limitation and work of 
breathing are both increased secondary to greater airway resistance [28]. Because heliox 
density is approximately one third of the room air, it allows smother flow of the air 
secondary to less turbulence within the large airways [28]. A review conducted by Hunt 
and colleagues [157] reported reduced dynamic hyperinflation and work of breathing as 
the main factors improving exercise tolerance in patients with moderate to severe COPD 
when patients breathed a heliox gas mixture compared to room air [152, 157]. 
Nevertheless, heliox administration has also positive circulatory effects and 
metabolic effects. In fact, it is previously reported that heliox administration increased 
peak oxygen uptake by 15% with small improvements in cardiac output and oxygen 
extraction [155, 158]. Authors concluded that reducing the work of the respiratory 
muscles allowed more blood flow to the locomotor muscles and thus, increased exercise 
capacity for a given cardiac output [158]. Increased systemic oxygen delivery, systemic 
oxygen content, and reduced exercise-induced muscle fatigue is also reported in a 
number of studies administrating heliox during exercise in patients with moderate-to-
severe COPD [144, 154, 159]. Finally in the study by Laveneziana and colleagues it 
was reported that heliox administration significantly accelerated mean response time for 
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heart rate; the above acceleration was significantly associated with the reduction in 
exercise-induced dynamic hyperinflation and the increase in exercise endurance time 
[153].  
2.6.4. Effect of interval exercise on dynamic hyperinflation and exercise tolerance in 
COPD 
The majority of patients with moderate-to-severe COPD cannot sustain high 
intensities of exercise for a long period of time [160, 161]. Furthermore, exercise of 
higher intensity of exercise is associated with greater physiological benefits in patients 
with COPD [75]. Interval exercise was initially introduced in 1960 to allow greater 
duration of high intensity of training in healthy individuals [162, 163], however, in the 
past two decades it is broadly applied in patients with COPD [23, 164, 165]. 
Interval exercise provides tolerable training loads whilst maintaining an effective 
stimulus for peripheral muscle adaptation in patients with moderately severe and severe 
COPD. Exercise training protocols of repeated brief bouts of high-intensity interval 
exercise (30 to 120 sec), followed by equally brief recovery periods, have demonstrated 
prolonged exercise tolerance compared to continuous exercise, secondary to smaller 
magnitudes of dynamic hyperinflation and breathlessness. Hence, with interval exercise 
patients can exercise longer at higher training loads before symptoms become 
intolerable [29]. Evidence suggests that interval exercise training is effective across a 
wide spectrum of severity in COPD [166], including patients with profound peripheral 
muscle loss [167]. 
The first study indicating interval exercise as an alternative training modality to 
continuous exercise was published by Vogiatzis and colleagues in 2002 [127]. During 
interval exercise, mean training intensity throughout 25 training sessions was almost 
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double  compared to the mean training intensity during continuous exercise (124% 
versus 67% WRpeak) [127]. In addition, both breathlessness and cardiac output were 
lower with interval exercise compared to continuous exercise indicating lower 
cardiovascular and ventilatory loads [127] thus, providing evidence of the effectiveness 
of interval exercise in a setting of pulmonary rehabilitation [127]. 
The above study was followed by another study from the same group, comparing the 
acute physiological responses during continuous and interval exercise in patients with 
moderate-to-severe COPD [29]. Authors reported a 3-fold increase in exercise 
tolerance, mainly due to lower ventilatory requirements, lower metabolic acidosis and 
lower symptoms of breathlessness and leg discomfort [29]. These finding were further 
supported by lower metabolic requirement (oxygen uptake, carbon dioxide production 
and respiratory exchange ratio) and greater ventilatory responses (greater inspiratory 
capacity and inspiratory reserved volume and lower minute ventilation, tidal volume, 
breathing frequency, dead space) [29]. Interestingly, oxygen uptake, minute ventilation 
and heart rate were not different between the exercise and the recovery phases during 
the interval exercise [29] suggesting that interval exercise is associated with stable and 
lower metabolic demands, minute ventilation and rate of dynamic hyperinflation 
although exercise duration is much greater compared to continuous exercise [29].  
2.7.Non-invasive ventilation 
Non-invasive ventilation (NIV) is widely used since 1980s as an effective way to 
treat patients with respiratory failure [168-171] both in the acute setting (during 
hospitalisation and ICU) [172] and at home (during daily living) [173]. The aim of NIV 
is to assist ventilation mainly by reducing work of breathing, improving inspiratory flow 
rate, controlling ventilation and resetting the central respiratory drive [173]. At the early 
days of NIV the number of the available modalities and ventilatory methods was very 
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limited. Nowadays, due to technological breakthroughs there are more than 30 different 
brands offering a wide number of ventilatory options [174]. As a result, different 
ventilatory modalities are available, but the large majority of the devices deliver either 
volume or pressure targeted ventilation [32]. 
Volume targeted ventilators deliver a fixed volume of air during a given time. During 
respiration airway pressure is not constant therefore, the delivered pressure varies 
throughout the duty cycle to achieve the targeted volume when volume targeted 
ventilators are applied [32]. In contrast, pressure targeted ventilators aim at maintaining 
the airway pressure constant, therefore the volume of the delivered air in the airways 
varies accordingly during each breath [32]. The combination of these two modalities 
creates a hybrid ventilatory modality which is capable of maintaining the targeted tidal 
volume by estimating the delivered tidal volume [32]. 
However, recent modes of ventilation have a more physiological background in 
delivering assistance flow consequently, their function is more complex. The most 
commonly used non-invasive ventilatory modalities are the following: continuous 
positive airway pressure (CPAP), proportional assisted ventilation (PAV), inspiratory 
pressure support (IPS) and pressure support ventilation (PSV). 
2.7.1. Physiological effects of NIV at resting conditions 
2.7.1.1. Effects of NIV on work of breathing 
Work of breathing (WoB) is assessed by measuring intrathoracic (esophageal and 
transdiaphragmatic) pressures using balloon catheters. In patients with different 
respiratory diseases and disease severity, it is well established that application of non-
invasive ventilation reduces inspiratory effort [175]. Compared to spontaneous 
breathing  NIV methods providing air with relatively high pressures (greater than 10 
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cmH2O), have been reported to reduce oesophageal [43, 175-183] and diaphragmatic 
pressures [175, 178, 179, 181, 183-188] (Appendix A Table 1) equivalent to an average 
of 0.41 Joules/L [43, 174, 175, 177, 182, 185, 188] (Appendix A Table 1). In addition, 
when positive end expiratory pressure was applied intrinsic PEEP (PEEPi) has 
consistently been reported to decrease by an average of 0.86 cmH2O [48, 175, 178-181, 
183-188] compared to spontaneous breathing (Appendix A Table 1). Finally, compared 
to spontaneous breathing application of NIV reduces electromyographic diaphragmatic 
activation [175, 177, 178, 183, 187, 189-191] (Appendix A Table 1). 
However, the effect on WoB varies between different NIV methods. Compared to 
spontaneous breathing Pressure Support Ventilation (PSV) has been reported to reduce 
oesophageal [43, 177-180, 182] and diaphragmatic pressures [177-179, 184-186, 188] 
(Appendix A Table 1). Work of breathing is also reduced when PSV is applied, whilst 
PEEPi and electromyographic diaphragmatic activation are both reduced compared to 
spontaneous breathing [43, 48, 177-180, 182, 184-186, 188] (Appendix A Table 1). 
Compared to spontaneous breathing, Continuous Positive Airway Pressure (CPAP) 
has been reported to reduce oesophageal [176] and diaphragmatic pressures [184, 188], 
whilst WoB [188] and PEEPi were reduced [184, 188] (Appendix A Table 2). 
Proportional Assist Ventilation (PAV) reduces oesophageal, [43, 179, 182, 183] and 
diaphragmatic pressures [179, 183], similarly to PSV. Furthermore, WoB, [43, 182] and 
electromyographic diaphragmatic activation [183] are reduced (Appendix A Table 2). 
On the other hand the effect on PEEPi is less clear as three studies reported a reduction 
[48, 179, 183], whilst one study found an increase [182] (Appendix A Table 2). The 
reduction in WoB and diaphragmatic activation is similar to PSV and greater than 
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CPAP. In contrast, the reduction in PEEPi is similar with PAV and PSV but lower 
compared to CPAP (Appendix A Table 2). 
There is limited evidences in the literature about the effect of the application of Bi-
level Positive Airway Pressure (BiPAP) on the WoB [191, 192] [86, 87] (Appendix A 
Table 2). In the study of Renston and colleagues application of inspiratory positive 
airway pressure (IPAP) (18 cmH2O) and expiratory positive airway pressure (EPAP) (2 
cmH2O) reduced diaphragmatic activation by 66%, compared to control breathing [191] 
(Appendix A Table 2). However, application of lower IPAP (10 cmH2O) and greater 
EPAP (4 cmH2O) does not have any effect at the WoB when measured in Joules per 
litre [192] (Appendix A Table 2). Finally, compared to spontaneous breathing 
application of 20 cmH2O during inspiration and 7 cmH2O during expiration has been 
reported to decrease oesophageal pressure [176] (Appendix A Table 2). 
2.7.1.2.Effects of NIV on breathing pattern 
In patients with different respiratory diseases and disease severity, it is well 
established that application of non-invasive ventilation improves breathing pattern 
compared to spontaneous breathing [60]. During application of different NIV methods 
that provide air with relatively high pressures (greater than 10 cmH2O) minute 
ventilation increases [48, 175-181, 183-185, 187, 188, 193] mainly due to an increase in 
tidal volume [43, 48, 176-188, 191, 193], whilst breathing frequency is reduced [43, 48, 
176-188, 191-193] compared to normal breathing. Compared to control breathing, 
application of NIV is not altering inspiratory time [48, 177, 184-186], whilst expiratory 
time [48, 177, 178, 184, 186] and total duty cycle time [177, 184, 186] are slightly 
increased. This leads to a decrease of inspiratory time over total duty cycle ratio [43, 48, 
177-184, 186]. 
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Compared to control breathing, application of PSV has shown to increase minute 
ventilation [177-180, 184, 185, 188] secondary to increased tidal volume [43, 48, 177-
180, 182, 184-186, 188], despite the reduction in breathing frequency [43, 48, 177-180, 
182, 184, 186, 188] (Appendix A Table 3). Furthermore, PSV application increases total 
duty cycle time [184, 186] compared to spontaneous breathing, due to a small increase 
in both inspiratory [48, 177, 184-186] and expiratory times [48, 177, 178, 184, 186] 
(Appendix A Table 3). As a result, inspiratory time over total duty cycle ratio is slightly 
reduced compared to normal breathing when PSV is applied [43, 48, 177-180, 182, 184] 
(Appendix A Table 3). 
Compared to spontaneous breathing, application of CPAP has adverse effects on 
breathing pattern. When CPAP is applied minute ventilation is reduced [176, 188] 
compared to quiet breathing, due to a reduction in both tidal volume [176, 188] and 
breathing frequency [176, 188] (Appendix A Table 4). In contrast, in the study by 
Appendini and colleagues [184] minute ventilation was greater (by 0.5 litres) compared 
to normal breathing mainly due to an increase in breathing frequency, whist tidal 
volume remains unchanged [184] when CPAP applied compared to normal breathing 
(Appendix A Table 4). Accordingly, inspiratory and expiratory times were slightly 
reduced when CPAP was applied leading to a small reduction in total duty cycle ratio 
by 0.3 seconds, compared to spontaneous breathing [184] (Appendix A Table 4). The 
discrepancy between the findings with CPAP is most likely due to the variability of the 
population included in these studies.  
In contrast to CPAP, application of PAV increased tidal volume [43, 48, 179, 182, 
183], and minute ventilation [48, 179, 183], whilst neither breathing frequency nor total 
duty cycle ratio were affected [43, 48, 179, 182, 183] compared to spontaneous 
breathing (Appendix A Table 4). However, in the study by Poggi and colleagues, 
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compared to normal breathing, expiratory time was greater (by 0.33 seconds) when 
PAV applied [48] (Appendix A Table 4). 
Application of IPAP (20 cmH2O) increases minute ventilation compared to normal 
breathing, secondary to greater tidal volume, whilst breathing frequency is lower [176, 
187] (Appendix A Table 4). However, when EPAP (7 mH2O) was added to the above 
IPAP pressure the improvement in minute ventilation, tidal volume and breathing 
frequency was limited [176] (Appendix A Table 4). 
2.7.1.3.Effects of NIV on central haemodynamic responses 
It is well documented that application of NIV during resting conditions causes 
adverse effects on circulatory responses both in healthy individuals and in patients with 
COPD [50, 51, 175]. In healthy individuals application of CPAP has been found to 
decrease cardiac index [194], cardiac output, secondary to a reduction in stroke volume 
[195-197], whilst heart rate and blood pressure remained unchanged [195-197]. Similar 
findings have been reported in patients with COPD as application of NIV has been 
found to decrease cardiac output secondary to a reduction in stroke volume whilst there 
was no effect on heart rate and blood pressure [198-201]. 
During normal inspiration, pleural pressure becomes more negative, compared to 
expiration, mainly as a result of the contraction of the diaphragm whilst alveolar 
pressure equals atmospheric pressure to allow the air to flow in the lungs [50]. 
Additionally, expiration is passive and based mainly on elastic recoil forces of the lung 
and the relaxation of the diaphragm [50]. In contrast, during NIV application, both 
alveolar and pleural pressures become positive during inspiration, whilst additional 
application of PEEP results in positive pleural pressure throughout the respiratory cycle 
[50]. 
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The main consequences of the aforementioned alternations in the alveolar and pleural 
pressures are the following: (i) increased ventilation/perfusion mismatch by 
compressing the alveolar vessels and increasing pulmonary vascular resistance and (ii) 
reduced venous return secondary to compression of the large intrathoracic blood vessels 
and increased right atrial pressure due to the greater intrathoracic pressure [50, 202, 
203]. Normally, a relatively small pressure of 4-8 mmHg is required to allow blood 
return to the heart [204], consequently increases in intrathoracic pressures can cause 
large decreases in stroke volume and thus cardiac output [51]. Increasing mean systemic 
filling pressure by increasing stressed volume or vessel tone can mitigate the reduction 
in venous return [205]. 
2.7.1.4.Physiological effects of PEEP  
During application of NIV, it is common to apply external positive end-expiratory 
pressure (PEEPe) to counterbalance the negative effects of PEEPi. In fact, application of 
PEEPe has been found to reduce the work of breathing, normalise breathing pattern and 
improve blood gas levels and synchronisation of the breathing between the patient and 
the ventilator [168-170]. Nevertheless, PEEPe level needs to be optimal to be beneficial 
for the patients [206]. If PEEPe is lower than PEEPi then the positive effects are 
minimised [206, 207]. On the other hand, when PEEPe exceeds PEEPi, this would 
increase dynamic hyperinflation and intrathoracic pressure swings, potentially adversely 
affecting venous return and cardiac output [171-173]. Accordingly, the applied level of 
PEEPe should be individualised in each patient. 
A study by Milesi and colleagues investigated the capability of a new ventilator to 
adjust breath-by-breath the applied PEEPe relative to PEEPi across different postures in 
patients with COPD. The study  showed that the optimal PEEPe for a population of 
moderate to severe COPD  in the seated position was approximately 4 cmH2O [206]. 
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However, the pressure of PEEPe that minimises PEEPi cannot be predicted by either 
baseline lung function, anthropometric characteristics or combination of those, 
suggesting that  PEEPe was optimal to abolish expiratory flow limitation in less than 
one third of the patients in sited position (i.e. 8 out of 26) [206]. These 8 patients had 
better lung function and less dynamic hyperinflation compared to the patients who did 
exhibit abolished expiratory flow limitation when PEEPe of 4 cmH2O applied [206]. 
2.7.2. Effect of NIV application on dynamic hyperinflation and exercise tolerance 
Over the past three decades a number of studies investigated the acute effects of NIV 
application on exercise tolerance in COPD patients [24, 49, 208]. Accordingly, it is well 
established that application of a variety of different NIV methods increases exercise 
tolerance in this population (Appendix A Table 5 & Table 6) [24, 49, 208]. 
Four studies investigated the effect of continuous positive airway pressure (CPAP) 
application on exercise tolerance [35, 36, 44, 46] (Appendix A Table 5 & Table 6). In 
the study by Bianchi and colleagues exercise tolerance was increased by 2.4 minutes 
when CPAP of 6 cmH2O was applied compared to sham [44]. The increase in exercise 
tolerance was secondary to lower breathlessness however, minute ventilation and 
inspiratory flow remained unchanged [44]. Similar findings reported in the study by 
Dolmage and colleagues where exercise tolerance was increased by 1.7 minutes when 
CPAP of 5 cmH2O was applied compared to sham CPAP [46]. However, in the latter 
study there were no differences in breathlessness or in ventilatory responses [46]. 
O’Donnell reported that application of CPAP of 4-5 cmH2O increased exercise 
tolerance by 2.8 minutes compared to sham secondary to lower breathlessness and 
respiratory rate at exercise iso-time, whilst there was no difference in dynamic 
hyperinflation [34]. The findings on dynamic hyperinflation are similar to those of 
Petrof and colleagues who also reported that application of CPAP of 7.5-10.0 cmH2O 
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did not reduce end-expiratory lung volumes compared to normal breathing [36]. In 
contrast, when CPAP of 6 cmH2O was applied during walking on a treadmill exercise 
tolerance or breathlessness were not improved in patients with severe COPD [37]. 
Application of proportional assist ventilation (PAV) has been also found to increase 
exercise tolerance in patients with COPD as reported in five studies [44-47, 209] 
(Appendix A Table 5 & Table 6). Bianchi and colleagues reported increased exercise 
tolerance compared to sham by an average of 5.3 minutes [44]. The increase in exercise 
tolerance was accompanied by lower breathlessness (2 units on 1-10 Borg scale), 
greater tidal volume (by 140 ml) and greater inspiratory flow (by 150 ml) [44]. In 
addition, Hernandez and colleagues reported an increase in exercise tolerance by 3.1 
minutes with PAV compared to normal breathing secondary to better ventilatory 
responses (i.e. greater tidal volume, lower breathing frequency and greater minute 
ventilation), greater duty cycle and better inspiratory and expiratory flow at iso-time 
[47]. In contrast, in the study by Dolmage and colleagues exercise tolerance was 
increased only by 0.5 minutes when PAV was applied compared to sham, whilst there 
was no difference in any ventilatory variables [46]. However, when PAV was combined 
with CPAP exercise tolerance increased two fold compared to sham whilst minute 
ventilation was greater secondary to greater tidal volume [46]. Similar increase in 
exercise tolerance (0.5 minutes) was also reported in the study by Carrascossa and 
colleagues when PAV was applied compared to control attributed to the high variability 
of the response of the patients when PAV was applied [45]. Finally, another study that 
applied PAV during submaximal exercise reported an increase in exercise tolerance 
compared to sham by 1 minute, mainly due to lower symptoms of breathlessness and 
leg discomfort at iso-time and greater oxygen availability in the locomotor muscles 
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[209]. The discrepancy of the above findings between the studies can be explained from 
the differences in the protocols applied. 
Inspiratory pressure support (IPS) has been used in three studies and the findings 
suggest that patients can be benefited from its application during exercise [37, 42, 210] 
(Appendix A Table 5 & Table 6). When IPS was applied during walking on a treadmill 
patients covered greater distance (149 meters more) compared to control breathing 
secondary to lower breathlessness [37]. Furthermore, when IPS was applied during 
cycling in patients with COPD, exercise tolerance was increased by 43% in one study  
[42] and by 64% in another study [210] by improving breathing pattern [42, 210] and by 
reducing dynamic hyperinflation [210] at exercise iso-time. 
Finally, when pressure support ventilation (PSV) was applied during cycling, 
patients with COPD were able to increase their exercise tolerance by 3.3 minutes 
compared to sham, secondary to lower breathlessness and better breathing pattern [44] 
(Appendix A Table 5 & Table 6). 
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3. General methods 
3.1. Study population and patient recruitment 
3.1.1. Patient cohorts 
Originally 29 COPD patients were screened and 24 patients met the eligibility 
criteria in the present study. The investigations were carried out following the rules of 
the Declaration of Helsinki of 1975 [211], revised in 2013. NHS Research Ethics 
Committee approval (REC: 17/NE/0085) and Clinical Trials registration 
(NCT03068026) were obtained. Data were collected at the Respiratory Department, 
North Tyneside General Hospital. All participants provided written consent [20] 
(Appendix B). 
Eligible patients were identified from those referred to pulmonary rehabilitation, by 
the multidisciplinary respiratory team of North Tyneside General Hospital which 
comprised of the usual care team, physicians, physiotherapists and specialist nurses, 
working within the trust, who provided initial information about the trial. The principal 
investigator then confirmed eligibility and discussed full details of the trial. Patients 
were given time to consider whether they were happy to participate in the study, 
including the equipment and testing procedures involved. 
Part of the clinical study described in Chapters 4 and 5 was the follow up assessment 
of the usability, applicability and comfort of using the VitaBreath device during 
activities of daily living (Chapter 7). Thus, the twenty-four (24) patients who completed 
the study described in Chapters 4 and 5 participated in the follow up assessment under 
the same NHS Research Ethics Committee approval (REC: 17/NE/0085) and the same 
Clinical Trials registration (NCT03068026). 
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3.1.2. Patient recruitment into a further study 
For the study presented in Chapter 6 (effect of pNIV on thoracoabdominal volumes 
during exercise), seven patients from the original cohort presented in Chapters 4, 5 and 
7 agreed to participate in the aforementioned study. The respiratory research team at 
North Tyneside General hospital contacted those who wished to be considered for 
further research and provided initial information about the trial. Patients were provided 
with an information sheet for the study and were given time to consider whether to 
participate in the trial, before written informed consent was obtained (Appendix C). 
 
3.2.Inclusion and exclusion criteria 
Inclusion criteria [20]: 
1) Male or female aged 40 years or older. 
2) Current or previous smoking history: 10 or more pack years. 
3) Spirometry confirmed stable COPD (GOLD stages II-IV) under optimal medical 
therapy. 
4) Exhibit substantial exercise-induced dynamic hyperinflation (change in IC from 
baseline > 0.15 L) [19] (only for studies presented in Chapters 5, 6 and 7). 
Exclusion criteria [20]: 
1) Orthopaedic, neurological or other concomitant diseases that significantly impair 
normal biomechanical movement patterns, as judged by the investigator. 
2) Moderate or severe COPD exacerbation within 6 weeks [212]. 
3) Unstable cardiac arrhythmia. 
4) Unstable ischaemic heart disease, including myocardial infarction within 6 
weeks. 
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5) Moderate or severe aortic stenosis or hypertrophic obstructive cardiomyopathy. 
6) Uncontrolled hypertension. 
7) Uncontrolled hypotension (SBP<85mmHg). 
8) Uncontrolled diabetes. 
9) Intolerance of the VitaBreath device (only for studies presented in Chapters 5, 6 
and 7). 
3.3.Baseline assessments 
Prior to the cardiopulmonary exercise test (CPET) (relevant to studies presented in 
Chapters 4, 5. and 7) and prior to the visit to Northumbria University (study presented 
in Chapter 6), patients underwent full lung function assessment in order to confirm their 
eligibility to the study and determine the severity of COPD by assessing: 1) forced 
expiratory volume at the first second (FEV1) and forced vital capacity (FVC), and b) 
resting lung volumes including: total lung capacity (TLC), inspiratory capacity (IC), 
functional residual capacity (FRC), residual volume (RV) and diffusion capacity 
(DLco). Lung function assessment was conducted at the Lung Function Laboratory of 
the North Tyneside General Hospital. Before each test, all devices were calibrated based 
on the manufacturer's instructions. 
Resting heart function was assessed by resting electrocardiogram (ECG) at the 
Cardiology Unit of the North Tyneside General Hospital in order to ensure that there 
were no existing cardiovascular complications. Medical history and physical 
examination were then performed by a clinician to confirm that each patient was 
eligible to participate in the study. 
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3.4.Participant preparation 
3.4.1. Chapters 4 and 5 
After baseline assessment and confirmation of patient’s eligibility, patients were 
prepared for the ramp incremental exercise test (CPET) (Chapter 4) and for the high- or 
the moderate-intensity intermittent exercise test (Chapter 5) according to the following  
steps: i) the skin sites were cleaned with an alcohol wipe and then the cardio-impedance 
(PhysioFlow) electrodes were placed (according to figure 3.3), ii) the gas exchange 
system (K4b
2
 Cosmed) was positioned in the harness and then placed on the patient 
(Figure 3.1) to allow ventilatory, gas exchange and metabolic recordings during 
exercise, iii) the cycle ergometer seat was set to the correct height for the participant and 
iv) when the participant was on the cycle ergometer, a blood pressure arm cuff and the 
pulse oximeter were placed on the right arm and the finger of the left hand, respectively. 
Before the test started a nose clip and mouthpiece were fitted, and the investigator 
confirmed the CPET protocol and explained how the participants should communicate 
if they wanted to stop the test.  
 
Figure 3.1. Placement of the harness and K4b
2
 on the patient. 
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3.4.2. Chapter 6 
During the visit to Northumbria University (Chapter 6), upon arrival to the 
laboratory, and prior to any intervention, adhesive skin markers for Opto-Electronic 
Plethysmography (OEP) (to assess thoracoabdominal wall dynamic hyperinflation), and 
adhesive optodes for portable cardio-impedance recordings (to assess circulatory 
responses) were attached to the skin following the same procedure described above. All 
procedures were explained in detail prior to each trial. 
3.5. Interventions 
3.5.1.  Ramp incremental cardiopulmonary exercise test (CPET) (Chapter 4) 
All ramp incremental CPETs were performed on an electromagnetically braked cycle 
ergometer (Ergoselect 200, ergoline GmbH, Bitz, Germany) with patients maintaining a 
pedalling frequency of 50–60 rpm [20]. The ramp incremental CPET (Figure 3.2) 
consisted of a 3-mins of rest period, followed by 3-min unloaded pedalling prior to 
ramp incremental loading of 5 or 10W [20]. The following pulmonary gas exchange and 
ventilatory variables were recorded breath-by-breath via a portable gas exchange 
analyser (K4b
2
, Cosmed, Shepperton, UK) throughout the test: oxygen uptake (VO2), 
carbon dioxide output (VCO2), respiratory exchange ratio (RER), minute ventilation 
(VE), tidal volume (VT), and breathing frequency (bf) [20]. Central haemodynamic 
responses were recorded continuously throughout the CPETs by the Physio Flow device 
(Enduro, PF-07, Manatec Biomedical, Folschviller, France) at a frequency of 6 seconds 
[20]. Arterial oxygen saturation and blood pressure were measured by pulse oximetry 
(Nonin 8600; Nonin Medical, Plymouth, MN, USA) and a sphygmomanometer 
(MABIS Healthcare PRECISION
ΤΜ
), respectively [20]. The modified Borg Scale was 
used to rate the magnitude of dyspnoea and leg discomfort at the end of the test [20, 
213]. Inspiratory capacity (IC) manoeuvres were performed at rest, every 2 min during 
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cycling and at peak exercise, in order to evaluate the rate of dynamic hyperinflation 
(DH) [19, 20]. A 3-litre air pump was used to perform the volume calibration (Cosmed). 
The O2 and CO2 calibration for the gas exchange analyser were performed using a gas 
concentration of 16% and 5% for O2 and CO2, respectively. Both calibrations were 
performed prior to each test in accordance with the manufacturer instructions. 
The peak work rate (WRpeak) was defined as the maximum mean of the last 30 
seconds. At least one of the following criteria were adopted for determining whether a 
patient reached the limit of exercise tolerance [214]: 
i) A plateau in V̇O2 [214]. 
ii) Peak exercise ventilation (V̇Epeak) exceeding 85% of or estimated 
Maximum Voluntary Ventilation (MVV).  
iii) Evidence of presence of dynamic hyperinflation indicated by a decrease 
from baseline in inspiratory capacity (IC) greater than 150 mL during 
exercise [19] . 
iv) Maximal RER during exercise exceeding 1.03. 
v) The patient reaching a HR at or above calculated HRmax.  
vi) V̇O2peak exceeds V̇O2peak predicted. 
 
 
Figure 3.2. Ramp incremental exercise protocol. 
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3.5.2. High intensity intermittent exercise protocol (Chapter 5) 
The high-intensity intermittent exercise protocol (sustained at 80% WRpeak) 
consisted of repetitive 2-min exercise bouts, separated by 2-min recovery periods to the 
limit of tolerance (Figure 3.3a) [20]. This was defined as the point at which the patient 
signalled the inability to continue exercising or could not maintain the required 
pedalling rate (i.e., 50–60 revolutions/min), despite being encouraged by the 
investigators [20]. IC manoeuvres were performed on the 2
nd
 minute of each exercise 
bout. During the 1
st
 min of each recovery period, participants used either pNIV 
(VitaBreath device) or PLB [20]. During the 2
nd
 min of each recovery period, 
participants performed an IC manoeuvre to assess the magnitude of dynamic 
hyperinflation (DH) and scored the intensity of their breathlessness and leg discomfort 
using the Borg scale (Figure 3.3a) [20]. Blood pressure measurements were performed 
on the 2
nd
 minute of each exercise bout following each IC manoeuvre [20]. 
3.5.3. Moderate intensity intermittent exercise protocol (Chapter 5) 
The moderate-intensity intermittent exercise protocol (sustained at 60% WRpeak) 
consisted of repetitive 6-min exercise bouts, separated by 2-min recovery periods to the 
limit of tolerance as described above [20]. Use of pNIV or PLB, and assessments were 
performed as above. IC manoeuvres followed by blood pressure measurements, were 
performed on the 2
nd
, 4
th
 and 6
th
 minute of each exercise bout [20]. An additional IC 
manoeuvre followed by breathlessness and leg discomfort recordings using the 
modified Borg scale were performed on the 2
nd
 minute of each recovery period 
following completion of each exercise bout (Figure 3.3b) [20]. 
3.5.4. High intensity intermittent exercise protocol (Chapter 6) 
Patients underwent two intermittent exercise protocols on a cycle ergometer (Figure 
3.3c). The exercise protocol consisted of five repeated 2-min exercise bouts at 80% of 
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predefined WRpeak (Chapter 4), separated by 2-min recovery periods, to allow 
application of the VitaBreath device or the PLB technique. During the first minute of 
each recovery period, patients breathed through the VitaBreath device or adopted the 
pursed lip breathing technique. During the second minute of each recovery period 
patients breathed normally. Patients also scored the intensity of their perceived 
dyspnoea using the Borg 1-10 scale. Cardiac output and stroke volume were measured 
non-invasively using a cardio-impedance method (physio-flow) throughout the exercise 
and recovery periods. In addition, arterial oxygen saturation was recorded throughout 
the exercise and recovery periods using a pulse oximeter. 
 
  
60 
 
 
Figure 3.3. Exercise protocols: (a) High-intensity 2-min intermittent exercise protocol to the limit of 
tolerance (Chapter 5) (b) Moderate-intensity 6-min intermittent exercise protocol to the limit of tolerance 
(Chapter 5) and (c)Five consecutive bouts of high-intensity 2-min intermittent exercise protocol (Chapter 
6). Within the two protocols (high-intensity (a) or moderate-intensity (b)), each patient performed two 
more visits/exercise tests using pNIV and PLB during recovery from exercise in balanced order. Within 
the high-intensity protocol (c) each patient performed two more exercise tests using pNIV and PLB 
during recovery from exercise in balanced order in one visit. Typical examples of high- and moderate-
intensity exercise bouts are shown by open squares and recovery periods by shadowed squares. pNIV or 
PLB was applied during the first minute of recovery whereas an inspiratory capacity manoeuvre was 
performed on the second minute of recovery (a and b) [20]. 
 
3.6.Familiarisation protocol (Chapter 5) 
Twenty-four patients who completed the ramp incremental cardiopulmonary exercise 
test (Chapter 4) participated in the familiarisation program. The aim of the 
familiarisation exercise program was to avoid early termination during either moderate- 
or high-intensity exercise trials due to excessive leg discomfort. In addition, patients 
were familiarised with the two different exercise modalities (high and moderate 
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intensity intermittent exercise) and the use of the VitaBreath device, to ensure that the 
patient would feel comfortable to use this during the experimental exercise 
protocols/data collection. Patients were familiarised with both intermittent protocols as 
they were then randomised to perform one of the protocols. 
3.7. Familiarisation Programme (4 weeks) (Chapter 5) 
The duration of the familiarisation programme was 4 weeks with a frequency of two 
exercise sessions per week [165]. The exercise programme, consisted of interval 
exercise on a bicycle ergometer with either 2 minutes of work at 80% of WRpeak 
interspersed by 2 minutes of rest (see section 3.5.2), or 6 minutes of work at 60% of 
WRpeak interspersed by 2 minutes of rest (see section 3.5.4), for 30 minutes. The initial 
load was individualised for each patient and was adjusted after each session, based on a 
target dyspnoea score of 4 on the modified Borg scale by the end of each session. When 
patients rated their dyspnoea at 3 or less the workload was increased by 5-10 watts at 
the next training session. The increase in workload with progressive familiarisation 
visits was towards the intended target workload (i.e. 60% and 80 % of WRpeak), in 
order to minimise the risk of inducing significant changes in exercise capacity during 
the familiarisation period due to training. During the familiarisation period, patients 
were taught how to score their breathlessness and leg discomfort using the modified 
Borg scale and how to use of the VitaBreath device, and during cycling. Additionally, 
patients were familiarised with the correct adoption of the pursed lip breathing (PLB) 
technique during the recovery periods between successive exercise bouts. Patients used 
the VitaBreath device and PLB at the first minute of each recovery period during the 
intermittent exercise protocols. 
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3.8. Application of portable non-invasive ventilation 
The VitaBreath device (Philips, Respironics, Morrisville, PA, USA) is a portable, 
handheld, battery-powered, non-invasive ventilation (pNIV) device intended to reduce 
activity-related shortness of breath [215]. It delivers 18 cmH2O inspiratory and 8 
cmH2O expiratory pressures, but can only be used during recovery periods interspersing 
bouts of physical activity [215]. Prior the application of the VitaBreath device, the level 
of the inspiratory and expiratory pressure was assessed using a differential pressure 
transducer (Validye Corp., Northbridge, CA, USA) and it was confirmed that the 
pressures levels provided by the manufacturer were accurate (Appendix D). 
3.9. Application of pursed lip breathing 
The pursed lip breathing technique is a commonly used breathing technique that 
patients with COPD learn to adopt, in order to reduce expiratory flow limitation and 
thus the degree of dynamic hyperinflation during exercise [216-218]. When patients 
adopt this technique, they should inspire through their nose and expire through their 
mouth, with their lips pursed the same way they would blow a candle. A respiratory 
nurse trained the COPD patients how to use the pursed lip breathing technique during 
recovery periods between consecutive exercise bouts, and at the end of exercise. 
3.10. Assessment of central haemodynamic responses 
Cardiac Output (CO), heart rate (HR) and stroke volume (SV) were recorded 
continuously at rest, during exercise and in recovery by the PhysioFlow device (Enduro, 
PF-07, Manatec Biomedical, Folschviller, France) at a frequency of 6 seconds [20]. The 
cardio-impedance method has been used for more than 50 years in order to non-
invasively record beat by beat changes in cardiac output [219]. The equations used to 
calculate the stroke volume were modified by Berstein [220]. During the last two 
decades, the method of cardio-impedance (PhysioFlow) has been used to continuously 
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record heart rate at rest and during exercise. Estimation of cardiac output is based on the 
resistance encountered by the alternating current passing through the chest. Then, a 
specific algorithm analyses these changes and displays the continuous non-invasive 
measurements of hemodynamic parameters [221]. 
This device (PhysioFlow, PF-07, Enduro) emits a high-frequency (75 kHz) and low-
intensity (3.8 mA peak-to-peak) alternating current through six electrodes placed on the 
chest of the patients, for abduction and reception of electrical signals [222] (Figure 3.4). 
 
Figure 3.4. Appropriate placement of the 6 electrodes of the Physio Flow, (Enduro, PF-07) cardio-
impedance device. Z1 & Z3: transmitter electrodes, Z2 & Z4: receiver electrodes, ECG1 and ECG2: 
electrocardiographic signal monitoring electrodes. 
 
Bio-impedance cardiography is a non-invasive method to record cardiac output, heart 
rate and stroke volume. The cardiac output recorded by the device (PhysioFlow, PF-07, 
Enduro Manatec, Macheren, France) is based on the following equation: 
Equation 1. COPF=HRPF× SVI × BSA 
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According to the equation, COPF (litres/minute) is the asking cardiac output, HRPF 
(pulses/minute) is the heart rate calculated from the time interval of RRs determined by 
the electrocardiographic signal, SVI (ml/m
2
) is the stroke volume index per square unit 
of body surface area and finally the BSA (m
2
) is the body surface expressed in (m
2
), 
calculated according to the Haycock equation: 
Equation 2. BSA = 0.024265 × BM0.5378 × H0.3964 
According to the equation, BM (kg) is body mass and H (cm) is height. Based on 
equation 1 for the SVI calculation, the stroke volume (SV) of the patient, measured by 
the rheographic method, is based primarily on the changes in the intra-thoracic current 
resistance (Z) during the extrusion of blood from the ventricles. The procedure for 
initiating the device included inputting the patients' demographic characteristics, 
evaluation of the stroke volume index (SVi), and inputting systolic and diastolic blood 
pressure values recorded at rest. 
The calculation of SVi was initially performed during the calibration phase of the 
system, based on the recording of 30 consecutive heart beats with the patient sitting on 
the cycle ergometer, remaining still and silent. 
Equation 3. SVical = k x [(dZ/dtmax) / (Zmax - Zmin)] x W (TFITcal) 
According to equation, k: constant, DZ / dtmax: contractility index, Zmax-Zmin = 
change in electrical conduction during cardiac contraction, W = algorithm that takes 
into account blood pressure (systolic-diastolic blood pressure), as recorded by a 
sphygmomanometer. Finally, the TFITcal index is the thoracic flow inversion time 
measured in the first mathematical derivative of the conductivity signal. This is the time 
period between the first zero value at the onset of the cardiac cycle (start of the QRS 
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pattern on the electrocardiogram) and at the first lower point immediately after the peak 
of the ejection speed (dZ / dtmax) (Figure 3.5). 
 
Figure 3.5. Waveforms from PhysioFlow, Enduro, PF-07. DZ: current resistance, Zmax: peak resistance 
value, dz/dt: the ratio of the change of the resistance signal over the time required to reach the signal its 
maximum value. 
The advantages of using this non-invasive method are that there is no risk of injury to 
the patient, which can be the case with the cardiac catheterization method [223], its 
relatively low cost, it’s simple to operate and it allows continuous recording of cardiac 
output at rest and during exercise [224]. 
Reliability of the PhysioFlow has been tested during rest and exercise on a cycle 
ergometer in healthy [225, 226], and patients with respiratory or cardiac diseases [222, 
227-229]. Results revealed that PhysioFlow slightly over-estimated the values of 
cardiac output during both rest and exercise [222, 224, 227-229]. The accuracy in beat 
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by beat heart rate recordings can be affected by respiratory effort, subcutaneous fat and 
the poor positioning or contact of the electrodes [230]. In addition, exercise causes rapid 
and large changes to the aforementioned factors, making it more difficult to calculate 
cardiac output [231, 232]. However, new software has been developed to optimize 
signal quality by providing a better data collection process, as the modified equation 
used to calculate stroke volume does not require the estimation of blood resistance, and 
the exact position of the electrodes is not essential to validate cardiac output [227, 229]. 
Systolic and diastolic blood pressures were measured manually from the left arm 
using a sphygmomanometer and a stethoscope at rest, every three minutes during 
exercise and during the last minute of exercise. When undertaken properly, manual 
measurements of blood pressure is considered more accurate than automated blood 
pressure, which have limited accuracy (65%) during cycling exercise [233]. To improve 
reliability, measures were taken by the same researcher throughout the exercise test. 
Peak heart rate was calculated using the following formula: 
HRpeak = 220 – age [234] 
From measurements of oxygen uptake and cardiac output, whole body arteriovenous 
oxygen difference content was calculated using the Fick equation [20, 221]: 
VO2 = Cardiac Output x (CaO2 – CvO2) 
 
Arterial O2 content (CaO2) was estimated as: 
CaO2 (ml/100 ml) = 1.39 X (Hb) X SpO2 [20] 
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Where (Hb) is haemoglobin concentration [209] and SpO2 is the oxygen saturation, 
measured by a pulse oximeter. Systemic oxygen delivery (DO2) was estimated by the 
following equation [20, 235]: 
DO2 = Cardiac Output X Arterial Oxygen Content (CaO2est), litres/min 
 
3.10.1. Kinetic analysis of central haemodynamic variables 
The kinetic response of cardiac output, heart rate and stroke volume refers to 63% of 
the rate of change in their values in the transition from rest to exercise (on-transient) and 
in the transition from exercise to recovery (off-transient) until the values reach a stable 
state. In recent years, kinetic analysis has been extensively applied to investigate the 
physiological mechanisms involved in altering the energy requirement of the organism. 
To date, there is no accurate interpretation of the physiological mechanisms that affect 
the cardiac output kinetic response at 63% of its exponential growth until its 
stabilization phase during high intensity exercise [236]. 
For the analysis of the kinetic response of cardiac output, the final minute of the last 
exercise bout and the first 3 minutes of recovery were used (off-transient response) for 
each exercise trial. The analysis was performed using Sigmaplot 11 software. This 
software uses the mono-exponential equation below to calculate the time required for a 
given variable to reach a steady phase as follows:  
Off-transient   → Y(t)= Y(SS)+A(1-e–(t-Td)/τ ) [237, 238] 
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3.11. Assessment of metabolic variables, breathing pattern and dynamic 
hyperinflation (Chapters 4 and 5) 
Metabolic and respiratory variables were measured breath-by-breath using a portable 
metabolic cart (K4b
2
, Cosmed, Shepperton, UK). Patients breathed through a disposable 
mouthpiece whilst using a nose clip and the following data were recorded: minute 
ventilation (VE), tidal volume (VT), inspiratory and expiratory time (Ti and Te 
respectively), breathing frequency (bf), oxygen uptake (VO2), and carbon dioxide 
output (VCO2). Before each test, the system was calibrated for volume using a 3 litres 
syringe (Cosmed) and gas calibration using a gas mixture containing 16% O2 and 5 % 
CO2 according to manufacturer instructions. 
The measurement and evaluation of dynamic hyperinflation was performed by 
assessing the inspiratory capacity (IC). The patient was sat on the cycle ergometer 
breathing normally through a mouthpiece, which was connected to the metabolic cart. 
After a few normal breaths, patients were instructed after a normal expiration to perform 
a maximum inspiratory effort up to the point of total lung capacity (TLC) and then to 
breath normally again. 
Inspiratory capacity manoeuvres were performed twice at rest and then the best 
manoeuvre was selected, ensuring that the difference between the two manoeuvres was 
less than 5% or 60ml [62]. Patients experiencing dynamic hyperinflation during exercise 
had to exhibit a reduction in inspiratory capacity (IC) from resting values ≥ 4.5% of the 
predicted normal value (reduction in the maximum inspiratory capacity compared to the 
resting value expressed as a percentage of the normal predicted value of IC at rest) or a 
difference from resting values of ≥ 150 ml [19]. 
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A plateau in oxygen uptake was identified by no change or increase of less than 150 
ml per minute in oxygen uptake (VO2) in relation to the corresponding increase in work 
load [239]. MVV was calculated using the formula below: 
FEV1 x 37.5 [240] 
3.12. Recordings of oxygen saturation 
Oxygen saturation was recorded throughout all trials using a pulse oximeter, which 
was placed on the right hand to avoid interference during blood pressure measurements. 
A meta-analysis of 21 oximeter models found a correlation coefficient ranging from r = 
0.986 to r = 0.591, with the majority of models being accurate within 2% (1 SD) or 5% 
(2 SD) of in vitro oximetry, when SpO2 is within the range of 70-100%. Additionally, 
measurements taken from the finger were found to be more accurate than those taken 
from the ear [241]. 
3.13.  Recordings of perceived symptoms 
Perception of dyspnoea and leg discomfort was recorded at the end of each test using 
the modified Borg scale [213]. This is a 10 point scale, where each point reflects a 
specific level of discomfort starting from 0 = nothing at all to 10 = maximal [213]. 
3.14. Operational thoracoabdominal volume measurements (Chapter 6) 
During both trials, chest thoracoabdominal kinematics were measured by the OEP 
(BTS, Milano, Italy) as follows: the movement of 89 retro-reflective markers placed 
front and back over the chest wall from clavicles to pubis were recorded [242]. Each 
marker was tracked by eight video cameras (Smart System BTS, Milan, Italy), four on 
the front of the subject and four behind [242]. Subjects were instructed to grasp handles 
positioned at the mid sternum level, which lifted the arms away from the rib cage so that 
the lateral markers could be visualised [242]. At baseline, patients were instructed after 
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3–4 regular tidal breaths to make two maximal inspiratory capacity (IC) efforts from 
End-Expiratory Chest Wall (EEcw) Volume to Total Chest Wall Capacity (TLCcw), in 
order to assess chest wall volume at TLC (TLCcw) and calculate Inspiratory Reserve 
Chest Wall Volume (IRVcw) at rest (Figure 3.6). Dedicated software reconstructed the 
three-dimensional coordinates of the markers in real time by stereophotogrametry and 
calculated total and compartmental chest wall volume and volume variations using 
Gauss’s theorem [242-244]. The chest wall was modelled as being composed of three 
compartments—the pulmonary and abdominal rib cage (Vrcp and Vrca), and the 
abdomen (Vab) [242]. Total thoracoabdominal volume (Vcw) is the sum of the three 
compartmental volumes [242, 245]. 
 
Figure 3.6. Typical experimental tracings of absolute chest wall volumes in a patient with COPD during 
quiet breathing (left panel) and at peak exercise (right panel). A gradual shift in volumes during exercise 
occurs because of an increase in mean end-inspiratory (EI) and mean end-expiratory (EE) chest wall 
volumes indicated by the dashed line. Chest wall volumes at total lung capacity (TLC) are indicated by an 
arrow following an inspiratory capacity manoeuvre. 
 
OEP has been used for the last two decades to non-invasively assess the total and 
compartmental chest wall volume kinematics (Vcw, Vrcp, Vrca and Vab), the total and 
compartmental breathing volumes (tidal volume, end-expiratory and end-inspiratory 
volumes) and aspects of the breathing circle (inspiratory and expiratory time, total duty 
cycle time, minute ventilation and breathing frequency), on a breath-by-breath basis 
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[245]. The validity, accuracy and reliability of the OEP have been assessed in different 
ways. OEP has a 30μm threshold for detecting linear movement, meaning that the 
software can detect changes in the position of reflecting markers, when the movement 
of the markers exceeds 30μm [245, 246]. This is translated  to a minimum change of 
around 9 ml of thracoabdominal volume for a normal adult [245]. Marker size and the 
number of cameras can affect OEP accuracy. In fact, the number of cameras can vary 
from 4 to 8 and markers from 6- to 12-mm diameters, but the greatest accuracy has been 
shown when more cameras and spherical 6-mm markers are applied [245, 246]. On the 
other hand, the accuracy of OEP to estimate dynamic volumes is not influenced by the 
magnitude of the thorax’s movement [245, 246]. The accuracy of the measurement of 
the volume recorded by OEP was investigated in the study by Massaroni and colleagues 
using a volume calibration device. They found that the volume measurement accuracy 
was always better than 6.0% of measured volume, with a volume repeatability of ±2.7 
ml [247]. 
The validity of OEP  to measure respiratory volume variations was assessed in 
healthy individuals by Aliverti and colleagues [248], by comparing the changes in chest 
wall volumes assessed by OEP,  with lung volume variations measured by spirometers 
and pneumonotachometers, which are considered the gold standard methods [249]. The 
maximum difference between spirometer and OEP measurements was reported to be 
less than 4%. In addition, the discrepancy of lung volume variations between OEP, 
spirometer and pneumotachography was lower than 5% in both the supine and prone 
position, in healthy subjects during both quiet and deep breathing [248]. 
Finally, intra-rater and inter-rater reliability of OEP has been assessed by the study of 
Vieira and colleagues, both at rest and during submaximal exercise on a cycle 
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ergometer. The intra-class correlation coefficient was higher than 0.75 and the 
coefficient of variation was lower than 10% [250]. 
The working principles of OEP are the same as those of 3D motion capture [245]. In 
particular, the 8 cameras that capture the position of the 89 reflecting markers are 
connected with a computer. The input and output information is analysed by  software  
that computes the marker 3D trajectories, integrating the information collected from 
each camera [245]. Then, a geometrical model is applied: a closed surface is defined 
starting from connecting each triplet of markers to form a triangle. From each closed 
surface, the volume contained in this surface is calculated [245]. 
For each triangle – identified by 3 markers – the area (S) and the direction of normal 
vector (n) are calculated and the volume contained in this surface can be calculated 
using the Gauss theorem [243, 244] as in the following equation: 
 [245], 
where F is an arbitrary vector, S is a closed surface, V is the volume enclosed by S, and 
n is the normal unit vector on S [245]. 
The OEP thoracoabdominal wall (CW) model can be divided into 3 compartments, 
consisting of the pulmonary rib cage (RCp), the abdominal rib cage (RCa), and the 
abdomen (Ab) (Figure 3.7). The 3-compartment model allows the following phenomena 
to be considered: (a) that RCp and RCa are exposed at different pressures during 
inspiration, (b) the diaphragm acts directly only on RCa, and (c) non-diaphragmatic 
inspiratory muscles act largely on RCp and not on RCa [251]. Regarding the abdomen 
(Ab), Ab volume change is defined as the volume swept by the abdominal wall [251-
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253], and it is the result of the conjunct action of the diaphragm and expiratory 
abdominal muscles [245]. 
 
Figure 3.7. OEP cameras (A & B), OEP markers placed on patient sitting on a cycle ergometer (C & D), 
graphical presentation of the 3D model and the three compartments (E, F & G). 
 
3.15. Assessment of usability, applicability and comfort of using the VitaBreath 
device during activities of daily living 
Data were collected via telephone interview conducted by a research respiratory 
nurse at the Respiratory Medicine Department, North Tyneside General Hospital [20]. 
Support was provided to the patients either by the respiratory nurses or the investigator 
via phone if necessary.  
3.16. Sample size justification (Chapters 4, 5 and 7) 
Verification of sample size within each exercise modality was based on the study by 
Bianchi and colleagues [44] comparing pressure support ventilation (PSV) to control 
breathing during exercise [20]. Using the mean difference in endurance time (3.4 min) 
between PSV and control breathing, and standard deviation (SD) (4.6 min), an alpha 
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significance level of 0.05 (2-sided) and 90% power, a minimum total sample size of 10 
patients was calculated to be sufficient to detect significant differences in endurance 
time between pNIV and PLB trials within each exercise modality [20]. To compensate 
for possible dropouts (i.e., 20%), a total sample size of 24 patients was recruited [20]. 
Randomisation was performed following the CPET by independent staff within North 
Tyneside General Hospital and stratified by WRpeak (<50 or ≥50 watts) and FEV1 (<50 
or ≥50% predicted) using a block size of 4. The study team was blinded to the 
randomisation sequence [20]. 
3.17. Statistical analysis 
3.17.1. Chapter 4 
This study was an observational study and therefore only descriptive statistical 
analysis has been performed within the results. The data collected is expressed as 
absolute values and presented as mean±SD or expressed as percentages of the total 
sample size (%) unless otherwise stated. The reference values of normal physiological 
responses during CPET for healthy, age matched subjects are presented in Table 3.1 
[254, 255]. The methodology used to identify if maximal effort was reached by patients 
during the test and which exercise responses limited exercise tolerance are presented in 
Figure 3.8 [214].  
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Table 3.1 Normal physiological responses during CPET 
Variable  Normative Value  
VO2 >83-84% predicted 
VE/MVV <0.75-0.80 
VE/VCO2 <34 
VT/IC <0.70-0.75 
Bf <50-60 breaths/min 
HR HRmax >90% age predicted 
VO2 /HR  >80% 
SpO2 >93% 
VO2, oxygen uptake; VE, minute ventilation; MVV, Maximum voluntary ventilation; 
VCO2, carbon dioxide expired; VT, tidal volume; IC, inspiratory capacity; bf, breathing 
frequency; HR, heart rate; SpO2, arterial oxygen saturation. [9, 255]  
 
 
Figure 3.8. Methodology to determine whether patients achieved peak effort during exercise (top left 
diagram), whether patients exercise response was abnormal (top right diagram) and to detect locus of 
limitation (bottom diagram) [214]. 
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3.17.2. Chapter 5 
Data are presented as mean±SD unless otherwise stated. Independent sample t-tests 
were employed to detect differences between the two groups in baseline characteristics 
and physiological responses during peak exercise. Independent sample t-tests were 
employed to detect differences in exercise tolerance (minutes) between moderate- and 
high-intensity exercise modalities and paired samples t-test between pNIV and PLB 
breathing modalities. Paired sample t-tests were employed to detect changes in mean 
response time of central haemodynamics between pNIV and PLB application. For each 
individual patient, the duration of exercise tolerance (including the recovery phases) 
when using the PLB technique was divided into four percentiles (i.e., 25%, 50%, 75% 
and 100%) of total endurance time in order to normalise endurance time across all 
patients [20]. A two-way ANOVA with repeated measurements followed by appropriate 
post hoc analysis was employed to compare changes at iso-time across these four 
percentiles between the PLB and pNIV trials for: IC, CO, DO2, breathlessness and leg 
discomfort. For IC, the change between recovery periods and the end of exercise bouts 
was calculated [20]. Analysis of data for the familiarisation phase included one-way 
ANOVA to detect differences in exercise load, symptoms of breathlessness and leg 
discomfort, heart rate and arterial oxygen saturation across the 8 sessions. Level of 
significance for all analyses was p<0.05. 
For the analysis between DH responders and DH non-responder (see below) data are 
presented as mean±SEM rather than SD because the comparisons of interest were in the 
mean values of various physiological variables under the two different breathing 
modalities (pNIV and PLB). Additionally, as exercise time was different between the 
pNIV and PLB trials within the high- and moderate-intensity intermittent protocols, 
physiological measures were compared at the time point where the shortest trial (pNIV 
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or PLB) was terminated (i.e. at exercise iso-time) [24]. Dynamic hyperinflation (DH) 
response at exercise iso-time was calculated as the difference in inspiratory capacity 
(IC) between PLB and pNIV [(i.e.: IC pNIV - IC PLB (a positive value indicating 
improvement with pNIV)]. Patients who showed a clinically significant increase in IC 
(≥ 4.5% of predicted resting IC [19]) when using pNIV compared to the PLB technique 
at exercise iso-time were identified as ‘DH non-responders’. Patients showing a less 
than the clinically significant increase, [19] or a decrease in IC using pNIV compared to 
PLB were defined as ’DH non-responders’. Independent sample t-tests were carried out 
to compare variables between responders and non-responders for the baseline 
demographic and lung function characteristics. Two-way ANOVA with repeated 
measures followed by LSD pot-hoc analysis was employed to compare physiological 
changes at exercise iso-time between pNIV and PLB techniques in both responders and 
non-responders. The level of significance for all analyses was set at p<0.05. 
3.17.3. Chapter 6 
Data are presented as mean±SD unless otherwise reported. The Shapiro-Wilk test 
was used to check that data was normally distributed. Thoracoabdominal and circulatory 
responses across the 5 exercise bouts using the pNIV method or the PLB technique 
were averaged over the last minute of each exercise bout, and over each minute of 
recovery. Two way repeated measures ANOVA was employed to detect differences 
across different time-points [baseline, exercise, first  minute of recovery (with pNIV or 
PLB) and second  minute of recovery (quiet breathing)] between the two breathing 
conditions (i.e. with and without use of the VitaBreath device) followed by LSD post-
hoc test for the following variables (compartmental thoracoabdominal volumes and 
central haemodynamic data). Paired t-tests were employed to compare breathing pattern 
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and ventilatory responses during the first minute of recovery between the pNIV and 
PLB methods. The level of significance for all analysis was set at p<0.05. 
3.17.4. Chapter 7 
Data are presented as median (IQR) or absolute number (%). The Wilcoxon signed-
rank test was used for comparing 2- and 12-week interval scale (Likert style) data and 
McNemar’s test for nominal response data. The level of significance for the analyses 
was set at p < 0.05 [20]. 
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4. Locus of exercise intolerance in the COPD 
population studied 
4.1.  Introduction 
Patients with COPD exhibit lower exercise capacity compared to age matched 
healthy individuals [17, 86]. Exercise intolerance in patients with COPD is 
multifactorial and includes ventilatory, gas exchange, central haemodynamic and 
locomotor muscle abnormalities [18]. The se abnormalities impair adequate oxygen 
transport to the working muscles thereby limiting oxygen utilisation and exacerbating 
leg discomfort [18]. 
Patients with COPD often have reduced ventilatory capacity due to expiratory flow 
limitation that causes air trapping in the lungs, a phenomenon called hyperinflation [18, 
55]. Hyperinflation is getting worse with increased ventilation (dynamic hyperinflation) 
and further increases end-expiratory lung volumes [55]. The increased end-expiratory 
lung volumes result in greater work of breathing, hence increasing metabolic 
requirements of the respiratory muscles [18]. 
In addition, dynamic hyperinflation increases intrathoracic pressure swings, which 
reduce venous return and thus cardiac output [57, 94, 98, 99]. This further impairs 
oxygen transport to the locomotor muscles [18]. Moreover, increased respiratory muscle 
work may potentially increase the competition for blood flow between the respiratory 
and locomotor muscles [18]. 
Non-invasive ventilation (NIV) is widely used as an effective way to treat patients 
with respiratory failure [168-171] both in the acute setting (during hospitalisation and 
ICU) [172] and at home (during daily living) [173]. The aim of NIV is to assist 
ventilation mainly by reducing the work of breathing, improving inspiratory flow rate, 
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controlling ventilation and resetting the central respiratory drive [175]. Thus, the main 
benefit of NIV is the improvement in expiratory flow limitation and dynamic 
hyperinflation collectively resulting in reduced work of breathing. 
The overarching purpose of this dissertation was to study the effects of portable NIV 
(pNIV) on dynamic hyperinflation, breathlessness and exercise tolerance in patients 
with COPD. Accordingly, the scope of the present cross sectional study was to identify 
patients experiencing profound exercise-induced dynamic hyperinflation as the primary 
locus of exercise limitation in order to subsequently investigate the effect of pNIV on 
dynamic hyperinflation on this population.  
4.1.1. Main outcomes 
4.1.1.1.Primary Outcome 
The primary outcome of the study was the manifestation of dynamic hyperinflation 
during incremental cardiopulmonary exercise testing (CPET). 
4.1.1.2. Secondary Outcomes 
Secondary outcomes included the following: 
 Ventilatory factors (breathing frequency, tidal volume, minute ventilation, 
minute ventilation / maximal voluntary ventilation, dyspnoea, minute 
ventilation / oxygen uptake and minute ventilation / carbon dioxide 
output) 
 Haemodynamic factors (heart rate, stroke volume, cardiac output, 
systemic oxygen delivery, systolic blood pressure, diastolic blood 
pressure and mean blood pressure) 
 Metabolic factors (oxygen uptake, carbon dioxide production, oxygen 
uptake relative to work rate, leg discomfort) 
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4.2.Methods 
4.2.1. Study design 
This was a cross sectional study investigating respiratory, central haemodynamic and 
metabolic factors during a cardiopulmonary exercise test to the limit of tolerance 
(Figure 3.2). During this study patients underwent a ramp incremental CPET in order to 
determine the locus of exercise limitation, magnitude of dynamic hyperinflation and 
peak exercise capacity (WRpeak). Patients were on optimal bronchodilator therapy 
including daily LAMA and LABA prior to their participation in the study. Tests were 
performed without supplemental oxygen.  
 
4.3.Results 
4.3.1. Patient characteristics 
Demographic characteristics of patients who performed the ramp incremental CPET 
are presented in table 4.1. Patients exhibited severe airway obstruction (GOLD stage 3) 
[1] and lung hyperinflation at rest. Prior to participation in the study, all patients were 
confirmed as previous smokers, had no exacerbations within the last six weeks and no 
other uncontrolled comorbidities, in accordance with the study inclusion and exclusion 
criteria. Five (20.8%) of the patients were current smokers, with 14 (58.3%) having 
been admitted to hospital for an exacerbation of COPD (ECOPD) in the past 12 months. 
The median number of ECOPD (hospital or community managed) in the past 12 months 
was 2 (1–4.75). The median extended MRC dyspnoea score (eMRCD) was 3.6 (3–4) 
(Table 4.1) [20, 212, 256]. 
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Table 4.1 Demographic characteristics of patients at baseline. 
Variable n = 24 
Gender (M/F) 10/14 
Age (years) 67±8 
BMI 26.3±6.9 
FEV1 (litres) 1.14±0.59 
FEV1 (% predicted) 46±18 
FVC (litres) 2.71±0.85 
FVC (% predicted) 89±20 
FEV1/FVC (%) 41±13 
RV (litres) 4.53±1.56 
RV (% predicted) 205±63 
IC (litres) 2.00±0.67 
IC (% predicted) 79±22 
TLC (litres) 7.30±1.66 
TLC (% predicted) 130±24 
FRC (litres) 5.31±1.55 
FRC (% predicted) 173±44 
IC/TLC (%) 28±9 
RV/TLC (%) 59±10 
DLco (litres) 2.99±1.97 
DLco (% predicted) 38±18 
eMRCD 3.6±0.5 
BMI, body mass index; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; 
RV, residual volumes; IC, inspiratory capacity; TLC, total lung capacity; FRC, functional residual 
capacity; DLco, transfer factor of the lung for carbon monoxide; eMRCD, median extended MRC 
dyspnoea score, M, male; F, female; values are mean ± standard deviation (SD) [20]. 
 
4.3.2. Cardiopulmonary exercise test (CPET) 
Peak exercise capacity was severely impaired; patients exhibited profound exercise-
induced dynamic hyperinflation and moderate arterial oxygen desaturation, at the limit 
of tolerance during the incremental CPET (Table 4.2) [20]. WRpeak and VO2peak were 
substantially reduced compared to normal predicted levels, and minute ventilation 
exceeded 85% of MVV (Table 4.2).  
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Table 4.2 Peak physiological variables at the limit of tolerance during 
cardiopulmonary exercise test (CPET). 
Variable All (n=24) 
WR (Watts) 48±26 
WR (% predicted) 46±23 
CPET duration (minutes) 6.8±2.5 
VO2 (ml/kg/min) 13.5±3.7 
VO2 (% predicted) 60±17 
VCO2 (ml/min) 909±463 
RER 0.91±0.08 
bf (breaths/min) 30±6 
VT (litres) 1.2±0.5 
VE(l/min) 37.5±18.1 
VE/VO2 38±5 
VE/VCO2 42±7 
VE/MVV (%) 99±24 
ΔIC from rest (litres) 0.55±0.35 
VT/IC (%) 60±10 
SpO2 (%) 92±4 
CO (L/min) 10.7±2.9 
HR (beats/min) 112±17 
HR (% predicted) 73±11 
SV (ml) 96±22 
VO2/HR (ml/beat) 8.7±3.2 
SBP (mmHg) 150±18 
DBP (mmHg) 88±10 
Dyspnoea (Borg 1–10) 4.0±1.1 
Leg discomfort (Borg 1–10) 3.6±1.4 
WR, work rate; VO2, oxygen uptake; VCO2, carbon dioxide expired; RER, respiratory 
exchange ratio; bf, breathing frequency; VT, tidal volume; VE, minute ventilation; MVV, 
Maximum voluntary ventilation; ΔIC, change from rest in inspiratory capacity; SpO2, arterial 
oxygen saturation; CO, cardiac output; HR, heart rate; SV, stroke volume; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; Values are mean ± SD. 
 
4.3.2.1.Presence and pattern of dynamic hyperinflation 
All 24 patients (100%) manifested exercise-induced dynamic hyperinflation as 
inspiratory capacity was reduced from baseline by more than 4.5% of predicted or by 
more than 150 ml at the limit of tolerance during the ramp incremental CPET [19] 
(Figure 4.1a). Furthermore, the results revealed that 83% of patients were hyperinflated 
in the early stages of exercise (early hyperinflators) whilst 17% of the patients were 
hyperinflated close to the end of the exercise (late hyperinflators) [85] (Figure 4.1b). 
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Figure 4.1. a) Percentage of patients hyperinflated during the ramp incremental CPET and b) percentage 
of patients that hyperinflated in early (black column) and late (grey column) stages of exercise. 
 
4.3.2.2. Ventilatory variables 
At the limit of tolerance, VE/MVV was 99±24% indicating that patients reached their 
ventilatory ceiling, whilst VT/IC was 60±10% indicating mechanical restriction to tidal 
volume expansion. In addition, the average change in inspiratory capacity from baseline 
was 0.55±0.35 litres, whilst data also demonstrated mild to moderate arterial oxygen 
desaturation. Furthermore, at the limit of tolerance moderate to severe dyspnoea was 
reported by the patients (4.0±1.1) (Table 4.2). 
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4.3.2.3. Central haemodynamic variables 
At the limit of tolerance cardiac output was 10.7±2.9 litres and heart rate reached 
73% of peak predicted heart rate (112±17 beats/min). Peak oxygen pulse was 8.7±3.2 
ml/beat, whilst both systolic and diastolic blood pressures were increased at the limit of 
tolerance (150±18 mmHg and 88±10 mmHg, respectively), responding appropriately 
during exercise (Table 4.2). 
4.3.2.4. Metabolic variables 
Peak exercise capacity was severely impaired reaching 46±23% of predicted (48±26 
Watts). Peak oxygen uptake was also impaired reaching only 60±17% of predicted 
(13.5±3.7 ml/min/kg); whilst VCO2 was 909±463 ml/min. Accordingly, average 
respiratory exchange ratio (RER) was relatively low (0.91±0.08). Finally, at the limit of 
tolerance patients felt moderate leg discomfort assessed by the Borg scale (3.6±1.4) 
(Table 4.2). 
4.3.2.5. Determinants of peak exercise capacity 
According the recent European Respiratory Society (ERS) statement on 
standardisation of CPET in chronic lung diseases [214], 23 patients (96%) reached their 
peak exercise capacity whilst only 1 patient (4%) stopped the test before reaching 
maximal effort (Figure 4.2a). Peak exercise capacity was established by a VO2 plateau 
in 20 patients, VE/MVV greater than 85% in 18 patients and RER greater than 1.05 in 1 
patient. None of the patients increased heart rate more than 90% predicted (Figure 4.2b).  
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Figure 4.2. a) Presentence of patients who reached peak (maximal) effort during exercise (black column) 
and patients who did not reach peak effort (grey column) and b) number of patients who met the criteria 
to determine maximal effort during the CPET. VO2, oxygen uptake; VE, minute ventilation; MVV, 
maximal voluntary ventilation; RER, respiratory exchange ratio. 
 
4.3.2.6. Evaluation of the abnormal exercise responses 
As previously mentioned, 23 participants reached peak/maximal effort during 
exercise during the ramp incremental CPET. The exercise response was abnormal 
relative to normal predicted values according to the criteria shown in Figure 3.8 [214]. 
Particularly, in 21 patients (92%) peak oxygen uptake was less than 85% of predicted 
and peak heart rate was lower than 90% of predicted (Figure 4.3). Moreover, in 18 
patients (79%) minute ventilation exceeded 85% of voluntary minute ventilation 
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indicating presence of ventilatory constraints, whilst 12 patients (54%) were severely 
desaturated (more than 5%) from baseline (Figure 4.3). Finally, in 7 patients (29%) 
oxygen uptake was less than 50% of predicted at the anaerobic threshold (Figure 4.3).  
 
Figure 4.3. Presence of abnormal responses during ramp incremental CPET. VO2, oxygen uptake; HR, 
heart rate; VE, minute ventilation; MVV, maximal voluntary ventilation; AT, anaerobic threshold.  
 
4.3.2.7. Locus of exercise limitation 
The limitation of exercise in patients with COPD can be the result of abnormal 
response of the respiratory, cardiovascular or peripheral cellular muscle metabolic 
function or a combination of abnormalities in all physiological systems [18]. The data 
revealed that 19 patients (83%) were limited by only one, 3 patients (13%) were limited 
by two, whilst 1 patient (4%) was limited by three of the aforementioned physiological 
system abnormalities. In twenty of the patients who achieve peak effort during the ramp 
incremental CPET (87%), exercise was limited due to respiratory function abnormalities 
(Figure 4.4). Three patients (13%) had cardiovascular limitations, four patients (17%) 
had peripheral muscle dysfunction and only one patient (4%) had physical 
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deconditioning (Figure 4.4). The primary locus of limitation was determined based on 
how many of the criteria within the different physiological systems were met (Figure 
3.8) [214]. 
 
Figure 4.4. Primary locus of exercise limitation. 
 
4.3.2.8. Perceived symptoms at the limit of tolerance 
The main symptom limiting exercise tolerance in the present study was 
breathlessness as 50% of the patients (n=12) reported this as the main reason for 
stopping the exercise. In contrast, 37% of the patients (n=9) reported that the main 
symptom that limited their exercise tolerance was leg discomfort, whilst 13% (n=3) of 
the patients reported that both symptoms were equally severe at the end of exercise, thus 
causing them to terminate exercise (Figure 4.5). 
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Figure 4.5. Reported reason for exercise termination 
 
4.4. Discussion  
The main finding of the current study was that all 24 participants were dynamically 
hyperinflated (Figure 4.2a) and the majority of participants were hyperinflated during 
the early stages of the ramp incremental CPET (Figure 4.2b). As a result the primary 
locus of exercise limitation was of respiratory origin (Figure 4.4) and the major limiting 
symptom was breathlessness (Figure 4.5). None of the participants reached the 
predicted maximal levels of exercise during the ramp incremental cardiopulmonary 
exercise test (Figure 4.1a).  
Dynamic hyperinflation is a key factor that limits exercise tolerance in patients with 
COPD [19] due to its effects on respiratory function [18, 19], oxygen transportation [18] 
and respiratory mechanics [98]. Previous studies have estimated that the phenomenon of 
dynamic hyperinflation during exercise manifests in approximately 80-85% of patients 
with moderate to severe COPD [19, 257]. However, a study by Vogiatzis and 
colleagues suggested that dynamic hyperinflation occurs in all patients with moderate to 
severe or severe COPD but at different levels of exercise [85]. In fact, it was found that 
60% of patients with severe COPD were hyperinflated during the early stages of a 
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CPET [85]. In the present study all patients were hyperinflated at the limit of tolerance; 
20 patients (83%) were hyperinflated in the early stages of exercise (early 
hyperinflators), whilst 4 patients (17%) were hyperinflated only at the very late stages 
of exercise (late hyperinflators), confirming the results from the study by Vogiatzis and 
colleagues [85]. 
Despite the presence of dynamic hyperinflation in all patients, 23 out of 24 patients 
were able to achieve true peak levels of effort during the ramp incremental CPET. 
When CPET is performed correctly it is considered the gold standard to identify the 
factors limiting exercise tolerance [258]. In the present study, CPET was performed in 
accordance to the European Respiratory Society statement on standardisation of CPET 
in chronic lung diseases [214]  and the outcomes were assessed based on the same 
guidelines [214]. Ideally, a ramp incremental CPET should last between 8 and 12 
minutes in order to be able to record valid diagnostic information [259]; however this is 
not always applicable in patients with COPD due to the pathophysiology of the disease. 
In the present study the average duration of the CPET was 6.8 minutes, which is in 
accordance with other studies in patients of similar severity of COPD [85, 260]. 
Although patients were able to reach maximal effort during exercise this was only 46% 
of the predicted normal peak work rate for this population. During the test one patient 
did not meet any of the criteria to characterise the effort as maximal. However, at the 
end of the CPET this patient reported severe leg discomfort and moderate 
breathlessness (5 and 3 in Borg scale, respectively), suggesting that early termination of 
the test was mainly due to physical deconditioning. 
Lower aerobic capacity in patients with COPD compared to age matched healthy 
sedentary individuals is well established [18, 255]. In the present study the average peak 
oxygen uptake (VO2peak) was 60% predicted and in the majority of patients (n=22). 
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These results are in accordance with the literature in patients with COPD, where the 
average peak oxygen uptake ranges between 50% and 62% predicted [19, 85]. Low 
oxygen uptake is the result of dysfunction in the systems involved in oxygen transport 
to the working muscles [18], which eventually limits exercise capacity. In addition, VO2 
at anaerobic threshold is another variable that is used to determine normal physiological 
responses during the CPET [214]. When VO2 at anaerobic threshold is less than 50% of 
predicted VO2peak it is deemed to be an abnormal response [214, 255], considering that 
normal values for healthy, age matched subjects usually exceed 83% predicted [255]. In 
the present study 7 out of 24 participants had a VO2 of less than 50% of predicted VO2. 
The causes of reduced VO2 both at the anaerobic threshold and at the limit of tolerance 
include i) low arterial oxygen content due to gas exchange abnormalities [18] ii) 
reduced cardiac output and oxygen transport due to reduced venous return secondary to 
dynamic hyperinflation and increased intrathoracic pressures swings [18, 258] and iii) 
low oxidative capacity of the locomotor muscles [18]. 
In the present study reduced cardiac output was also associated with increased heart 
rate reserve as peak heart rate reached only 73% predicted. This was mainly the result of 
the low peak exercise capacity of the patients, as exercise testing was terminated, 
primarily due to ventilatory restrictions well before the cardiovascular system was 
highly taxed [18]. In fact, in the current study ventilatory reserve as reflected by the 
ratio of VE/MVV was 99%. In healthy people VE/MVV does not exceed 80% [255] at 
peak exercise. Values exceeding 85% are considered abnormal [214, 258] and are 
associated with the presence of dynamic hyperinflation [19, 85, 261] and increased 
breathlessness during exercise [70, 262] and thus, it is a common factor that limits 
exercise tolerance in patients with COPD [18]. 
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The present study succeeded in identifying patients with ventilatory constraints as the 
main locus of exercise limitation. The most common factor limiting exercise appeared 
to be the respiratory system, which as a primary limiting factor was evident in 87% of 
the patients. This was expected as respiratory limitation is a defining characteristic 
during exercise in patients with COPD, as the pathophysiology of the disease is strongly 
associated with expiratory flow limitation during high levels of ventilation leading to 
dynamic hyperinflation [18, 19, 29, 85, 257]. Furthermore, small number of patients 
also manifested additional limitations of the cardiovascular system and to a lesser 
degree of muscle cellular dysfunction [18, 263, 264].   
Symptom sensation is another factor that contributes to exercise limitation. In the 
present study half of the patients reported breathlessness, whilst 9 patients reported leg 
discomfort as the primary reason for stopping exercise. Finally, 3 patients reported that 
breathlessness and leg discomfort were equally intolerable at the limit of tolerance. 
These findings provide further evidence of the interaction between the different 
impaired physiological systems, as explained earlier in this section. The data of the 
present study are in line with other studies that used the same ramp incremental CPET 
protocol in patients with COPD [85]. 
Study limitations 
The present study has some limitations. Firstly, dynamic hyperinflation was assessed 
using inspiratory capacity (IC) manoeuvres. IC manoeuvres are deemed to be a reliable 
method to assess dynamic hyperinflation [19, 85], however they are dependent on the 
ability of the patient to perform the manoeuvre properly during exercise. Patients were 
familiarised with the manoeuvre, but it is possible that this may have influenced the 
recording data in some cases. Another limitation of the study was that patients might 
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have overestimated or underestimated their symptoms of breathlessness and leg 
discomfort at the limit of tolerance. To minimise this, all patients were familiarised with 
the Borg scale prior to the test and some patients used this scale during past 
rehabilitation programmes. Moreover, the seat of the bike was uncomfortable for most 
of the patients, however this did not prevent patients from completing the test 
successfully. 
4.5. Conclusions 
The present study identified dynamic hyperinflation as the main factor limiting 
exercise tolerance in patients with moderate to severe and severe COPD.  The purpose 
of the study was to confirm the presence of dynamic hyperinflation and abnormal 
ventilatory response in this population, and thus to confirm patient eligibility to 
participate in subsequent studies investigating the effect of pNIV application on 
exercise tolerance. Accordingly, Chapter 5 reports on the effect of pNIV application on 
exercise tolerance in patients with COPD. 
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5. Acute effects of the use of the VitaBreath device 
during exercise in patients with Chronic Obstructive 
Pulmonary Disease (COPD) 
5.1.  Introduction 
Exercise training is the cornerstone of Pulmonary Rehabilitation (PR), inducing 
clinically meaningful improvements in exercise tolerance in patients with chronic 
obstructive pulmonary disease (COPD) [20, 265]. Dynamic hyperinflation (DH) during 
exercise limits the normal increase in tidal volume, worsening breathlessness and 
reducing exercise capacity [19, 20]. Additionally, DH and the concomitant high mean 
intrathoracic pressure swings are associated with adverse effects on central 
hemodynamic regulation, reducing the supply of oxygenated blood to deconditioned 
peripheral muscles [18, 20, 21]. This contributes to leg discomfort and further limits 
exercise tolerance. Different ergogenic strategies have been successfully employed to 
reduce exercise-induced breathlessness and leg discomfort, including oxygen and heliox 
supplementation, non-invasive ventilation (NIV) and various intermittent exercise 
modalities [20, 22-25]. Oxygen supplementation is commonly used during exercise in 
order to reduce desaturation and breathlessness [20, 26]. Heliox supplementation is 
beneficial but impractical and expensive, therefore it is primarily used for research 
purposes [28]. Standard NIV is infrequently used due to the difficulties associated with 
applying bulky equipment and the need for close supervision during exercise training 
[20, 49]. 
The VitaBreath (Philips, Respironics, Morrisville, PA, USA) is a portable, handheld, 
battery-powered, non-invasive ventilation device (pNIV) intended to reduce activity-
related shortness of breath [20, 215]. It delivers 18 cm H2O inspiratory and 8 cm H2O 
expiratory pressures, but can only be used during recovery periods interspersing bouts 
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of physical activity. The purpose of this study was to test the effect of pNIV compared 
to pursed lip breathing (PLB) on dynamic hyperinflation, breathlessness and exercise 
tolerance in patients with COPD [20]. A secondary aim of the present study was to 
compare the baseline characteristics, the respiratory and circulatory responses during 
exercise and qualitative outcomes between dynamic hyperinflation DH responders and 
DH non-responders. Response was defined in terms of DH as it is an objective 
physiological index that determines the clinical response. Exercise tolerance comprised 
two different intermittent protocol modalities, namely moderate-intensity (6 min at 60% 
peak work rate (WRpeak)) and high-intensity (2 min at 80% WRpeak) exercise [20]. As 
both modalities are recommended by the British Thoracic Society and joint American 
Thoracic Society/European Respiratory Society guidelines for PR [165, 266], the 
purpose was to explore whether pNIV support was equally as effective during exercise 
comprising different intensity and duration characteristics [20]. 
It was hypothesised that the use of pNIV compared to PLB would increase exercise 
tolerance by reducing dynamic hyperinflation and the intensity of breathlessness during 
bouts of moderate- or high-intensity intermittent exercise and would confer greater 
benefit if used more frequently with the high-intensity protocol [20]. 
5.1.1. Main outcomes 
5.1.1.1. Primary Outcome 
The primary outcome of the study was exercise tolerance during moderate and high 
intensity exercise [20]. 
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5.1.1.2. Secondary Outcomes 
Secondary outcomes include the following [20]: 
 Dynamic hyperinflation 
 Symptoms of breathlessness and leg discomfort 
 Central haemodynamic responses (cardiac output, stroke volume and 
heart rate, systemic oxygen delivery, systolic blood pressure, diastolic 
blood pressure and mean blood pressure) 
 Respiratory and gas exchange responses (oxygen uptake, carbon dioxide 
production, minute ventilation, tidal volume, breathing frequency and 
inspiratory capacity) 
5.2. Methods 
5.2.1. Study design 
This was a randomised, open-label cross-over trial comparing the use of pNIV to 
PLB during recovery periods in two different intermittent exercise regimes (Figure 3.3 a 
& b) [20]. Prior to exercise testing all patients underwent a 4-week familiarisation 
programme to be accustomised with the exercise protocols, the use of the VitaBreath 
device and the correct adoption of PLB with guidance from a physiotherapist [20]. 
Following the familiarisation phase, patients were randomly assigned to a high-intensity 
(HI) or a moderate-intensity (MOD) protocol [20]. Within these groups, each patient 
performed two visits using both pNIV and PLB during recovery from exercise in a 
balanced order (Figure 3.3 a & b) [20]. Patients were on optimal bronchodilator therapy 
including daily LAMA and LABA and no changes to medication were made during the 
trial. Tests were performed without supplemental oxygen [20].  
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5.3.Results 
5.3.1. Patient characteristics and peak exercise data between high-intensity and 
moderate-intensity 
Patients randomised to the two different exercise modalities were matched in terms 
of demographic and clinical characteristics, exhibiting severe airflow limitation and 
lung hyperinflation at rest without resting hypoxemia (Table 5.1.) [20]. In addition, 
patients in the two different exercise modalities were matched in terms of their peak 
exercise capacity and the responses during the ramp incremental CPET (Table 5.2.) 
(findings from the ramp incremental CPET are presented in details in Chapter 4). Prior 
to randomisation, all participants were confirmed as previous smokers, had no 
exacerbations within the last six weeks and no other uncontrolled comorbidities, in 
accordance with the study inclusion and exclusion criteria [20]. Five (20.8%) of the 
patients were current smokers, with 14 (58.3%) having been admitted to hospital for an 
exacerbation of COPD (ECOPD) in the past 12 months. The median number of ECOPD 
(hospital or community managed) in the past 12 months was 2 (1–4.75) [20]. The 
median extended MRC dyspnoea score (eMRCD) was 4 (3–4) [212, 256]. 
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Table 5.1 Demographic characteristics of patients at baseline. 
Variable 
High-Intensity 
(n = 13) 
Moderate-
intensity (n = 11) 
p-Value 
Gender (M/F) 5/8 5/6  
Age (years) 66±7 68±10 0.510 
BMI 26.9±6.9 25.6±6.8 0.659 
FEV1 (% predicted) 46±15 46±21 0.948 
FVC (% predicted) 87±18 91±21 0.605 
FEV1/FVC (%) 43±14 37±12 0.487 
IC (litres) 1.96±0.56 2.03±0.78 0.810 
IC (% predicted) 79±22 78±23 0.807 
TLC (% predicted) 130±29 131±15 0.975 
FRC (% predicted) 172±49 175±37 0.845 
DLco (% predicted) 38±18 38±20 0.980 
M, male; F, female; BMI, body mass index; FEV1, forced expiratory volume in the first second; FVC, 
forced vital capacity; IC, inspiratory capacity; TLC, total lung capacity; FRC, functional residual 
capacity; DLco, transfer factor of the lung for carbon monoxide; WR, work rate, values presented as 
mean ± standard deviation (SD) [20]. 
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Table 5.2. Peak physiological variables at the limit of tolerance during 
cardiopulmonary exercise testing (CPET). 
Variable 
High-Intensity 
(n = 13) 
Moderate-Intensity 
(n = 11) 
p-Value 
WR (Watts) 48±25 48±26 0.977 
WR (% predicted) 46±19 45±26 0.883 
VO2 (ml/kg/min) 13.5±3.9 13.4±3.2 0.808 
VO2 (% predicted) 60±12 61±21 0.911 
VCO2 (ml/min) 907±471 912±476 0.981 
RQ 0.89±0.06 0.93±0.09 0.287 
bf (breaths/min) 31±5 29±6 0.551 
VT (litres) 1.2±0.5 1.2±0.5 0.917 
VE(l/min) 39.1±20.2 35.5±16.0 0.633 
VE/VO2 (%) 39±5 37±6 0.620 
VE/VCO2 (%) 43±9 41±8 0.407 
VE/MVV (%) 1.00±0.21 0.99±0.26 0.787 
ΔIC from rest (litres) 0.60±0.38 0.47±0.33 0.399 
VT/IC (%) 61±10 58±10 0.407 
SpO2 (%) 92±5 92±3 0.827 
CO (L/min) 10.5±3.9 11.2±2.7 0.635 
HR (beats/min) 113±15 110±18 0.728 
HR (% predicted) 74±10 72±12 0.651 
SV (ml) 94±30 101±19 0.513 
VO2/HR (ml/beat) 8.8±3.6 8.6±2.9 0.905 
SBP (mmHg) 149±15 151±22 0.817 
DBP (mmHg) 89±6 87±13 0.466 
Dyspnoea (Borg 1-10) 4.2±1.2 3.8±0.7 0.269 
Leg discomfort (Borg 1-10) 3.8±1.1 3.3±1.6 0.442 
WR, work rate; VO2, oxygen uptake; VCO2, carbon dioxide expired; RQ, respiratory quotient 
for oxygen uptake; bf, breathing frequency; VT, tidal volume; VE, minute ventilation; MVV, 
Maximum voluntary ventilation; ΔIC, change from rest in inspiratory capacity; SpO2, arterial 
oxygen saturation; CO, cardiac output; HR, heart rate; SV, stroke volume; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; Values are mean ± SD. 
 
 
5.3.2. Effect of familiarisation program on exercise capacity, symptoms, heart rate 
and oxygen saturation 
Exercise capacity was significantly increased at the end of the familiarisation period 
by 86% (38.3±19.4 Watts) compared to the first session (20.6±15.0 Watts) (p=0.002) 
(Figure 5.1).  
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Figure 5.1. Progression of work rate during each familiarisation session. *=p<0.05 compared to 1
st
 
session. Data are presented as mean ± standard error of the mean (SEM). 
 
Despite the increase in work load, symptoms of both dyspnoea (p=0.835) (Figure 
5.2) and leg discomfort (p=0.982) (Figure 5.3) remained unchanged during the eight 
familiarisation sessions indicating true physiological training effects. 
 
 Figure 5.2. Progression of dyspnoea during each familiarisation session. Data are presented as mean ± 
standard error of the mean (SEM). 
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Figure 5.3. Progression of leg discomfort during each familiarisation session. Data are presented as mean 
± standard error of the mean (SEM). 
 
Furthermore, during the exercise familiarisation sessions heart rate was not increased 
(p=0.423) (Figure 5.4), whilst arterial oxygen saturation was unaffected (p=0.973) 
(Figure 5.5) during the eight familiarisation sessions. 
 
Figure 5.4. Progression of heart rate during each familiarisation session. Data are presented as mean ± 
standard error of the mean (SEM). 
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Figure 5.5. Progression of arterial oxygen saturation during each familiarisation session. Data are 
presented as mean ± standard error of the mean (SEM). 
 
5.3.3. Effect of pNIV on endurance time during high- and moderate-intensity 
exercise 
Compared to PLB, pNIV increased exercise endurance time for both intermittent 
exercise modalities (HI-pNIV: from 26.2±6.9 to 31.4±8.3 min (p = 0.008); MOD-pNIV: 
from 30.3±11.3 to 36.1±11.0 min (p = 0.016)) without differences in the magnitude of 
improvement between the two exercise modalities (p = 0.244) (Figure 5.6) [20]. The 
order of testing (pNIV or PLB first) did not affect exercise endurance time (p=0.820) 
(Figure 5.7).   
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Figure 5.6. a) Exercise endurance time using pNIV (black bars) and PLB (grey bars) during high- and 
moderate-intensity exercise protocols. Dotted lines denote exercise iso-time. Effect of pNIV on individual 
patient exercise endurance time during b) high-intensity and c) moderate-intensity exercise protocols. 
Thick lines denote mean values [20]. 
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Figure 5.7. Exercise endurance time balancing the two breathing modalities (pNIV and PLB) when using 
pNIV in the first trial and PLB afterwards (black bars), or when using PLB in the first trial and pNIV 
afterwards (grey bars). Endurance time was not affected by the sequence of the breathing modality, whilst 
endurance time was consistently increased with pNIV compared to PLB.   
 
5.3.4. Effect of pNIV on Dynamic Hyperinflation 
5.3.4.1. High- vs moderate-intensity 
The mean increase in IC during recovery periods compared to the end of exercise 
exceeded the clinically meaningful margin (i.e., >4.5% of predicted normal IC: 110–119 
ml) [19, 24], when patients used pNIV for both HI-pNIV: 140±110 ml and MOD-pNIV: 
170±80 ml exercise modalities (Figure 5.8.a & c). The mean change in IC in recovery 
compared to the end of exercise with PLB did not reach a clinically meaningful margin 
neither for HI-PLB: 10±290 ml nor for MOD-PLB: 100±140 ml exercise modalities 
(Figure 5.8.a & c). Compared to PLB at the limit of tolerance, the change in IC from 
rest was not different (p=0.379) between the two intermittent exercise modalities with 
the use of pNIV (Table 5.5). However, in 6 out of 24 patients the improvement in 
dynamic hyperinflation was greater with PLB compared to pNIV (Figure 5.9) [20]. 
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Figure 5.8. Effect of the application of pNIV (closed circles) compared to PLB (open circles) on 
inspiratory capacity calculated as the change between recovery periods and the end of high-intensity 
intermittent (a) and moderate-intensity (c) exercise bouts and symptoms of breathlessness during recovery 
from high-intensity (b) or moderate-intensity (d) exercise. Responses are shown for both PLB and pNIV 
at iso-time across the four percentiles (25%, 50%, 75% and 100%) of the total endurance time when using 
the PLB technique. Data are presented as mean ± standard error of the mean (SEM) [20]. 
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Figure 5.9. Effect of the application of pNIV on individual patient inspiratory capacity as the change 
between recovery periods and the end of a) high-intensity and b) moderate-intensity exercise. Solid lines 
indicate non-responders, thinner dotted lines indicate responders. There were 3 patients in each group 
who worsened DH in response to pNIV as compared to PLB [20]. 
 
5.3.4.2. DH responders vs DH non-responders 
Based on the dynamic hyperinflation data at exercise iso-time, 8 participants were 
identified as ‘DH non-responders’ to pNIV, whilst the remaining 16 participants were 
deemed as ‘DH responders’. At exercise iso-time in DH non-responders IC was 240±40 
ml (p=0.001) lower with pNIV compared to PLB, exceeding the minimum clinically 
important difference (>4.5% of predicted resting IC) [19, 24], whilst IC was 220±50 ml 
(p=0.001) greater in DH responders when pNIV was applied compared to PLB (Figure 
5.10a & b & Table 5.4) as expected. Thus, demonstrating a significant difference 
(p=0.001) in the magnitude of change in dynamic hyperinflation between the two 
groups. Across all 24 patients, the magnitude of change in exercise endurance time with 
pNIV compared to PLB was associated with the magnitude of change in dynamic 
hyperinflation (r=0.46, p=0.022) (Figure 5.11a). Furthermore, resting dynamic 
hyperinflation (inferred by RV/TLC %) was negatively associated with the magnitude 
of exercise-induced dynamic hyperinflation when using pNIV compared to PLB (r=-
0.42, p=0.043) (Figure 5.11b). 
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Figure 5.10. (a & b): individual differences in inspiratory capacity (IC) at exercise iso-time and in 
endurance time (c & d) between pNIV and PLB, in DH non-responders (left panel) and DH responders 
(right panel) following the use of pNIV compared to PLB. Data presented as mean±SEM. Thick lines 
denote mean values. Asterisks denote significant differences (p<0.05) between pNIV and PLB within 
each group. 
 
Figure 5.11. a) Association between differences in endurance time and in inspiratory capacity (IC) 
between pNIV and PLB application at exercise iso-time and b) association between differences in IC 
when using pNIV compared to PLB at exercise iso-time with baseline residual volume as a fraction of 
total lung capacity ratio (RV/TLC). Open symbols denote DH non-responders and closed symbols DH 
responders. 
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5.3.5. Baseline demographic and peak exercise data between DH responders and 
DH non-responders 
The baseline characteristics of the patients are presented in table 5.3. DH responders 
exhibited a tendency for greater FEV1, FVC, VC and resting IC compared to the DH 
non-responders. In addition, RV/TLC% was greater and IC/TLC was lower in DH non-
responders compared to the DH responders (p=0.028 and p=0.047, respectively), 
indicating greater resting lung hyperinflation and mechanical restriction to tidal volume 
expansion (Table 5.3). In addition, DH non-responders had lower baseline peak exercise 
capacity (41±8% predicted) during cardiopulmonary exercise testing compared to DH 
responders (48±6%), but aerobic capacity as reflected by VO2peak was similar between 
the two groups (Table 5.3). 
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Table 5.3. Demographic and peak exercise data at baseline in DH non-
responders and DH responders  
 
DH Non-
responders 
(n=8) 
DH 
Responders 
(n=16) 
p 
Gender (M/F) 4/4 6/10  
Age (years) 67±3 67±2 0.934 
BMI 24.4±3.1 27.2±1.5 0.363 
FEV
1
 (litres) 0.96±0.20 1.23±0.16 0.297 
FEV
1
 (% predicted) 40±8 49±4 0.292 
FVC (litres) 2.57±0.35 2.78±0.20 0.594 
FVC (% predicted) 86±7 91±5 0.590 
FEV
1
/FVC 37±5 43±3 0.298 
VC (litres) 2.77±0.40 3.06±0.21 0.482 
VC (% predicted) 89±8 97±5 0.380 
FRC (litres) 5.62±0.43 5.15±0.44 0.513 
FRC (% predicted) 188±14 166±12 0.288 
RV (litres) 4.72±0.33 4.44±0.47 0.634 
RV (% predicted) 218±20 198±17 0.470 
TLC (litres) 7.36±0.49 7.28±0.47 0.916 
TLC (% predicted) 135±6 128±7 0.564 
IC (litres) 1.74±0.26 2.12±0.16 0.203 
IC (% predicted) 70±7 84±6 0.164 
IC/TLC (%) 24±3 30±2 0.047 
RV/TLC (%) 65±4 56±2 0.028 
DLco (litres) 2.60±1.01 3.17±0.44 0.556 
DLco (% predicted) 33±11 40±5 0.494 
WRpeak (% predicted) 41±8 48±6 0.471 
VO2peak (%predicted) 59±7 61±4 0.722 
M, male; F, female; BMI, body mass index; FEV1, forced expiratory volume in the first 
second; FVC, forced vital capacity; VC, vital capacity; FRC, functional residual capacity; 
RV, residual volume; TLC, total lung capacity; IC, inspiratory capacity; DLco, transfer 
factor of the lung for carbon monoxide; WR, work rate; VO2, oxygen uptake; values 
presented as mean ± standard error of the mean (SEM). 
 
 
5.3.6. Effect of pNIV application on exercise tolerance in DH responders and DH 
non-responders 
In DH non-responders, exercise endurance time was not different when using the 
pNIV device (30.9±3.4 min) compared to PLB (29.9±3.3 min) (p=0.603). In DH 
responders, exercise endurance time was significantly greater (p=0.001) with pNIV 
application (34.9±2.4 min) compared to PLB (27.1±2.3 min) (Figure 5.10c & 5.10d & 
110 
 
Table 5.4), thereby revealing a significant difference (p=0.008) in the magnitude of 
improvement in endurance time between the two groups. 
 
Table 5.4. Ventilatory and central haemodynamic responses with PLB and pNIV 
application at iso-time in DH non-responders and DH responders 
 
DH Non-Responders DH Responders 
 
PLB pNIV p PLB pNIV p 
Endurance time 
(min) 
29.9±3.3 30.9±3.4 0.603 27.1±2.3 34.9±2.4
#
 0.001 
Minute ventilation 
(litres/min) 
28.0±5.8 30.7±5.6 0.021 37.8±4.1 36.8±4.0
#
 0.224 
Tidal volume 
(litres) 
1.0±0.2 1.0±0.2 0.482 1.2±0.1 1.3±0.1
#
 0.018 
bf (breaths/min) 28±2 30±2 0.046 30±1 29±1
#
 0.216 
IC (litres) 2.14±0.24 1.90±0.25 0.001 2.19±0.17 2.41±0.18
#
 0.001 
VT/IC (%) 47±3 53±3 0.001 56±2 53±2 0.010 
Inspiratory time 
(sec) 
0.8±0.1 0.7±0.1 0.017 0.8±0.1 0.8±0.1
#
 0.059 
Expiratory time 
(sec) 
1.5±0.1 1.3±0.1 0.010 1.3±0.1 1.4±0.1
#
 0.116 
Duty cycle (sec) 2.3±0.1 2.0±0.1 0.008 2.1±0.1 2.2±0.1
#
 0.071 
Stroke volume (ml) 88±7 88±6 0.971 95±5 98±5 0.122 
Heart rate 
(beats/min) 
111±6 114±6 0.223 109±4 108±4 0.913 
Cardiac output 
(litres/min) 
9.5±0.9 9.9±0.8 0.335 10.3±0.6 10.9±0.6 0.035 
Double Product 
(mmHg/beat/min) 
24,681±1,126 26,185±1,006 0.009 25,649±796 25,951±711
#
 0.423 
Systolic blood 
pressure (mmHg) 
136±9 148±8 0.024 148±6 151±5 0.377 
Diastolic blood 
pressure (mmHg) 
77±5 84±4 0.042 80±4 82±3 0.336 
Mean blood 
pressure (mmHg) 
96±6 106±5 0.006 103±4 105±4 0.237 
PLB, pursed lip breathing; pNIV, portable non-invasive ventilation; VT, tidal volume; IC, inspiratory 
capacity; bf, breathing frequency 
#
, significant differences (p<0.05) in the pattern of response between the 
two groups; values presented as mean ± standard error of the mean (SEM) 
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Table 5.5. Metabolic and respiratory responses at the limit of tolerance of high- and moderate-intensity exercise. 
 
High-Intensity Moderate-Intensity 
Variable PLB pNIV Support p-Value PLB pNIV Support p-Value 
Work Rate (watts) 38±20 (80%) 38±20 (80%) - 30±17 (60%) 30±17 (60%) - 
ΔIC (litres) −0.37±0.31 (62%) −0.37±0.28 (62%) 0.964 −0.29±0.25 (62%) −0.27±0.24 (58%) 0.819 
Dyspnoea (Borg) 4.8±1.2 (114%) 3.9±1.4 (93%) 0.005 4.0±1.1 (105%) 3.3±1.1 (87%) 0.004 
Leg Discomfort (Borg) 4.5±1.5 (118%) 4.1±1.8 (108%) 0.027 4.1±1.2 (124%) 3.3±1.6 (100%) 0.011 
VO2 (ml/min/kg) 11.9±3.2 (88%) 12±3.5 (89%) 0.879 12.8±3.3 (96%) 12.7±3.1 (95%) 0.778 
VE (litres/min) 34.8±18.4 (89%) 36.5±18.1 (93%) 0.206 34.6±14.6 (98%) 33.8±14.3 (95%) 0.444 
VT (litres) 1.2±0.5 (100%) 1.2±0.5 (100%) 0.202 1.2±0.5 (100%) 1.2±0.5 (100%) 0.549 
RF (breaths/min) 29±5 (94%) 30±5 (97%) 0.256 30±5 (103%) 29±3 (100%) 0.409 
CO (litres/min) 9.9±2.6 (94%) 10.5±2.7 (100%) 0.070 10.3±2.4 (92%) 10.5±2.3 (94%) 0.193 
HR (beats/min) 105±13 (93%) 108±15 (96%) 0.172 114±19 (104%) 114±16 (104%) 0.725 
SV (ml/beat) 94±23 (100%) 96±22 (102%) 0.487 90±16 (89%) 91±13 (90%) 0.485 
SBP (mmHg) 146±23 (98%) 158±23 (106%) 0.002 142±29 (94%) 148±22 (98%) 0.285 
DBP (mmHg) 82±8 (92%) 89±9 (100%) 0.024 78±18 (90%) 84±17 (97%) 0.049 
a-vO2 (mL/100ml) 8.9±2.9 8.3±3.1 0.205 8.9±2.9 8.6±2.9 0.371 
SpO2 (%) 92±5 93±4 0.104 94±3 93±3 0.148 
ΔIC, change from baseline in inspiratory capacity; VO2, oxygen uptake; VE, minute ventilation; VT, tidal volume; RF, breathing frequency; CO, cardiac output; HR, heart rate; 
SV, stroke volume; SBP, systolic blood pressure; DBP, diastolic blood pressure; a-vO2, whole body arteriovenous oxygen difference content; SpO2, arterial oxygen saturation; 
pNIV, portable Non-Invasive Ventilation; PLB, Pursed lip breathing technique. Values are mean ± SD [20] and as a fraction of peak values recorded during the CPET.
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5.3.7. Perceived symptoms 
5.3.7.1.High- vs moderate-intensity 
Compared to PLB across different fractions of total endurance, time application of 
pNIV was associated with a clinically meaningful reduction [24, 267] in breathlessness 
during HI-pNIV (by: 1.2±1.7, p=0.022) and MOD-pMIV (by: 1.0±0.7, p=0.002) 
exercise modalities (Figure 5.8 b & d). There were no significant differences (p=0.518) 
in breathlessness scores between the two modalities with pNIV [20]. 
Compared to PLB across different fractions of total endurance time, the application 
of pNIV was associated with lower leg discomfort during HI-pNIV (by: 0.5±0.8, 
p=0.050) and MOD-pNIV (by: 0.8±1.1 (p=0.031)) exercise modalities (Figure 5.12 c,f). 
There were no differences (p=0.268) in leg discomfort scores between the two 
modalities with pNIV [20]. 
5.3.7.2.DH responders vs DH non-responders 
When patients were classified as DH responders or DH non-responders, at exercise 
iso-time, use of pNIV compared to PLB was associated with reduced breathlessness by 
a clinically meaningful margin (by 1.3±0.3 units, p=0.001) in DH responders [24, 27]. 
In DH non-responders the reduction in breathlessness with the use of pNIV compared to 
PLB (by 0.6±0.5 units, p=0.118) was not clinically meaningful. In addition, use of pNIV 
compared to PLB reduced leg discomfort in both DH responders and non-responders 
(by 0.6±0.2 units, p=0.026 and by 0.8±0.3 units, p=0.034, respectively), albeit by non-
clinically meaningful margins (<1.0 unit on a Borg 1-10 scale) [267]. There was not a 
significant difference in the magnitude of improvement with pNIV compared to PLB in 
breathlessness (p=0.236) and leg discomfort (p=0.650) between the two groups. 
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5.3.8. Central haemodynamic responses and kinetics 
5.3.8.1. High- vs moderate-intensity 
In comparison to PLB, across different fractions of total endurance time, CO and 
systemic oxygen delivery were greater with pNIV during both HI-pNIV (by 0.3±1.1 
litres/min (p=0.035) and by 70±40 ml/min (p=0.040), respectively) and MOD-pNIV (by 
0.8±0.9 litres/min (p=0.045) and 160±40 ml/min (p=0.040), respectively) exercise 
modalities (Figure 5.12). There were no differences (p=0.519 and 0.463, respectively) 
in these variables between the two exercise modalities with pNIV (Figure 5.12) [20]. 
Compared to PLB, at the limit of tolerance, off transient kinetic response of cardiac 
output, stroke volume and heart rate were significantly slower with pNIV during both 
HI-pNIV (CO by 42±48 sec (p=0.022); SV by 44±56 sec (p=0.036) and HR by 34±36 
sec (p=0.017)) and MOD-pNIV (CO by 61±52 sec (p=0.007); SV by 39±52 sec 
(p=0.054); and HR by 46±49 sec (p=0.022)) (Figure 5.13). 
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Figure 5.12. Effect of the application of pNIV (closed circles) compared to PLB (open circles) on cardiac 
output (CO: a & d), estimated systemic oxygen delivery (DO2: b & e) and symptoms of leg discomfort (c 
& f) during high- and moderate-intensity exercise protocols, respectively. Responses are shown for both 
PLB and pNIV at iso-time across the four percentiles (25%, 50%, 75% and 100%) of the total endurance 
time when using the PLB technique. Data are presented as mean±SEM [20]. 
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Figure 5.13. Effect of the application of pNIV (black bars) compared to PLB (grey bars) on mean 
response time (MRT) of cardiac output (a & d), stroke volume (b & e) and heart rate (c & f) during the 
recovery phase after termination of the high- (left panel) and moderate-intensity (right panel) exercise 
protocols. Data are presented as mean±SEM. 
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5.3.8.2.DH responders vs DH non-responders 
There were no differences in stroke volume and heart rate responses with pNIV 
compared to PLB in either of the groups (Table 5.4). However, in DH responders 
cardiac output was greater with pNIV compared to PLB (by 0.6±0.3 litres/min, 
p=0.035) (Table 5.4), whereas cardiac output was not different between pNIV and PLB 
in DH non-responders. In addition, in DH non-responders there was an increase in 
systolic (by 12±5 mmHg, p=0.024), diastolic (by 7±3 mmHg, p=0.042)  and mean (by 
9±3 mmHg, p=0.006) blood pressure with the use of pNIV compared to PLB, whilst 
there were no differences in blood pressure between the two breathing modalities in DH 
responders (Table 5.4). In DH non-responders the increased systolic blood pressure 
resulted in a greater double product when pNIV was applied compared to PLB (by 
1,503±524 mmHg/beat/min, p=0.009), whilst there were no differences in the DH 
responders group (Table 5.4). Hence, there was a significant difference in the double 
product (p=0.044) between DH responders and non-responders.   
5.3.9. Breathing pattern  
5.3.9.1.High- vs moderate-intensity 
In comparison to PLB, at the limit of tolerance, there was no difference both in 
breathing frequency and in tidal volume with pNIV during both HI-pNIV [(p=0.256) 
and (p=0.202), respectively] and MOD-pNIV [(p=0.409) and (p=0.549), respectively] 
exercise modalities (Table 5.5). Accordingly, compared to PLB, at the limit of 
tolerance, there was no difference in minute ventilation with pNIV during both HI-
pNIV (p=0.206) and MOD-pNIV (p=0.444) (Table 5.5). 
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5.3.9.2.DH responders vs DH non-responders 
In DH responders, at exercise iso-time application of pNIV compared to PLB 
reduced minute ventilation (by 1.0±0.8 litres, p=0.224) due to lower breathing 
frequency (by 1±1 breaths/min p=0.216), whilst tidal volume was increased (by 
0.1±0.02 litres, p=0.018) (Table 5.4). In contrast, in DH non-responders pNIV 
compared to PLB increased minute ventilation (by 2.7±1.1 litres, p=0.021) secondary to 
increased breathing frequency (by 2±1 breaths/min, p=0.046), whilst tidal volume was 
unaffected (Table 5.4). Thus, there was a significant difference in the breathing pattern 
between DH responders and non-responders with pNIV compared to PLB in minute 
ventilation (p=0.012), breathing frequency (p=0.026) and tidal volume (p=0.046).  
At exercise iso-time, the fraction of tidal volume to inspiratory capacity (VT/IC %) 
was increased in DH non-responders (by 6±2%, p=0.001) with the use of pNIV 
compared to PLB, whereas VT/IC %was decreased (by 3±1%, p=0.010) in DH 
responders (Table 5.4). In addition, at exercise iso-time in DH non-responders there was 
a reduction in inspiratory time (by 0.1±0.03 sec, p=0.017) and expiratory time (by 
0.2±0.1 sec, p=0.010), and total duty cycle (by 0.3±0.1 sec, p=0.008) with the use of 
pNIV compared to PLB (Table 5.4). There were no differences between pNIV and PLB 
in duty cycle in DH responders (Table 5.4). Thus, there was a significant difference in 
the pattern of response between DH responders and non-responders with pNIV 
compared to PLB in inspiratory time, expiratory time and duty cycle (p=0.004; p=0.004; 
p=0.002, respectively). DH responders and non-responders experienced similar 
exercise-induced arterial oxygen desaturation from baseline to exercise iso-time when 
pNIV was applied compared to PLB (Table 5.6). 
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5.3.9.3.Metabolic responses 
5.3.9.4.High- vs moderate-intensity 
In comparison to PLB, at the limit of tolerance, there was no difference in arterio-
venous oxygen difference with pNIV during both HI-pNIV (p=0.205) and MOD-pNIV 
(p=0.317) exercise modalities (Table 5.5). Additionally, compared to PLB, both oxygen 
uptake and arterial oxygen saturation were similar at the limit of tolerance when pNIV 
was applied during both HI-pNIV [(p=0.879) and (p=0.104), respectively] and MOD-
pNIV [(p=0.778) and (p=0.148), respectively] exercise modalities (Table 5.5). 
5.3.9.5.DH responders vs DH non-responders 
In DH responders, arterio-venous oxygen difference was significantly lower with 
pNIV application compared to PLB (p=0.026), whilst oxygen uptake and carbon 
dioxide production were similar at exercise iso-time when pNIV was applied compared 
to PLB (Table 5.6). Additionally, systemic oxygen delivery was greater at exercise iso-
time in the DH responders group when pNIV were applied compared to PLB (p=0.016). 
Furthermore, in DH non-responders arterio-venous oxygen difference, oxygen uptake 
and carbon dioxide production were similar when pNIV was applied compared to PLB 
at exercise iso-time (Table 5.6). Finally, there was no difference in systemic oxygen 
delivery in DH non-responders when pNIV was applied compared to PLB at exercise 
iso-time (Table 5.6).  
 
 
 
 
119 
 
Table 5.6. Metabolic responses with PLB and pNIV application at exercise iso-time in 
non-responders and responders 
 
DH Non-Responders DH Responders 
 
PLB pNIV p PLB pNIV p 
ΔSpO2 (%) -2.5±1.2 -2.6±1.0 0.839 -3.6±0.9 -2.8±0.7 0.158 
Arteriovenous 
oxygen difference  
(ml/100ml) 
8.6±1.0 8.3±1.0 0.409 9.0±0.7 8.3±0.7 0.026 
Oxygen uptake 
(ml/kg/min) 
12.3±1.2 12.7±1.1 0.232 12.2±0.8 11.9±0.8 0.206 
Carbon dioxide 
(ml/min) 
664±139 702±131 0.311 828±98 787±92 0.129 
Systemic oxygen 
delivery (litres/min) 
1.9±0.2 1.9±0.2 0.356 2.0±0.1 2.1±0.1 0.016 
PLB, pursed lip breathing; pNIV, portable non-invasive ventilation; Δ, change from baseline; SpO2, 
arterial oxygen saturation; values presented as mean±standard error of the mean (SEM) 
 
5.4. Discussion 
The major finding of the study is that the use of pNIV during recovery periods 
interspersing moderate- and high-intensity bouts of intermittent exercise significantly 
improved exercise tolerance compared to PLB [20]. This is probably due to more rapid 
recovery from exercise-induced dynamic hyperinflation, with associated improvements 
in cardiac output and systemic oxygen delivery [20]. The physiological responses 
shown were matched by a reduction in breathlessness and leg discomfort during the 
recovery from exercise [20]. However, at exercise iso-time, 8 patients did not improve 
dynamic hyperinflation (DH non-responders) whilst the remaining 16 patients reduced 
dynamic hyperinflation (DH responders). The analysis revealed that only DH 
responders showed an improvement in exercise tolerance with pNIV compared to PLB. 
DH non-responders showed similar exercise tolerance with pNIV and PLB. Compared 
to DH responders, DH non-responders had greater resting dynamic hyperinflation, thus 
greater mechanical restriction to tidal volume expansion during exercise, and tended 
towards more severe airflow obstruction. The application of pNIV worsened ventilatory 
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responses in DH non-responders, who adopted a more tachypnoeic breathing pattern, 
but improved the ventilatory response in DH responders. 
NIV has previously been used during exercise training in patients with severe COPD, 
to lessen breathlessness and increase exercise capacity [20, 49, 208]. A Cochrane 
analysis of studies using NIV during exercise training, provides conflicting and 
moderate quality evidence of the beneficial effects on exercise capacity and therefore 
the role of this intervention remains unclear [20, 52, 268-271]. The main drawbacks of 
NIV described in this review were the difficulty and costs associated with using the 
equipment during pulmonary rehabilitation, including the time required to supervise 
patients during training [20, 269]. Nevertheless, recent meta-analyses conclude that 
there is a need for further randomised clinical trials [20, 269, 272]. 
The VitaBreath device is designed to overcome the problems associated with the use 
of traditional NIV, and is primarily intended to aid recovery from breathlessness after 
activities of daily living. It is light, handheld and battery operated. This, and future 
pNIV devices, may offer benefits within pulmonary rehabilitation, particularly in 
intermittent/interval training regimes. One technical limitation of the VitaBreath device 
is that the expiratory and inspiratory positive airway pressures (EPAP and IPAP, 
respectively) are fixed. Excessive EPAP can worsen hyperinflation and circulatory 
compromise. In the present study population, the majority of patients showed no 
worsening of DH or circulatory compromise whilst using pNIV during recovery 
periods. However, in six patients (three per group) the improvement in DH was greater 
with PLB than pNIV, thereby suggesting that the fixed pressures were sub-optimal in at 
least some of the patients. Accordingly, in future devices the ability to adjust EPAP and 
pressure support is desirable and could potentially be automated [20]. 
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Recently, a non-invasive “open” ventilation (NIOV) system operating in conjunction 
with a portable oxygen tank was found to decrease respiratory muscle activation and 
dyspnoea, as well as improve cycle ergometer exercise tolerance [145]. In the current 
study the use of pNIV (VitaBreath) during intermittent exercise is associated with 
longer exercise endurance time (by 19–20%), with less DH and breathlessness [20]. 
Continuous positive pressure support throughout exercise is much less practical in daily 
life, but confers greater improvement in exercise tolerance, including the use of: 
continuous positive airway pressure (26–40%) [44, 46], proportional assist ventilation 
(23–43%) [44, 46, 209], pressure support ventilation (by 32–38%) [44, 210], inspiratory 
pressure support (46%) [42] and NIOV (by 245%) [145]. Notably, when the NIOV 
system was powered by compressed air rather than oxygen, exercise endurance time 
was increased only by 13% [145]. The aforementioned ventilation support strategies 
provide continuous unloading of the respiratory muscles and reduce the work of 
breathing [49, 208], and as such, are expected to yield greater improvements in exercise 
capacity compared to the intermittent application of pNIV during recovery from 
exercise [20]. This argument is further supported by the absence of a reduction in 
ventilatory requirement or an increase in arterial oxygen saturation during the 
successive bouts of high- or moderate-intensity exercise, with the application of pNIV 
compared to PLB in the present study (Table 3.4) [20]. Whilst intermittent use of pNIV 
offered less improvement in exercise tolerance, it is more practical in typical pulmonary 
rehabilitation settings and daily life [20]. Studies in the future may investigate the 
additive effect of oxygen supplementation to intermittent NIV support during typical 
pulmonary rehabilitation [20]. 
When patients categorised as DH responders and DH non-responders, application of 
pNIV induced a significant improvement in exercise tolerance in DH responders, whilst 
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in DH non-responders the improvement in exercise tolerance was of no account [273]. 
Findings within DH responders are supported by previous research into different NIV 
modes, where increases in exercise tolerance similar to the present study are reported 
[49, 208]. Lack of improvement in exercise endurance time in DH non-responders may 
be attributed to the failure of pNIV to relieve symptoms of breathlessness. There is 
strong evidence that a reduction in the mechanical restriction to tidal volume expansion 
is closely related to a reduction in symptoms of exertional breathlessness [19, 274, 275]. 
Therefore, the potential mechanism explaining the lack of improvement in exercise 
tolerance in DH non-responders when using pNIV compared to PLB is probably the 
failure to alleviate such mechanical constraints [27, 274, 275] and subsequently to 
reduce symptoms of breathlessness by a clinically meaningful amount (>1.0 on a Borg 
1-10 scale) as observed with the DH responders [24] . 
Of note, in the present study patients scored relatively low breathlessness and leg 
discomfort at the limit of tolerance, both during high- and moderate-intensity exercise. 
Similar findings are also reported in other studies when repeated constant load exercise 
was performed [276, 277]. In the study by Mador and colleagues [277], the Borg scale 
was used to assess dyspnoea perception during 5 constant load tests at 66% of peak 
work rate. The study reported that patients were unable to distinguish the sense of 
respiratory effort and discomfort during exercise. Additionally, the variability of 
dyspnoea scores was greater compared to the objective exercise parameters, despite the 
fact that dyspnoea levels were correlated with objective indices of exercise intensity 
[277]. Moreover, a study by Belman and colleagues [276] reported that dyspnoea levels 
assessed by the Borg scale decreased progressively, especially at more strenuous levels 
of exercise when patients performed the same exercise test on four different days [276]. 
Furthermore, authors reported that the proportionately greater fall in the Borg ratings 
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with repetitive testing was independent of a true physiologic training effect, clearly 
suggesting a learning effect [276]. In the present study, there was a 4-week 
familiarisation period in order to minimise the potential learning effect between the two 
visits, most likely justifying the relatively low breathlessness score reported at the end 
of exercise by the patients. 
A recent study by Souza and colleagues [278] reported that application of BiPAP 
(IPAP: 15 cmH2O, EPAP: 5 cmH2O) in moderate COPD reduced operational lung 
volumes and breathlessness, increasing exercise tolerance at different levels of exercise 
[278]. However, in contrast to the present study BiPAP was applied throughout exercise 
and IPAP and EPAP pressures were tailored to a level that was comfortable to the 
individual patient [278]. The VitaBreath device delivers fixed pressures of 18 cmH2O 
during inspiration and 8 cmH2O during expiration. For NIV to be beneficial in COPD 
patients, the external positive end-expiratory pressure (PEEPe) provided by the 
ventilator must match the patients intrinsic PEEP (PEEPi) [279]. The fixed pressures of 
VitaBreath are in contrast to other commonly used, adjustable, NIV methods, and it is 
likely that the pressures provided by the pNIV device were excessive for the DH non-
responders [280]. A study by Nava and colleagues reported that application of PEEPe 
greater that PEEPi significantly increased end-expiratory lung volumes [178]. In the 
present study, 8 patients exhibited greater dynamic hyperinflation, whilst 16 patients 
experienced less dynamic hyperinflation with pNIV compared to PLB. Although PEEPi 
was not assessed in this study, the level of PEEPe (8 cmH2O) provided by the 
VitaBreath device was suboptimal compared to the average intrinsic PEEPi (in the 
range of 2.5-10.0 cmH2O) reported in the literature for patients with similar severity of 
COPD to those in the present study, most likely worsened dynamic hyperinflation in 
DH non-responders [178, 184, 281, 282]. Furthermore, when intrinsic and extrinsic 
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PEEP matching is suboptimal, there is increased risk of developing patient-ventilator 
asynchronies [207], resulting in increased work of breathing, poor alveolar ventilation 
and insufficient gas exchange [283]. This supports our view that the ability to match 
PEEPe to the individual patient’s needs in future pNIV devices should improve 
synchrony and lead to a greater reduction in exercise induced DH, thus improving 
exercise tolerance and breathlessness. 
The findings of the present study suggest that pNIV improved exercise tolerance 
compared to PLB, not only by its direct effect on respiratory mechanics (reducing DH), 
but also by partial alleviation of the associated adverse hemodynamic responses [20]. 
Use of pNIV resulted in an increase in cardiac output and systemic oxygen delivery 
during exercise [20]. This is most likely a result of reduced DH and improved venous 
return, which is in line with previously published reports following application of PAV 
[209] and administration of bronchodilators or heliox [144, 284]. This finding confirms 
that a common basis for enhanced exercise performance in COPD may be associated 
with improved peripheral muscle oxygen availability and reduced symptoms of leg 
discomfort, afforded by interventions targeting the abnormal respiratory mechanics in 
COPD [20]. 
The delay of on- and off-transient kinetics in central haemodynamic responses during 
constant-load exercise and the 6MWT has been associated with the disease severity 
possibly reflecting greater cardiovascular impairment and/or greater physical 
deconditioning in patients with advanced COPD compared to those patients in early 
stages [194].  
In the present study, the delay in central haemodynamic kinetic responses when 
pNIV was applied may be for the result of greater CO when using pNIV compared to 
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PLB (Figure 5.13. a & d). Specifically, the off-transient kinetics analysis revealed that 
application of pNIV was associated with a delayed response in HR, SV and CO mean 
response time at the limit of tolerance compared to PLB. These findings suggest that 
that alleviation of dynamic hyperinflation and associated increase in venous return and 
stroke volume increased cardiac output more when using pNIV compared to PLB thus 
leading to a longer recovery time for all central hemodynamic responses. 
To the author’s knowledge, this is the first study that investigates the effects of NIV 
application on central haemodynamic off-transient mean response time, following an 
exercise protocol. However, the application of NIV has previously been found to 
acutely modify resting heart rate variability in patients with COPD [285]. In fact, there 
was an increase in sympathetic activity and a decrease in parasympathetic activity when 
BiPAP (IPAP: 14, EPAP: 5 cmH2O), of similar levels to this study, was applied at rest 
in patients with COPD [285]. This increase in sympathetic activity may partially explain 
the delay in CO recovery during the recovery periods between consecutive bouts of 
exercise, mainly due to the delay in the recovery of HR. 
Although application of NIV at rest is associated with adverse haemodynamic effects 
in patients with COPD, a study stratifying patients into responders and non-responders 
(according to the change in exercise tolerance) when proportional assist ventilation 
(PAV) was applied compared to normal breathing, reported similar responses in central 
haemodynamic variables between the two groups [45]. The findings of the present study 
are in accordance with the existing literature. There were only small, non-significant, 
differences in stroke volume and heart rate, whilst cardiac output was greater only in the 
responders group. Additionally, the duration of pNIV application was very brief, and 
therefore less likely to cause any adverse haemodynamic responses. 
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In the literature there is conflicting evidence as two studies report no changes in 
blood pressure when NIV was applied compared to control conditions during exercise 
[286, 287], whilst one study reported greater diastolic blood pressure when combined 
NIV and oxygen were applied compared to oxygen alone [288]. The results of the 
present study showed that in DH responders blood pressure was not different between 
pNIV and PLB application during exercise, but interestingly, application of pNIV in 
DH non-responders increased systolic and mean blood pressures compared to PLB. This 
might be due to greater dynamic hyperinflation in this group when using pNIV, as 
increased intrathoracic pressure swings are associated with increased pressure in the 
chest cavity [289]. 
Increased blood pressure led to greater double product, as heart rate was unchanged 
in the DH non-responder group when pNIV was applied compared to PLB. Double 
product is an index assessing the load of the heart during each beat, as it is the product 
of systolic blood pressure and heart rate [290]. Increased double product is related to a 
lower ejection fraction in patients with chronic heart failure [291]. Greater arterial blood 
oxygenation is associated with lower double product values during a 6MWT in patients 
with CHF [292]. In the present study the greater double product with pNIV application 
in the DH non-responder group might be associated with the greater degree of resting 
and exercise-induced dynamic hyperinflation, but also with the slightly higher heart rate 
reported at iso-time. 
VitaBreath provides positive inspiratory pressure support to reduce the work of 
breathing and positive expiratory pressure to keep the airways open during expiration, 
thereby reducing air trapping [20, 215]. The mean increase in IC during the recovery 
periods compared to the end of exercise bouts with pNIV (high-intensity: 140 mL; 
moderate-intensity: 170 mL) was within the clinically meaningful margin for 
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bronchodilator trials (138–175 mL) [20, 293], most likely reflecting the improvement in 
expiratory flow and thus lung emptying [20, 24, 27, 293]. The increase in IC during 
recovery was matched by a significant reduction in breathlessness that reached the 
minimal clinically important difference (1.0 unit) [20, 24, 27]. In contrast, PLB was not 
consistently associated with a clinically meaningful improvement in IC during recovery; 
this is in keeping with previous work showing that exercise-induced DH normally 
persists for several minutes following the end of exercise [20, 85]. Furthermore, the 
mean reduction in breathlessness scores during recovery from exercise did not reach the 
minimal clinically important difference [20, 24, 27]. 
Dynamic hyperinflation is an important factor limiting exercise tolerance in patients 
with COPD [19, 27, 274]. Compared to DH responders, DH non-responders tended to 
have a lower FEV1, thus greater expiratory flow limitation, increased lung volumes and 
greater lung hyperinflation at rest [19]. These findings are consistent with advanced 
COPD with emphysema [294]. Moreover, greater resting expiratory flow limitation is 
associated with smaller improvements in exercise tolerance secondary to increase in 
end-expiratory lung volume [295]. Although both groups exhibited a reduction in Borg 
scale breathlessness when using pNIV, only DH responders achieved a clinically 
meaningful reduction (>1.0 units) [24]. In COPD, dynamic hyperinflation causes 
inspiratory muscle shortening and tidal volume constraints, effecting ventilatory and 
central motor output [274, 296] and thus increasing work of breathing and consequent 
breathlessness. 
Only one study in the literature comparing oxygen supplementation and inspiratory 
pressure support (IPS) has reported data on inspiratory capacity during iso-time exercise 
[210]. The data revealed greater inspiratory capacity at iso-time with IPS (by 200 ml) 
compared to oxygen supplementation, secondary to lower minute ventilation [210]. In 
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contrast, another study reported that application of PEEPe at rest in patients with acute 
exacerbation of COPD did not cause any change in end expiratory lung volume 
compared to normal breathing [184]. However, authors suggested that intrinsic PEEP 
should be assessed and the level of applied PEEPe should be individualised [184]. 
The reduction in the magnitude of dynamic hyperinflation when using pNIV 
compared to PLB in DH responders is most likely associated with the greater ability to 
expand tidal volume during exercise, resulting in improved ventilatory coupling and 
subsequent reduced breathlessness [274, 296]. Use of pNIV in DH responders was 
associated with an increase tidal volume with lower breathing frequency, thereby 
increasing the duty cycle. In contrast, the more tachypnoeic breathing pattern adopted 
by DH non-responders resulted in less expiratory time and thus increased air trapping 
and exacerbated breathlessness [18, 27, 274, 275]. The increased fraction of tidal 
volume to inspiratory capacity (VT/IC %) in DH non-responders demonstrates that were 
more likely to reach the point during exercise where they were unable to further 
increase tidal volume when using pNIV compared to PLB (Table 5.4) [19]. It is possible 
that in some patients the fixed EPAP was insufficient to overcome flow limitation thus, 
failed to facilitate expiration or that excessive pressures directly worsening dynamic 
hyperinflation. Use of self-adjusting EPAP tailored to the individual patient may lead to 
better outcomes. 
Two intermittent protocols with different duration and intensity characteristics were 
applied to explore the influence of intermittent pNIV on exercise tolerance in COPD 
patients with baseline and exercise-induced dynamic hyperinflation [20]. It was 
expected that the use of pNIV during recovery following successive 2-min exercise 
bouts at high-intensity would have conferred greater benefit, due to the device being 
used more frequently compared to 6-min bouts of moderate-intensity exercise [20]. This 
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hypothesis was not confirmed. The high-intensity protocol elicited greater exercise-
induced DH compared to the moderate intensity protocol (Table 5.5), hence the 
effectiveness of positive pressure ventilation on exercise tolerance, physiological 
responses and symptoms was highly comparable between the two intermittent 
modalities [20]. The findings of the study suggest that pNIV could be applied in the 
pulmonary rehabilitation setting to either prolong endurance at a sustained moderate 
intensity training load and/or to allow greater training loads, such as the high-intensity 
protocol used in the present study [20]. Further research is required to confirm this as 
the present study provides evidence only during acute application of portable NIV; 
hence these data cannot be extrapolated to give information about the effects during a 
long period of training [20]. 
Exercise training is the cornerstone of pulmonary rehabilitation and is associated 
with significant increases in exercise capacity in patients with COPD [106]. Previous 
studies have shown that the application of interval exercise during a pulmonary 
rehabilitation program allows for higher training loads, due to reduced ventilatory 
requirement, less metabolic acidosis and lower symptoms of breathlessness and leg 
discomfort compared to continuous exercise [28, 111]. Therefore, interval exercise was 
the best approach to increase exercise tolerance and simultaneously familiarise patients 
with the testing procedures. 
In the study by Vogiatzis and colleagues [111], following a PR program including 24 
training sessions, work load increased by 66% in the interval exercise group. In the 
present study, work load increased by 86% following 8 exercise sessions, however 
initial load was lower compared to the study [111]. This was mainly because the 
primary target of the training sessions was to familiarise the patient with the testing 
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procedures. The second aim was to ensure that patients would be able to complete the 
exercise testing without being severely limited by leg discomfort. 
Study limitations 
This was a single centre study and blinding the patients or investigators to the 
breathing modality was not possible due to the lack of a sham pNIV device [20]. Thus, 
the risk of a placebo effect cannot be excluded, especially when considering the effect 
of the pNIV device on the reduction in breathlessness [20]. Measurements of the work 
of breathing were not performed directly during the recovery periods from exercise 
[20]. This would have allowed assessment of the effect of pNIV on respiratory muscle 
unloading. Use of optoelectronic plethysmography would permit continuous assessment 
of end-expiratory volumes in the transition from exercise to recovery [20, 85].  
Responders and non-responders were defined in terms of dynamic hyperinflation and 
not the primary outcome of the study. Inspiratory and expiratory positive airway 
pressures provided by the pNIV device were fixed, therefore adjustment of the 
aforementioned pressures was not possible. This is distinct to other studies applying 
NIV in COPD patients given that the level of provided pressure is individualised to 
maximise the benefit of use. This represents a very important disadvantage of the 
VitaBreath device, which clearly mitigated the beneficial impact it had on some 
patients. 
5.5.Conclusions 
Use of pNIV during the recovery periods interspersing moderate or high intensity 
exercise bouts enhanced exercise tolerance compared to pursed lip breathing, by 
lessening the symptoms of breathlessness and enhancing systemic oxygen availability 
[20]. Future studies should investigate the applicability and benefits of intermittent 
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application of other available positive pressure ventilation strategies during the recovery 
periods of high-intensity intermittent exercise in COPD [20]. 
Application of fixed positive inspiratory and expiratory pressures during the recovery 
periods between exercise bouts is beneficial for the majority of the COPD patients; 
however this is not the case in patients with severe resting dynamic hyperinflation and 
poor lung function. In fact, workload of the myocardium seems to increase in these 
patients, potentially increasing the risk to cause adverse circulatory effects. Thus, the 
present dissertation has investigated the cardiovascular and respiratory muscle kinetic 
response of fixed positive inspiratory and expiratory pressures in a subset of patients 
with COPD during exercise (Chapter 6). 
The findings of the present study suggest that, although pNIV presents with 
promising results and favourable practical benefits, it is not effective in improving 
dynamic hyperinflation in all COPD patients. This may be because the fixed pressures 
were suboptimal in some of the patients. Further studies in auto-adjusted ventilators are 
warranted in this population.   
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6. Effect of pNIV on thoracoabdominal volumes and 
circulatory responses during recovery from exercise 
in patients with COPD 
6.1. Introduction 
This study investigated the acute effect of pNIV application compared to the PLB 
technique on thoracoabdominal volume regulation, pulmonary rib cage and abdominal 
kinematics and circulatory responses, during recovery from intermittent exercise in 
COPD. Chapter 5 investigated the effect of pNIV application compared to the PLB 
technique on dynamic hyperinflation during recovery from exercise, but not during the 
acute application of pNIV as it was not possible to perform IC manoeuvres when using 
pNIV. Accordingly, the present study constitutes an exploratory mechanistic study to 
appreciate the acute adjustments of ventilation and circulation when using the 
VitaBreath device compared to the PLB technique in recovery from exercise.  
In addition, Chapter 5 presented different patterns of response in terms of the 
manifestation of dynamic hyperinflation in patients using pNIV compared to the PLB 
technique during recovery from intermittent exercise. Thus, it was deemed necessary to 
further investigate the different patterns of dynamic hyperinflation response to pNIV 
application during exercise in these COPD patients.  
Moreover, Chapter 5 assessed the effect of using the VitaBreath device compared to 
the PLB technique on exercise tolerance in 24 patients with COPD. Use of the 
VitaBreath device during the recovery periods enhanced exercise tolerance compared to 
PLB, and reduced symptoms of breathlessness and leg discomfort. Reduced 
breathlessness was attributed to more rapid recovery from exercise-induced dynamic 
hyperinflation, assessed by periodic volitional inspiratory capacity manoeuvres 
performed through a spirometer at the end of exercise bouts and following application 
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of pNIV or PLB. The actual mechanism by which the VitaBreath device influences the 
magnitude of dynamic hyperinflation is thought to be the provision of positive end-
expiratory pressure, preventing airway collapse and thus facilitating more complete lung 
emptying [20]. However, in the study of Chapter 5 it was not possible to assess breath-
by-breath changes in operational lung volumes during the acute application of pNIV 
compared to PLB technique. By employing Opto-Electronic Plethysmography (OEP) 
this chapter investigated breath-by-breath changes in operational thoracoabdominal 
volumes in the transition from exercise to pNIV or PLB application and subsequently to 
normal breathing during recovery. 
In addition, one technical limitation of the VitaBreath device is that the expiratory 
and inspiratory positive airway pressures (EPAP and IPAP, respectively) are fixed. 
Excessive EPAP can worsen hyperinflation and circulatory compromise [50, 51] in 
some patients.  In Chapter 5, the majority of patients (16/24) showed no worsening of 
dynamic hyperinflation or circulatory compromise whilst using the VitaBreath device 
during recovery periods (DH responders). However, in six patients (three per group) the 
improvement in dynamic hyperinflation was greater with PLB than the VitaBreath 
device [20] (DH non-responders) at the limit of tolerance, thereby suggesting that the 
fixed pressures were sub-optimal in at least some of the patients in the clinical study. 
The more detailed analysis presented in Chapter 5, revealed worsening of dynamic 
hyperinflation in response to pNIV application in terms of manifestation of dynamic 
hyperinflation in 8/24 patients (DH non-responders) at an identical sub-maximal time 
point (iso-time) during exercise. Thus, it was deemed necessary to further investigate 
the different type of thoracoabdominal muscle kinematic response to pNIV application 
in patients who displayed-worsened dynamic hyperinflation with pNIV. Accordingly, 
an additional objective of this study was to identify the pattern of dynamic 
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hyperinflation that worsens with the application of the VitaBreath device, as it is 
recognised that patients with COPD experience different patterns of dynamic 
hyperinflation during exercise, categorised as early or late hyperinflators [85] or 
evolumics [123].  
Dynamic hyperinflation can be assessed by either instructing the patient to perform 
successive inspiratory capacity manoeuvres, which provides a picture of the magnitude 
of dynamic hyperinflation at a given time point or on a breath-by-breath basis using 
OEP [18]. In the present study use of OEP allowed continuous assessment of end-
inspiratory and end-expiratory volumes of the thoracoabdominal wall and its 
compartments (rib cage and abdomen). Thus, thoracoabdominal dynamic hyperinflation 
could be directly assessed, without requiring patients to perform volitional inspiratory 
capacity manoeuvres. OEP is a valid and reliable method to assess thoracoabdominal 
wall volumes [245, 247, 248, 250] and has previously been used in patients with COPD 
during exercise, to assess the rate and pattern of dynamic hyperinflation [85, 86, 297]. 
Accordingly, the purpose of this study was to use OEP during acute application of 
the VitaBreath device in recovery from exercise in patients with COPD, in order to: 1) 
appreciate the acute mechanisms by which the VitaBreath device influences the 
magnitude and pattern of thoracoabdominal wall dynamic hyperinflation in comparison 
to the PLB technique, 2) evaluate the relative rib cage and abdominal wall muscle 
kinematic response, inferred by changes in the volumes of the rib cage and abdominal 
compartments in patients improving or worsening dynamic hyperinflation with the 
pNIV device compared to the PLB technique and 3) assess the effect of application of 
fixed expiratory and inspiratory positive airway pressures (EPAP and IPAP, 
respectively) on circulatory responses when using the pNIV device. 
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6.1.1. Main outcomes 
6.1.1.1. Primary Outcome 
The primary outcome of the study was the magnitude and pattern of change in end-
inspiratory and end-expiratory thoracoabdominal wall dynamic hyperinflation, assessed 
by OEP when using the pNIV device compared to the PLB technique during recovery 
from exercise. 
6.1.1.2. Secondary Outcomes 
Secondary outcomes included differences in the following variables, when using the 
pNIV device compared to the PLB technique in recovery from exercise: 
 Compartmental thoracoabdominal wall volumes (rib cage and abdominal 
volumes) assessed by OEP 
 Central haemodynamic responses assessed non-invasively by cardio impedance 
technology: 
o Heart rate 
o Stroke volume 
o Cardiac output 
6.2. Methods 
6.2.1.  Study design 
This was an exploratory study investigating the acute effect of the short term (1-min) 
application of pNIV on thoracoabdominal volumes and circulatory responses compared 
to the pursed lip breathing technique (PLB), in COPD patients exhibiting different 
patterns of dynamic hyperinflation. Patients performed two identical exercise tests in a 
balanced order and the intervention (VitaBreath) was compared to control breathing. 
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Patients underwent two exercise tests on a cycle ergometer on the same day, using 
both the VitaBreath device and the pursed-lip breathing technique during recovery from 
exercise. The investigations were carried out following the rules of the Declaration of 
Helsinki of 1975 [211], revised in 2013. NHS Research Ethics Committee approval 
(REC: 19/NE/0091) and Clinical Trials registration (NCT03848819) were obtained 
(Appendix F). 
The study included two visits. During the first visit, patients underwent a clinical 
assessment including: medical history, physical examination, ECG and full lung 
function assessment including spirometry, lung volumes and diffusion capacity, to 
ensure patients were clinically stable. During the second visit, patients performed two 
intermittent exercise tests lasting 20 minutes each, consisting of 2-min work bouts at 
80% of peak work rate (WRpeak) as determined in the clinical study (REC reference: 
17/NE/0085 - IRAS project ID: 221120) (Chapters 4 & 5) with 2-min recovery periods 
in between work bouts, using either the VitaBreath device or the pursed lip breathing 
technique during the recovery periods in a balanced order sequence.  
6.3.Results 
6.3.1. Patient characteristics 
Baseline characteristics of the patients who participated in the study are presented in 
table 6.1. Patients exhibited moderate to severe airflow limitation and lung 
hyperinflation at rest without resting hypoxemia (Table 6.1.). In addition, peak exercise 
capacity and aerobic capacity of the patients assessed by the ramp incremental CPET 
were reduced (Table 6.2.). Prior to inclusion to the study, all participants were 
confirmed as previous smokers, had no exacerbations within the last six weeks and no 
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other uncontrolled comorbidities, in accordance with the study inclusion and exclusion 
criteria. 
 
Table 6.1 Demographic characteristics of patients at baseline. 
Variable n=7 
Gender (M/F) 4/3 
Age (years) 64±8 
BMI 27.9±5.0 
FEV1 (% predicted) 52±18 
FVC (% predicted) 103±13 
FEV1/FVC (%) 40±13 
IC (litres) 2.11±0.32 
IC (% predicted) 85±24 
TLC (% predicted) 122±18 
FRC (% predicted) 154±34 
DLco (% predicted) 43±17 
M, male; F, female; BMI, body mass index; FEV1, forced expiratory volume in the first second; FVC, 
forced vital capacity; IC, inspiratory capacity; TLC, total lung capacity; FRC, functional residual 
capacity; DLco, transfer factor of the lung for carbon monoxide; WR, work rate, values presented as 
mean ± standard deviation (SD). 
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Table 6.2. Peak physiological variables at the limit of tolerance during 
cardiopulmonary exercise testing (CPET). 
Variable n=7 
WR (Watts) 66±29 
WR (% predicted) 57±18 
VO2 (ml/kg/min) 16.0±4.3 
VO2 (% predicted) 69±16 
VCO2 (ml/min) 1205.5±495.5 
RQ 1.0±0.1 
bf (breaths/min) 31±6 
VT (litres) 1.4±0.4 
VE(litres/min) 46.6±22.3 
VE/VO2 (%) 36.4±4.5 
VE/VCO2 (%) 37.8±4.4 
VE/MVV (%) 1.0±0.3 
ΔIC from rest (litres) -0.6±0.3 
VT/IC (%) 65±11 
SpO2 (%) 93±3 
CO (litres/min) 12.9±3.0 
HR (beats/min) 120±17 
HR (% predicted) 108±17 
SV (ml) 108±17 
VO2/HR (ml/beat) 80±8 
SBP (mmHg) 158±16 
DBP (mmHg) 91±7 
Dyspnoea (Borg 1–10) 4.0±0.8 
Leg discomfort (Borg 1–10) 3.9±1.0 
WR, work rate; VO2, oxygen uptake; VCO2, carbon dioxide expired; RQ, respiratory quotient 
for oxygen uptake; bf, breathing frequency; VT, tidal volume; VE, minute ventilation; MVV, 
Maximum voluntary ventilation; ΔIC, change from rest in inspiratory capacity; SpO2, arterial 
oxygen saturation; CO, cardiac output; HR, heart rate; SV, stroke volume; SBP, systolic blood 
pressure; DBP, diastolic blood pressure; Values are mean ± SD. 
 
6.3.2. Total thoracoabdominal volume acute responses 
Figure 6.1b shows a typical experimental tracing of absolute thoracoabdominal 
volume measurements at baseline, over the last min of exercise, during the first minute 
of recovery with pNIV application and during the second minute of recovery breathing 
quietly. A gradual increase in end-expiratory thoracoabdominal volume took place 
during exercise, indicating thoracoabdominal dynamic hyperinflation. During acute 
application of pNIV both end-inspiratory and end-expiratory thoracoabdominal volumes 
further increased. During quiet breathing in the second minute of recovery, 
thoracoabdominal volumes regressed towards the levels seen at the end of exercise.   
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Figure 6.1. Pattern of thoracoabdominal kinematic response with a) PLB and b) pNIV at baseline (QB), during exercise, during application of PLB (a) and pNIV (b) and 
recovery. TLC, total lung capacity assessed by an inspiratory capacity manoeuvre; EI, end-inspiratory volume; EE, end-expiratory volume. 
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Exercise bouts induced comparable levels of end-expiratory thoracoabdominal 
dynamic hyperinflation prior to the use of the pNIV method (by: 0.3±0.2 litres) or the 
PLB technique (by: 0.3±0.2 litres). Figure 6.2a shows the average changes in 
thoracoabdominal volumes using the pNIV and PLB technique for all patients. During 
the first minute of recovery both pNIV and PLB application induced further increases in 
end-expiratory thoracoabdominal volumes, to a similar degree [pNIV: by 0.3±0.4 litres 
and PLB: by 0.3±0.3 litres (p=0.779)].  The pattern of change in total end-inspiratory 
chest wall volume in the first minute of recovery was different between pNIV 
application and the PLB technique. Application of pNIV further increased end-
inspiratory volume (by 0.3±0.2 litres), whilst the PLB technique reduced end-
inspiratory volume (by 0.1±0.2 litres) (p=0.035) (Figure 6.2a & 6.3a). During the 
second minute of recovery thoracoabdominal end-inspiratory and end-expiratory 
volumes were not different after pNIV or PLB application but still significantly elevated 
compared to baseline (Figure 6.2a), thereby indicating incomplete recovery for both 
end-inspiratory and end-expiratory dynamic hyperinflation. Thoracoabdominal volumes 
at TLC were unchanged between baseline and exercise (Figure 6.2a). 
6.3.3. Rib cage compartment acute responses 
During the first minute of recovery following exercise, pNIV application did not 
induce any change in end-expiratory rib cage volume, indicating persistent end-
expiratory rib cage dynamic hyperinflation. PLB application, however, reduced end-
expiratory rib cage volume. In the first minute of recovery end-inspiratory chest wall 
volume increased with pNIV application (by 0.2±0.2 litres) but it was reduced with the 
PLB technique (by 0.6±1.0 litres) (Figure 6.2b & 6.3b). During the second minute of 
recovery rib cage end-inspiratory and end-expiratory volumes regressed towards 
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baseline but were still greater compared to baseline indicating persistent rib cage wall 
hyperinflation (Figure 6.3b). 
6.3.4. Abdominal compartment volume acute responses 
During the first minute of recovery following exercise, both pNIV and PLB 
application induced an increase in end-expiratory volume [pNIV: by 0.3±0.3 litres and 
PLB: by 0.4±0.5 litres (p=0.137)], whilst the increase in end-inspiratory volume was 
similar during application of pNIV and PLB [pNIV: by 0.1±0.2 litres and PLB: by 
0.1±0.2 litres (p=0.668)] (Figure 6.2c & 6.3c). During the second minute of recovery 
abdominal end-inspiratory and end-expiratory volumes were similar after pNIV or PLB 
but still greater compared to baseline, indicating persistent abdominal wall 
hyperinflation (Figure 6.2c). 
Figure 6.3 shows that nearly identical end-expiratory dynamic hyperinflation with 
both pNIV and PLB application was due to greater end-expiratory rib cage 
hyperinflation with pNIV that was, however, compensated by greater end-expiratory 
abdominal recruitment. In contrast, greater end-inspiratory dynamic hyperinflation with 
pNIV compared to PLB was due to greater end-inspiratory rib cage dynamic 
hyperinflation but similar end-inspiratory abdominal volume. 
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Figure 6.2. Effect of the application of pNIV (closed symbols) compared to pursed lip breathing (open 
symbols) on a) total thoracoabdominal volume, b) rib cage volume and c) abdominal volume. End-
expiratory volume (circles), end-inspiratory volume (triangles). Data are presented as mean ± standard 
error of the mean (SEM). Dotted line in figure (a) indicates total lung capacity. * p<0.05 pNIV vs pursed 
lip breathing (PLB). 
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Figure 6.3. Effect of the acute 1-min application of pNIV (black bars) compared to pursed lip breathing 
(grey bars) on: a) total thoracoabdominal, b) rib cage and c) abdominal end-expiratory (EEcw) and end-
inspiratory (EIcw) volumes. Data are presented as mean ± standard error of the mean (SEM). * p<0.05 
pNIV vs pursed lip breathing (PLB). 
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6.3.5. Breathing pattern 
Table 6.3 shows breathing pattern variables during use of the VitaBreath device 
compared to PLB. Compared to PLB, application of pNIV did not affect either 
inspiratory (pNIV: 1.1±0.2 seconds and PLB: 1.0±0.2 seconds, p=0.801) or expiratory 
time (pNIV: 1.7±0.3 seconds and PLB: 1.7±0.4 seconds, p=0.726), neither total 
breathing cycle time (pNIV: 2.8±0.4 seconds and PLB: 2.7±0.4 seconds, p=0.821). 
However, application of pNIV compared to PLB induced greater minute ventilation 
(pNIV: 43.0±20.0 litres/min and PLB: 37.3±16.0 litres/min, p=0.049), secondary to 
increased tidal volume (pNIV: 1.9±0.8 litres and PLB 1.5±0.4 litres, p=0.178), whilst 
breathing frequency was similar between the two breathing modalities (pNIV: 23±4 
breaths/min and PLB: 25±6 breaths/min, p=0.658). Interestingly, use of pNIV compared 
to PLB induced greater inspiratory (pNIV: 1.9±0.8 litres/sec versus PLB: 1.7±0.6 
litres/sec, p=0.034) and expiratory flow rates (pNIV: 1.2±0.6 litres/sec versus PLB: 
1.0±0.5 litres/sec, p=0.044). On average breathlessness scores tended to be lower with 
pNIV compared to the PLB technique (by: 0.3±0.5) and leg discomfort was similar 
between pNIV (2.6±0.8 units) and PLB (2.5±0.9).   
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Table 6.3. Effect of 1-min pNIV application following exercise on breathing pattern and 
circulatory responses 
Variable pNIV PLB p 
bf (breaths/min) 23±4 25±6 0.658 
VT (litres) 1.9±0.8 1.5±0.4 0.178 
VE (litres/min) 43.0±20.0 37.3±16.0 0.059 
Ti (seconds) 1.1±0.2 1.0±0.2 0.801 
Te (seconds) 1.7±0.3 1.7±0.4 0.726 
Ttot (seconds) 2.8±0.4 2.7±0.4 0.821 
SV (ml) 107±34 100±36 0.240 
HR (beats/min) 117±23 112±27 0.055 
CO (litres/min) 12.1±4.1 11.3±4.8 0.204 
Data are presented as mean±SD; pNIV, portable non-invasive ventilation; PLB, pursed lip 
breathing; bf, breathing frequency; VT, tidal volume; VE, minute ventilation; Ti, inspiratory 
time; Te, expiratory time; Ttot, total duty cycle; SV, stroke volume; HR, heart rate; CO, cardiac 
output. 
6.3.6. Central haemodynamic acute responses 
Compared to pursed lip breathing, 1-min application of pNIV induced greater SV [by 
7±14 ml (p=0.240)], HR [by 5±5 beats/min, p=0.055] and CO [by 0.8±1.5 litres/min, 
p=0.204)] (Figure 6.4). Following 1-min application of pNIV SV, HR and CO remained 
elevated compared to pursed lip breathing [by 11±11 ml (p=0.032)], [by 2±6 beats/min 
(p=0.343)] and [by 1.3±1.6 litres/min (p=0.069)], respectively (Figure 6.4). 
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Figure 6.4. Effect of 1-min application of pNIV (closed symbols) compared to pursed lip breathing (open 
symbols) on a) stroke volume, b) heart rate and c) cardiac output. Data are presented as mean ± standard 
error of the mean (SEM). * p<0.05 pNIV vs pursed lip breathing (PLB). 
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6.3.7. Different patterns of recovery of dynamic hyperinflation in COPD 
Example A: Improved dynamic hyperinflation with pNIV (responder) 
Figure 6.5 presents an example of a patient who reduced the degree of end-expiratory 
dynamic hyperinflation with the application of pNIV whilst with PLB no improvement 
was exhibited (Figure 6.5a). This pattern was seen in 2/7 patients identified as 
responders in Chapter 5. The difference in the pattern of end-expiratory dynamic 
hyperinflation was due to greater end-expiratory rib cage and abdominal activation 
(Figure 6.5b & c). Despite the greater reduction of end-expiratory rib cage and 
abdominal volumes with pNIV, stroke volume and heart rate responses were not 
different with the application of pNIV or the PLB technique. (Figure 6.5d). 
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Figure 6.5. Effect of 1-min application of pNIV (closed symbols) compared to pursed lip breathing (open 
symbols) on: a) thoracoabdominal, b) rib cage and c) abdominal end-expiratory volume (circles) and end-
inspiratory volume (triangles) of the total thoracoabdominal volume and d) stroke volume (circles) and 
heart rate (triangles). 
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Example B: worsening of dynamic hyperinflation with pNIV but not PLB (non-
responder) 
Figure 6.6 presents an example of a patient who experienced a greater degree of end-
expiratory dynamic hyperinflation with application of pNIV, whilst with the PLB 
technique end-expiratory dynamic hyperinflation was abolished. This pattern was seen 
in 2/7 patients identified as non-responders in Chapter 5. As presented in figure 6.6b 
application of pNIV increased end-expiratory rib cage volume and end-expiratory 
abdominal volume. This pattern differed in comparison to the responders (example A), 
as both compartments (rib cage and abdominal) were further hyperinflated with pNIV 
compared to PLB (Figures 6.6b & c). Despite greater compartmental hyperinflation 
with pNIV, stroke volume and heart rate responses were similar between pNIV and 
PLB applications (Figure 6.6d). 
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Figure 6.6. Effect of 1-min application of pNIV (closed symbols) compared to pursed lip breathing (open 
symbols) on: a) thoracoabdominal, b) rib cage and c) abdominal end-expiratory volume (circles) and end-
inspiratory volume (triangles) of the total thoracoabdominal volume and d) stroke volume (circles) and 
heart rate (triangles). 
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Example C: worsening of DH with both pNIV and PLB  
Figure 6.7 presents the results of a patient who experienced a greater degree of end-
expiratory and end-inspiratory dynamic hyperinflation with both pNIV and PLB 
application. However dynamic hyperinflation was greater with pNIV compared to PLB, 
mainly due to greater end-inspiratory and end-expiratory rib cage hyperinflation 
(Figures 6.7b & c). This pattern was seen in 3/7 patients, which was not identified as a 
response pattern in Chapter 5. Stroke volume was similar between the two methods, 
albeit unchanged from the end of exercise in both cases (Figure 6.7d). In contrast, heart 
rate recovered to a greater extent with the application of PLB compared to pNIV 
application, where heart rate remained at similar levels as during exercise (Figure 6.7d). 
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Figure 6.7. Effect of 1-min application of pNIV (closed symbols) compared to pursed lip breathing (open 
symbols) on: a) thoracoabdominal, b) rib cage and c) abdominal end-expiratory volume (circles) and end-
inspiratory volume (triangles) of the total thoracoabdominal volume and d) stroke volume (circles) and 
heart rate (triangles). 
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6.4.Discussion 
Compared to the PLB technique, pNIV application in patients with COPD was 
associated with increased end-inspiratory and end-expiratory thoracoabdominal 
volumes. This finding is justified by the fixed IPAP and EPAP (18 and 8 cm H2O, 
respectively) provided by the VitaBreath device, which has also been reported with 
other NIV methods in healthy subjects [242, 298, 299] and in patients with COPD [178, 
300, 301]. Furthermore, pNIV application was associated with increased tidal volume, 
minute ventilation and inspiratory and expiratory flow rates. The VitaBreath device is 
designed to unload the inspiratory muscles during inspiration and keep the airways open 
during expiration. Hence, greater expiratory flow rates reported in the present study are 
indicative of reduced expiratory flow limitation and more adequate lung emptying. 
Interestingly, breathlessness tended to be lower after pNIV application compared to the 
PLB technique. However, on average increased expiratory flow rates and reduced 
breathlessness were not accompanied by reduced end-expiratory thoracoabdominal 
volumes, when using the pNIV device compared to PLB. The discrepancy is most likely 
due to the different patterns of hyperinflation response seen in the population studied, 
but also due to the fact that the optoelectronic plethysmography imaging method 
captures changes in thoracoabdominal and not only lung volumes, including gas 
volume, gas compression and blood volumes [125]. In the present study, greater cardiac 
output was reported with the pNIV device compared to the PLB technique, possibly 
justifying the increased blood volume within the thoracoabdominal cavity. Furthermore, 
the effect of pNIV with fixed IPAP and EPAP would be expected to induce greater rates 
of gas compression compared to PLB, and thus greater thoracoabdominal volumes. 
Acute application of pNIV in 7 out of 24 patients originally recruited and presented 
in Chapter 5, revealed different patterns of response in end-expiratory and end-
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inspiratory dynamic hyperinflation, namely improved dynamic hyperinflation with 
pNIV as in example A (seen in 2/7 patients), and worsened dynamic hyperinflation as in 
examples B and C that was seen in 5/7 patients. In respect to the latter category two 
different response patterns were further identified namely: i) worsened dynamic 
hyperinflation with pNIV compared to PLB as presented in example B and ii) worsened 
dynamic hyperinflation with both pNIV and PLB as presented in the typical example C. 
Regardless of the pattern of change in end-expiratory and end-inspiratory 
thoracoabdominal hyperinflation, no circulatory adverse effects were demonstrated in 
any of the patients tested. Absence of adverse circulatory effects with the use of the 
pNIV method is in accordance with the findings in healthy individuals, thereby 
suggesting that the brief use of pNIV is insufficient to adversely impact on circulation 
[242]. 
Furthermore, the findings of the present study confirm the different patterns of end-
expiratory dynamic lung hyperinflation reported in Chapter 5 and the findings in 
healthy individuals, where acute application of pNIV increased both end-expiratory and 
end-inspiratory thoracoabdominal volumes both during normal breathing and following 
hyperventilation [242].  
The results of the present study are in accordance with the existing literature, as other 
studies have previously reported that application of non-invasive ventilation with or 
without additional PEEP increases end-expiratory lung volumes in patients with COPD 
[178, 300, 301]. The mean average PEEPi from a number of studies was 3.4 cmH2O as 
reported in the review by Kallet and Diaz [175], whilst application of external PEEP of 
5 cmH2O caused an average reduction of 1.8 cmH2O in PEEPi [175]. In contrast, 
application of IPAP of 15 cmH2O and zero PEEPe caused an increase in PEEPi by 1.8 
cmH2O [302] and thus increased end-expiratory lung volume [178, 300]. Application of 
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IPAP (18 cmH2O) with pNIV, most likely increased PEEPi causing acutely end-
expiratory thoracoabdominal hyperinflation in this cohort of patients. The increase in 
end-expiratory lung volume seems to be the result of mechanical impairment of the 
respiratory muscles [178, 301]. According to the length-tension relationship, the 
capacity of the inspiratory muscles to generate power decreases with increased end-
expiratory lung volume, owing to the fact that inspiratory muscles become shorter. 
Furthermore, according to Laplace relationship, the flatter the diaphragm becomes as 
result of increased lung volume, the less pressure it generates for any given 
diaphragmatic tension [303, 304]. In contrast to the majority of the literature reporting 
increased tidal volume and reduced breathing frequency [176-182], application of the 
VitaBreath device, in the present study, resulted in increased ventilation due to greater 
tidal volume compared to PLB, whilst breathing frequency was not different to PLB 
[183, 184, 189, 300]. The breathing pattern adopted during the application of pNIV 
increased ventilation and thus induced greater end-inspiratory thoracoabdominal 
dynamic hyperinflation compared to the end of exercise. 
Although dynamic hyperinflation is a commonly reported manifestation in patients 
with COPD, not all patients exhibit a homogenous pattern of hyperinflation during 
exercise. In fact, a study by Aliverti and colleagues [123] reported two different patterns 
of end-expiratory chest wall volume regulation during peak exercise in patients with 
COPD, namely hyperinflators (exhibiting exercise-induced dynamic hyperinflation) and 
euvolumics (not exhibiting exercise-induced dynamic hyperinflation) [123]. The 
distinguishing characteristic of the two different patterns of chest wall volume 
regulation was the greater increase in end-expiratory and end-inspiratory volume of the 
rib cage compartment in the hyperinflators compared to the euvolumics and the greater 
reduction of end-expiratory volume of the abdominal compartment in the euvolumics 
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compared to hyperinflators [123]. However, not all studies agree with these findings as 
Vogiatzis and colleagues [85] reported that patients with COPD fall into two main 
categories, namely those who progressively hyperinflate during exercise (early 
hyperinflators) and those who hyperinflate only during the late stages of exercise (late 
hyperinflators) [85]. In the present study, all patients hyperinflated progressively during 
exercise and the majority remained hyperinflated after two minutes of recovery with 
either pNIV or PLB application. These findings are in agreement with the literature, as 
it has been reported that end-expiratory chest wall volume takes at least five minutes to 
recover following exercise in patients with COPD [85]. However, the 3 different 
dynamic hyperinflation patterns reported in the present study when pNIV was applied 
suggests that some patients exhibited an evolumic breathing pattern, whilst others 
demonstrated a hyperinflator pattern during application of pNIV according to Aliverti 
and colleagues [123]. Moreover, although all patients hyperinflated during exercise, the 
different patterns of respiratory muscle kinematic response recorded when the 
VitaBreath device was applied indicate greater recruitment of the expiratory abdominal 
muscles combating dynamic hyperinflation just like the evolumic pattern described by 
Aliverti and colleagues [123]. It has been postulated that such a contraction is beneficial 
because lengthening of the diaphragm results in greater generation of negative pleural 
pressure (better position of the length-tension relationship) [64, 65]. Thus, adopting 
such a breathing pattern could assist the patient to fight against the provided inspiratory 
and expiratory pressures. 
The VitaBreath device provides fixed high expiratory pressures. Thus, PEEP 
generated by the VitaBreath device may be excessive to overcome the emphysematous 
airway changes observed in some patients. Although the PEEP provided by the device 
is necessary for preventing airway collapse and subsequently improving expiratory 
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flow, it will not be beneficial if it is not matching the individual patient’s intrinsic PEEP 
[305]. Thus, the expiratory pressure provided by the VitaBreath device is likely to be 
suboptimal for some patients not facilitating reduced end-expiratory thoracoabdominal 
volume, likely due to the inability of the device to individualise the aforementioned 
pressures. Furthermore, when there is a mismatch between the PEEPi and PEEPe there 
is increased risk of patient-ventilatory asynchronies to occur [207], which could lead to 
increased work of breathing and greater mismatch between alveolar ventilation and 
perfusion [283]. Thus, the ability of the patient to synchronise with the device might 
reduce the effectiveness of the ventilator. 
Previous studies have reported that application of NIV in patients with COPD at rest 
reduces cardiac output [198, 200], whilst similar findings are reported in patients with 
CHF [196, 199, 201, 306]. The short application of pNIV (1-min) may have prevented 
adverse circulatory effects, as opposed to the existing literature where NIV application 
exceeded 5 minutes, resulting in adverse circulatory responses [196, 198-201, 306]. 
Interestingly, the study by Baratz and colleagues in patients with CHF reported that in 7 
out of 13 patients a reduction in left ventricular afterload without a change in the 
systemic arterial pressure and arterial oxygen content resulted in increased cardiac 
output [199]. In the present study stroke volume and cardiac output were not adversely 
affected by the application of the VitaBreath device. In fact, cardiac output was slightly 
greater when pNIV was applied compared to PLB, due to both increased stroke volume 
and heart rate. The respiratory kinematic findings of this study indicate increased rib 
cage and abdominal wall muscle recruitment, most likely to accommodate the increased 
IPAP and EPAP, which could lead to increased circulatory responses. 
Moreover, greater activation of the respiratory muscles with pNIV, as inferred by the 
rib cage and abdominal compartmental analysis in the present study, would be expected 
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to increase respiratory muscle energy requirement, potentially mitigating the impaired 
venous return caused by increased IPAP and EPAP. Although a number of studies 
report a reduction in diaphragmatic and oesophageal pressures with NIV, indicating 
reduced work of breathing [177-181, 183-186, 302, 307], a recent study that applied 
high levels of PEEP (10 and 15 cmH2O) found an increase in the parasternal and 
sternocleidomastoid muscle activation, respectively [308]. The VitaBreath device 
delivers higher inspiratory and expiratory pressures (18 and 8 cm H2O, respectively) 
compared to those usually reported in the literature [24, 33, 42, 44, 49, 128, 175, 177-
181, 183-186, 209, 210, 271, 302, 307]. The high pressures further increased dynamic 
hyperinflation following exercise which justify an increase in respiratory muscle 
activation as described above, in order to accommodate the increase in breathing 
volumes; this extra volume regulation would be expected to increase the energy 
requirement of the respiratory muscles and thus maintain stroke volume and cardiac 
output at high levels during recovery compared to the end of exercise. 
The present study has some limitations. The main limitation as in the previous 
chapters was that the VitaBreath device provides fixed inspiratory and expiratory 
pressures and thus it was not possible to individualise the pressures for each patient. In 
addition, although opto-electronic plethysmography is a more accurate method to detect 
breath-by-breath changes in thoracoabdominal volumes compared to inspiratory 
capacity manoeuvres, thoracoabdominal volumes include not only lung volumes but 
also blood volumes and compressed gas volumes. Thus, the failure to detect differences 
in end-expiratory thoracoabdominal volumes between the two breathing modalities 
could be due to differences in blood volume (increased cardiac output) and gas 
compression with excessive EPAP and IPAP.  
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Application of pNIV provided by the VitaBreath device acutely worsened end-
inspiratory and end-expiratory dynamic hyperinflation following cessation of exercise 
in a subset of patients with COPD, but conversely lessened end-expiratory dynamic 
hyperinflation in some patients. This pattern of response was also seen in Chapter 5, 
which identified DH responders and DH non-responders, however in the present study 
only 7 out of the original 24 patients agreed to participate. Nevertheless, the clinical 
implications described in Chapter 5 also apply in this study, as it is apparent that one 
size does not fit all patients. Therefore, prior to prescription of any NIV device to assist 
activities of daily living, the health care professional should investigate whether the 
device improves or worsens the patient symptoms.   
6.5.Conclusions 
As with any pharmacological or non-pharmacological intervention in COPD, it was 
shown that the thoracoabdominal response pattern to pNIV application was variable 
among patients. Patients who could afford expiratory abdominal muscle recruitment, 
exhibited reduced end-expiratory thoracoabdominal dynamic hyperinflation with the 
pNIV method without concurrent adverse circulatory effects. Patients not demonstrating 
expiratory abdominal recruitment exhibited increased thoracoabdominal hyperinflation. 
Regardless of the thoracoabdominal response pattern identified in the present study, an 
important limitation of the VitaBreath device is that inspiratory and expiratory pressures 
were fixed; therefore adjustment of the aforementioned pressures was not possible in 
patients exhibiting different breathing patterns. This is distinct to other studies applying 
NIV in COPD, where the level of provided pressure is individualised to maximise the 
benefit of use. This represents a very important disadvantage of the VitaBreath device, 
which clearly mitigated the beneficial impact it had on some patients. 
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The findings of this study suggest that, although the VitaBreath device presents with 
promising results and favourable practical benefits, it is not effective in improving 
thoracoabdominal dynamic hyperinflation in all COPD patients. It is therefore important 
that clinicians investigate whether the VitaBreath or any other NIV device improves or 
exacerbates symptoms on an individual basis. This will enable the device to be 
implemented both clinically and cost effectively, to ensure patients are able to reap the 
desired benefits from the device, and subsequently improve their overall quality of life. 
Considering the variation in response reported in Chapters 5 and 6, it is important 
considering that clinicians need to assess the response to pNIV on an individual basis. 
Moreover, the VitaBreath device was designed to be used during activities of daily 
living, in order to relieve breathlessness. Thus, it is important to investigate patient 
perceptions of the usability and applicability of the device when used during daily 
physical activities. Accordingly, Chapter 7 reports on usability and applicability of the 
device, as well as perceived symptoms when COPD patients used the VitaBreath during 
their daily physical activities. 
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7. Acceptability, comfort and usability of portable non-
invasive ventilation during activities of daily life in 
patients with COPD 
7.1. Introduction 
Patients with COPD exhibit lower exercise capacity and reduced daily physical 
activity, reflected by lower daily steps and intensity of movement, compared to healthy 
age matched individuals [265, 309-315]. Interestingly, lower levels of physical activity 
are associated with a greater risk of exacerbation-related hospitalisations [265, 316-325] 
and mortality [265, 324-326]. Accordingly, increasing levels of daily physical activity is 
of great importance in this population. 
Reduced exercise capacity and daily physical activity is often the result of intolerable 
breathlessness when performing different activities [262], secondary to a host of 
pathophysiological factors, including ventilatory constraints, gas exchange impairment, 
cardiovascular and metabolic dysfunction [18]. Different strategies have been employed 
to reduce dynamic hyperinflation, as well as increase exercise tolerance and daily 
physical activity including bronchodilators, supplemental oxygen, inspiratory muscle 
training, heliox supplementation, pulmonary rehabilitation and non-invasive ventilation 
(NIV) [22-24, 28, 128, 327-329]. However, apart from bronchodilators and 
supplemental oxygen therapy which are commonly used in standard care, non-invasive 
ventilation and heliox supplementation have poor applicability for ambulatory use, 
mainly due to the difficulty of using the equipment during activities of daily living [49] 
and high cost [28], respectively. Moreover, although oxygen supplementation is easy to 
apply during daily life [330, 331], sometimes it is inadequate to meet the needs of 
patients with significant ventilatory constraints [332-334]. 
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NIV is domiciliary used mainly to treat obstructive sleep apnoea, central sleep 
apnoea and hypoventilation in the form of continuous positive airway pressure (CPAP). 
CPAP is usually applied via a nasal, oral or a combined method (i.e. mask). However, 
the adherence to commonly used NIV methods is very poor and is associated with the 
disease severity, the pressure level, the type of interface, and the duration of the 
treatment which is usually during sleeping hours [335-337]. 
Nevertheless, due to recent technological developments, devices that are easy to 
operate during daily physical activities, including portable non-invasive ventilators have 
been developed [338]. However, there is not enough evidence in the literature 
investigating the applicability and adherence to these interventions during activities of 
daily life. In a study investigating ease of use, comfort and preference of a non-invasive 
open ventilator (NIOV), patients felt less breathless, had more energy when performing 
tasks and felt more comfortable when using the NIOV device, compared to oxygen 
supplementation within a five days period [339].  
This dissertation has shown that application of pNIV via use of the VitaBreath device 
increased exercise tolerance in patients with COPD by reducing breathlessness 
secondary to reduced dynamic hyperinflation[20]. However, given that the main 
purpose of pNIV is to be easy and comfortable to use during daily life by patients with 
COPD, it was also important to investigate the adherence with and the applicability of 
the use of the VitaBreath device during activities of daily life. Thus, in collaboration 
with Philips Respironics a questionnaire (Appendix E) was developed to assess 
adherence and applicability of the VitaBreath device when patients used the device 
during daily activities.  
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Therefore, the purpose of this study was to investigate patient adherence with pNIV, 
as well as the effects of pNIV on anxiety, symptom burden and the ability to perform 
activities of daily living [20]. Accordingly, the frequency and usability of the 
VitaBreath device, alongside symptom burden and attitudes towards the device in the 12 
weeks following completion of the laboratory based study described in Chapter 5 were 
also assessed within the present dissertation [20]. 
7.1.1. Main outcomes 
7.1.1.1. Primary Outcome 
The primary outcome of the study was to assess patient adherence to using the device 
during activities of daily living in patients with COPD. 
7.1.1.2. Secondary Outcomes 
Secondary outcomes included self-reported anxiety, symptom burden and ability to 
perform daily physical tasks. 
7.2. Methods 
7.2.1. Study design 
This was a survey research study assessing adherence to pNIV during activities of 
daily living. Adherence to the device was assessed using a questionnaire provided by 
Philips (Appendix E), which was administered over the phone. Following completion of 
the three visits of the study presented in Chapter 5, all 24 patients were given a 
VitaBreath device to use at home as they wished. Use of, and perceived benefit from, 
the VitaBreath device was examined at 2 and 12 weeks following completion of the first 
experimental study of the present thesis [20]. The survey included questions on 
symptom burden, ability to perform daily tasks and perceived benefit from the device 
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(Appendix E) [20]. Patients received advice on how to use the device for symptomatic 
relief during exertion, but the frequency of use was not prescribed [20]. 
7.3.Results 
7.3.1. Patient characteristics 
Baseline characteristics of patients that participated in the follow up study are 
presented in table 7.1. Patients exhibited severe airway obstruction and lung 
hyperinflation at rest. Five (20.8%) of the patients were current smokers, with 14 
(58.3%) having been admitted to hospital for an exacerbation of COPD (ECOPD) in the 
past 12 months. The median number of ECOPD (hospital or community managed) in 
the past 12 months was 2 (1–4.75). The median extended MRC dyspnoea score 
(eMRCD) was 4 (3–4) [20]. 
Table 7.1. Demographic characteristics of patients at baseline. 
Variable n=24 
DH Non-
Responders 
DH 
Responders 
Gender (M/F) 10/14 4/4 610 
Age (years) 67±8 67±3 67±2 
BMI 26.3±6.9 24.4±3.1 27.2±1.5 
FEV1 (% predicted) 46±18 40±8 49±4 
FVC (% predicted) 89±20 86±7 91±5 
FEV1/FVC (%) 38±13 37±5 43±3 
IC (litres) 2.00±0.67 1.74±0.26 2.12±0.16 
IC (% predicted) 79±22 70±7 84±6 
TLC (% predicted) 130±24 135±6 128±7 
FRC (% predicted) 173±44 188±14 166±12 
DLco (% predicted) 37±21 33±11 40±5 
BMI, body mass index; FEV1, forced expiratory volume in the first second; FVC, forced vital 
capacity; IC, inspiratory capacity; TLC, total lung capacity; FRC, functional residual capacity; 
DLco, transfer factor of the lung for carbon monoxide; M, male; F, female; values are mean ± 
standard error of the mean (SEM) [20]. 
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7.3.2. Use and Perceived Benefits of the VitaBreath Device 
7.3.2.1. Adherence and usability of the VitaBreath device 
When comparing responses at 2 and 12 weeks, it became apparent that there was no 
attrition in the frequency of use of the device in DH responders (p=1.000) and DH non-
responders (p=0.317). At 12 weeks, 23/24 (15/16 DH responders and 8/8 DH non-
responders) patients continued to use the device at least once per week, and 16/24 
(11/16 DH responders and 5/8 DH non-responders) used the device on a daily basis 
[20]. Whilst both DH responders and DH non-responders described the VitaBreath as 
easy to use (good or better), most DH non-responders described its portability as poor or 
fair (87.5%). In contrast, 50% of DH responders described its portability as poor or fair. 
Additionally at 12 weeks, DH non-responders and DH responders reported a similar 
impact of the VitaBreath device on their quality of life, assessed using a 5-point likert 
scale [3.5 (1.5-4.75); 3.5 (2.25-5), p=0.665]. At 12 weeks, the median (IQR) of 
likelihood to recommend the VitaBreath to others was respectively 9.5 (IQR: 7.5–10) 
and 10 (6.25-10) in DH non-responders and DH responders. However, the likelihood to 
purchase the device was respectively 3 (1–4) and 2.5 (1.25-5) on a 10-point likert scale 
for DH non-responders and DH responders (Table 7.2) [20]. Finally, patients reported 
that they were unlikely to buy the device online, even if they could afford it [DH non-
responders: 1.5 (1-3.75); DH responders 2 (1-3), p= 0.803).  
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Table 7.2. Frequency of use of the VitaBreath device in responders and non-responders. 
 
DH Non-Responders DH Responders 
Question 
Two weeks of 
VitaBreath 
Twelve weeks 
of VitaBreath 
p-Value 
Two weeks of 
VitaBreath 
Twelve weeks of 
VitaBreath 
p-Value 
How often do you use 
VitaBreath? 
      
        
Several Times a day 6 (75%) 5 (62.5%)  11 (68.8%) 10 (62.5%)  
Once a day 0 (0%) 0 (0%)  1 (6.3%) 1 (6.3%)  
Couple times a week 1 (12.5%) 1 (12.5%) 0.317* 2 (12.5%) 4 (25.0%) 1.000* 
Once a week 1 (12.5%) 1 (12.5%) 
 
1 (6.3%) 1 (6.3%)  
Not at all 0 (0%) 1 (12.5%)  
 
1 (6.3%) 1 (4.2%)   
How would you rate 
VitaBreath for ease of use? 
Excellent 
Very Good 
Good 
Fair 
Poor 
n/a 
 
 
2 (25%) 
4 (50%) 
2 (25%) 
0 
0 
n/a n/a 
 
 
6 (37.5%) 
5 (31.3%) 
5 (31.3%) 
0 
0 
0.845
$#
 
How would you rate 
VitaBreath for portability? 
Excellent 
Very Good 
Good 
Fair 
Poor 
n/a 
 
 
0 
1 (12.5%) 
0 
2 (25%) 
5 (62.5%) 
n/a n/a 
 
 
3 (18.8%) 
4 (25%) 
1 (6.3%) 
5 (31.3%) 
3 (18.8%) 
0.028
$#
 
Would you say that 
VitaBreath has impacted 
your quality of life? 
 
Scale 1 (No difference) to 
5 (Tremendous difference) 
n/a 
Median 3.5 
(1.5-4.75) 
 n/a 
Median 3.5 (2.25-
5) 
0.655
$#
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DH Non-Responders DH Responders 
Question 
Two weeks of 
VitaBreath 
Twelve weeks 
of VitaBreath 
p-Value 
Two weeks of 
VitaBreath 
Twelve weeks of 
VitaBreath 
p-Value 
Given your recent 
experience with 
VitaBreath, how likely is it 
that you would recommend 
VitaBreath to a friend or 
colleague, or other people 
with COPD?§ 
 
1 (Not at all likely) to 10 
(Extremely likely) 
Median 8.5 
(7.25-10) 
Median 9.5 
(7.5-10) 
*0.260 
3 less 
likely to 
recommend 
4 more 
likely to 
recommend 
1 Ties 
Median 10 (7-10) 
§ 
Median 10 (6.25-
10) 
*0.150 
7 less 
likely to 
recommend 
2 more 
likely to 
recommend 
6 Ties 
If not given by NHS would 
you purchase yourself for 
£499? 
 
Scale 1 (Definitely not) to 
5 (Definitely yes) 
n/a Median 3 (1-4)  n/a 
Median 2.5 (1.25-
5) 
0.864
$#
 
If you could buy 
VitaBreath online, how 
likely would you be to 
purchase it online? 
Scale 1 (Definitely not) to 
5 (Definitely yes) 
n/a 
Median 1.5 (1-
3.75) 
 n/a Median 2 (1-3) 0.803
$#
 
Data presented as Absolute number (%); *Wilcoxon Signed-rank test, 
#
 Mann-Whitney U test 
$
 denotes p value for comparison between the two groups, § 1 
missing record at 2 weeks. 
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7.3.2.2. Use of the VitaBreath device during daily physical activity 
Patients found improvements in the speed, duration and confidence in which they 
could undertake activities of daily living, with no loss of these effects at 12 weeks 
(Table 7.3) [20]. Patients described being more active with the VitaBreath than without 
it at 2 weeks (DH non-responders: 5/8; DH responders: 8/16) and 12 weeks (DH non-
responders: 5/8; DH responders: 9/16) (Table 7.3). Similar improvements were also 
reported in speed, duration and confidence during activities of daily living when 
patients were divided into responders and non-responders (Table 7.3) [20]. Moreover, 5 
out of 8 (62.5%) and 8 out of 15 (53.3%) patients in the DH non-responders and DH 
responders group respectively, were more active compared to before using the 
VitaBreath and this improvement was maintained at 12 weeks in 62.5% and 56.2% in 
DH non-responders and responders group, respectively (Table 7.3). 
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Table 7.3. Effect of the VitaBreath device on daily physical activity in DH non-responders and DH responders. 
 
DH Non-Responders DH Responders 
Question 
Two weeks of 
VitaBreath 
Twelve weeks 
of VitaBreath 
p-Value 
Two weeks of 
VitaBreath 
Twelve weeks 
of VitaBreath 
p-Value 
Has VitaBreath helped your 
ability to perform activities? 
      
Speed^       
1 Not at all 3 (37.5%) 2 (25%) 0.414* 7 (50%) 6 (37.5%) 0.670* 
2 1 (12.5%) 0 (0%) 
 
0 (0%) 1 (6.3%) 
 
3 1 (12.5%) 3 (37.5%) 2 improvements 2 (14.3%) 3 (18.8%) 
4 
improvements 
4 2 (25%) 2 (25%) 1 worse 4 (28.6%) 0 (0%) 3 worse 
5 Yes, Definitely 1 (12.5%) 1 (12.5%) 5 ties 1 (7.1%) 6 (37.5%) 7 ties 
Duration^       
1 Not at all 3 (37.5%) 3 (37.5%) 0.705* 5 (35.7%) 3 (18.8%) 0.668* 
2 1 (12.5%) 0 (0%) 
 
0 (0%) 3 (18.8%) 
 
3 1 (12.5%) 4 (50%) 1 improvements 2 (14.3%) 1 (6.3%) 
6 
improvements 
4 2 (25%) 0 (0%) 3 worse 4 (28.6%) 3 (18.8%) 3 worse 
5 Yes, Definitely 1 (12.5%) 1 (12.5%) 4 ties 3 (21.4%) 6 (37.5%) 5 ties 
Confidence§       
1 Not at all 0 (0%) 2 (25%) 0.461* 2 (13.3%) 2 (12.5%) 0.509* 
2 1 (12.5%) 0 (0%) 
 
1 (6.7%) 1 (6.3%) 
 
3 3 (37.5%) 3 (37.5%) 2 improvements 4 (26.7%) 2 (12.5%) 
6 
improvements 
4 2 (25%) 1 (12.5%) 2 worse 4 (26.7%) 4 (25%) 3 worse 
5 Yes, Definitely 2 (25%) 2 (25%) 4 ties 4 (26.7%) 7 (43.8%) 6 ties 
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DH Non-Responders DH Responders 
Question 
Two weeks of 
VitaBreath 
Twelve weeks 
of VitaBreath 
p-Value 
Two weeks of 
VitaBreath 
Twelve weeks 
of VitaBreath 
p-Value 
How active have you been since 
VitaBreath, compared to 
before?§ 
      
Median (IQR) 6 (5-7) 6 (5-7.75)  6 (5-7) 6 (5-7.75)  
1(Much less active) to 4 1 (12.5%) 1 (12.5%) 0.679* 1 (6.7%) 1 (6.3%) 0.832* 
5= The same 2 (25%)  2 (25%)   6 (40%)  6 (37.5%)   
6 to 10 (much more active) 5 (62.5%) 5 (62.5%)  8 (53.3%) 9 (56.2%)  
Data presented as Median (IQR); Absolute number (%); *Wilcoxon Signed-rank test; § 1 missing record at 2 weeks; ^2 missing records at 2 
weeks. 
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7.3.2.3. Effect of use of the VitaBreath device during daily physical activity on self-
reported anxiety and symptom burden  
Compared to the pre-VitaBreath period, when patients were divided into DH 
responders and non-responders, at 12 weeks patients were less anxious about becoming 
breathless [DH non-responders: pre-VitaBreath = 8.00 (6.00–8.00), 12 weeks = 4.50 
(2.25–7.25), (p=0.127); DH responders: pre-VitaBreath = 8.00 (5.25–9.75), 12 weeks = 
3.50 (2.00–5.75), (p=0.001)]. In addition, 5 out of 8 DH non-responders (p=0.034) and 
11 out of 16 DH responders (p=0.002) perceived a shorter recovery time from 
breathlessness (Table 7.4). 
7.3.2.4. Additional comments and feedback about VitaBreath 
A number of patients provided further comments and feedback of their experience 
using the VitaBreath device during activities of daily living. One DH non-responder 
patient mentioned that the device was “a bit heavy to carry around” after 2 weeks of 
use. This was supported by another DH non-responder who stated that the device “does 
not fit in the pockets” and added that the device “helps with wheeze however, its 
effect/usefulness varies depending on severity of breathlessness”. Furthermore, two DH 
non-responders reported a few concerns about the weight of the device as “the device 
was too heavy to carry outside” and “it should have a carrying case”. Finally, a patient 
from the same group reported some technical issues such as “the mouthpiece keeps 
coming out and the screw at the back to clean out the filter is broken”. 
In contrast, at 2 weeks only two patients in the DH responders group reported that 
the device was “bulky and too heavy”. However, 3 patients mentioned that they “would 
like to be able to buy one but could not afford it”. Finally, two patients reported that 
“the device is marvellous” and “transformed my life”. Following 12 weeks of using the 
device at home, four patients reported that they “would buy it but would struggle at that 
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price” however, the overall feedback was positive as these patients reported that the 
device “has given my life back”, feel like my whole life has improved, would hate to be 
without it and my attitude has improved”. Finally one patient reported that the device 
was “easy to maintain and use”, whilst another patient reported that the device “is not 
doing much benefit and there is no appreciable difference” following 12 weeks of use 
during activities of daily living. 
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Table 7.4. Effect of the use of VitaBreath device on anxiety and recovery from breathlessness in DH non-responders and DH responders. 
 
DH Non-Responders DH Responders 
Question Pre-VitaBreath Post-VitaBreath p-Value Pre-VitaBreath Post-VitaBreath p-Value 
How anxious are you about becoming 
short of breath (SOB)? 
8.00 (6.00–8.00) 4.50 (2.25–7.25) 
0.127 * 
8.00 (5.25–9.75) 3.50 (2.00–5.75) 
0.001 * 
1 = Not at all anxious 6 improvements 
15 
improvements 
10 = Very anxious 1 worse 
 
  1 ties 1 ties 
How long did it take you to recover 
from SOB?   
0.034 *   0.002 * 
<1 min 0 (0%) 2 (25%) 5 improvements 1 (6.3%) 4 (25%) 
11 
improvements 
2–3 min 3 (37.5%) 3 (37.5%) 
 
3 (18.8%) 6 (37.5%) 1 worse 
4–5 min 1 (12.5%) 1 (12.5%) 3 ties 2 (12.5%) 3 (18.8%) 4 ties 
5–7 min 2 (25%) 0 (0%)  2 (12.5%) 1 (6.3%)  
7–10 min 0 (0%) 0 (0%)  6 (37.5%) 2 (12.5%)  
More than 10 min 2 (25%) 2 (25%)  2 (12.5%) 0 (0%)  
Data presented as median (IQR) or absolute number (%); *Wilcoxon signed-rank test. 
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7.4.Discussion 
The major finding of the study is that patients’ adherence to using the VitaBreath 
device when performing activities of daily living was satisfactory, mainly due to the 
simplicity of its operation. Furthermore, use of the VitaBreath device improved anxiety 
around breathlessness, as well as perceived time of recovery from it during activities of 
daily living. However, the main drawback of the device was its portability.  
All participants were given a device to use in daily life. Data suggests that the 
VitaBreath device improved anxiety around breathlessness, as well as perceived time to 
recover from breathlessness [20]. These findings further support the clinically 
meaningful improvement of inspiratory capacity and breathlessness during recovery 
from exercise that was reported during the clinical study (Chapter 5) [20]. Patients felt 
benefits in speed, duration and confidence associated with their activities of daily living, 
which were maintained at 3 months [20]. The VitaBreath device does not change the 
underlying disease process and, as expected, there was no change in the frequency of 
breathlessness, nor the need to plan around, or stop activities due to breathlessness [20]. 
Patients described the device as easy-to-use, but its portability was unfavourable [20]. 
However, it is important to note that over 95% of patients continued to use the device 
regularly, and most would recommend it to another person with COPD [20]. Despite 
these benefits, few patients would purchase a device [20]. This may, at least in part, 
reflect the UK National Health Service, which provides treatment free at the point of 
delivery, and the socioeconomic status of this patient group [20]. 
Previous studies suggest poor adherence with domiciliary use of other NIV methods. 
Continuous positive airway pressure which is widely applied to manage patients with 
obstructive sleep apnoea, central sleep apnoea and hypoventilation often causes 
discomfort to patients due to the pressure level, the interface type or the duration of the 
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treatment which is usually during sleeping hours [335]. However, there is limited 
information about usability and adherence of portable devices in the literature. 
One of the first studies that tried to investigate the applicability of non-invasive 
ventilation during activities simulating those performed in daily life was conducted in 
2007 by Dreher and colleagues [288]. Patients covered greater distance and reported 
lower breathlessness during the 6 minute walk test when NIV was added to oxygen 
supplementation compared to oxygen supplementation alone [288]. This was the first 
study [288] suggesting that NIV can be applied during activities of daily living on top of 
nocturnal application. However, the setup used in this study (patients had to push a 
wheelchair with the ventilator on it) makes it impractical to use during everyday 
activities. 
Recently a study by Carling and colleagues investigated the effects of a portable non-
invasive open ventilation (NIOV) system on activities of daily living in patients with 
COPD [338]. Patients performed activities under two different conditions (with oxygen 
supplementation and using NIOV system) for as long as tolerable [338]. In contrast to 
the present study, patients performed these activities during a single home visit [338]. 
Authors reported that application of the NIOV system improved endurance time, 
oxygen saturation, dyspnoea, fatigue and discomfort levels during activities of daily 
living in patients with COPD [338]. In addition, the NIOV system was well tolerated 
when patients used it during activities of daily life [338]. However, only the acute 
effects were assessed, therefore the findings cannot be generalised to long term 
outcomes. The results of the current study confirm the results of previous studies [338, 
339], showing that the use of smaller ventilators that are easier to operate is feasible 
during activities of daily living in patients with COPD. Devices such as the VitaBreath 
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and NIOV can increase the adherence to domiciliary NIV application mainly due to the 
simplicity of their operation. 
Although anxiety is a common comorbidity of COPD [340, 341], previous studies 
have reported conflicting results on  the association between disease severity and 
anxiety levels in patients with COPD, reporting either no correlation [342, 343] or 
greater levels of anxiety in patients with more severe COPD [344]. This discrepancy is 
most likely due to the heterogeneous methods used to assess anxiety in these studies. 
However, in the study by Tsujimura and colleagues anxiety levels were also 
significantly correlated with poor daily physical activity levels in patients with severe 
COPD [344]. In the present study, only 63% of DH non-responders reported faster 
recovery from breathlessness after 12 weeks of using the VitaBreath device compared to 
75% of DH responders. Furthermore, only patients in the DH responders group reported 
significant reductions in anxiety related to breathlessness during activities of daily life. 
These findings expand the results of the laboratory-based study that pNIV did not 
improve dynamic hyperinflation and breathlessness in DH non-responders most likely 
because they exhibited worse baseline lung function (Chapter 5) [344]. 
In regards to the feedback provided by few patients, it is confirmed that most patients 
were benefited by using the VitaBreath device during activities of daily living, and that 
the main disadvantage was its portability and price. However, there were two patients 
who reported no benefit of using the device. As patients were using the device at home, 
supervision and feedback on using the device was not available beyond the completion 
of the two exercise trials reported in Chapter 5. However, patients were encouraged to 
contact the research team if they had any questions in regards to using the device and a 
couple of patients contacted the research team during the 12 week follow up to ask for 
clarifications on the use and the maintenance of the device. 
177 
 
The main limitation of the present study was that the adherence to the use of pNIV, 
as well as the degree of breathlessness and the levels of daily physical activity where 
were self-reported and no objective measurements were employed in order to assess the 
aforementioned outcomes. Future studies should use activity monitors in order to 
capture the effect of the application of pNIV application on daily physical activity 
outcomes such as steps per day and movement intensity alongside questionnaires. 
7.5. Conclusions 
Application of pNIV during activities of daily living can be beneficial for reducing 
anxiety and dyspnoea related to activities in patients with COPD, leading to increased 
levels of daily physical activity. Future studies should focus on using standardised tools 
to assess the effect of pNIV on anxiety, dyspnoea and daily physical activity. 
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8. General discussion 
As the VitaBreath device is no longer commercially available, but similar devices 
may come to market, the present study provides proof of concept on how pNIV can be 
applied intermittently during exercise in patients with COPD, and how to select patients 
most likely to respond. This in turn may encourage development of more suitable 
devices. This concept was tested in patients who demonstrated substantial dynamic 
hyperinflation and ventilatory constraints to tidal volume expansion during exercise to 
the limit of tolerance (Table 5.2).  
The dominant symptom of exercise intolerance in the majority of patients recruited 
was breathlessness (Figure 4.5). This was expected as respiratory limitation is a 
defining characteristic during exercise in patients with COPD, experiencing expiratory 
flow limitation and dynamic hyperinflation [18, 19, 29, 85, 257]. Furthermore, a 
significant proportion of patients complained of leg discomfort in addition to 
breathlessness; this was expected as COPD patients present substantial peripheral 
muscle dysfunction [18, 263, 264]. 
Hence, prior to the investigation of the acute effects of intermittent pNIV application 
on exercise tolerance, it was deemed necessary that all selected COPD patients 
underwent a number of exercise training sessions on a cyclo-ergometer in order to: i) 
improve leg muscle stamina, ii) familiarise themselves with the intermittent exercise 
testing protocols and iii) become accustomed with the correct breathing, technique 
using the pNIV apparatus or the PLB technique (Figure 5.1).  
Previous studies have shown that use of intermittent exercise in COPD is associated 
with reduced ventilatory requirement, metabolic acidosis and lower symptoms of 
breathlessness and leg discomfort compared to continuous exercise [28, 111]. 
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Importantly, application of intermittent exercise in the studies presented in this 
dissertation was essential in order to intermittently apply pNIV or PLB during the 
recovery periods.  
A total of 24 COPD patients were randomised to perform two intermittent exercise 
protocols sustained at different work intensities (60% and 80% of WRpeak) and 
exercise durations (6-min bouts and 2-min bouts, respectively) to resemble exercise 
training programs adopted during pulmonary rehabilitation in the UK (Figure 3.3 a & c) 
[165]. Within each intermittent exercise modality, patients performed two identical 
exercise tests using either the pNIV method or the PLB technique during the recovery 
phases in a balance order sequence. 
The findings of this study showed that with both intermittent protocols endurance 
time was on average greater when the pNIV method was applied compared to PLB 
(Figure 5.6), which is in accordance with the existing literature using continuous NIV 
methods [24, 33, 49, 128]. Improvements in exercise tolerance were in most of the 
patients due to lower degrees of dynamic hyperinflation and breathlessness with pNIV 
compared to PLB (Figure 5.9). 
VitaBreath provides positive inspiratory pressure support to reduce the work of 
breathing and positive expiratory pressure to keep the airways open during expiration, 
thereby reducing air trapping [215]. The mean increase in inspiratory capacity during 
the recovery periods compared to the end of exercise bouts with pNIV (high-intensity: 
140 ml; moderate-intensity: 170 ml) was within the clinically meaningful margin 
reported in bronchodilator trials (138–175 ml) [293], most likely reflecting the 
improvement in expiratory flow and thus lung emptying [24, 27, 293] with pNIV. The 
increase in inspiratory capacity during recovery was matched by a significant reduction 
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in breathlessness that reached the minimal clinically important difference (1.0 unit) [24, 
27]. In contrast, PLB was not consistently associated with a clinically meaningful 
improvement in inspiratory capacity during recovery; this is in keeping with previous 
work showing that exercise-induced dynamic hyperinflation normally persists for 
several minutes following the end of exercise [85]. Furthermore, the mean reduction in 
breathlessness scores during recovery from exercise did not reach the minimal clinically 
important difference [24, 27] with PLB. 
However, an important observation made with the aforementioned study was that a 
subgroup of patients worsened dynamic hyperinflation with the pNIV method compared 
to the PLB technique (Figure 5.10) and thus failed to improve exercise endurance time. 
It was thus deemed necessary to investigate the characteristics and respiratory pattern 
responses of these patients not responding to the pNIV method (DH non-responders) in 
relation to those patients who responded to the pNIV method (DH responders). 
Retrospective analysis identified that DH non-responders experienced greater resting 
hyperinflation (Table 5.3), greater exercise-induced dynamic hyperinflation and 
breathlessness, as well as reduced endurance time compared to DH responders (Figure 
5.8). The greater dynamic hyperinflation and breathlessness during exercise in DH non-
responder was the result of the adoption of a more tachypnoeic pattern of breathing 
when patients used the VitaBreath device. In fact, minute ventilation at exercise iso-
time was lower in the DH responders when pNIV was applied compared to PLB, 
secondary to greater tidal volume and slightly lower breathing frequency. In contrast, in 
DH non-responders minute ventilation was greater at iso-time when pNIV was applied 
compared to PLB, secondary to lower tidal volume and greater breathing frequency. 
Accordingly, inspiratory and expiratory times were slightly increased in the DH 
responders, but decreased in DH non-responders. These results suggest that the 
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application of pNIV compared to PLB, improved ventilatory efficiency in DH 
responders, but worsened ventilatory efficiency in DH non-responders, thus suggesting 
that one type of pNIV does not benefit all patients. 
This dissertation also investigated the acute effects of pNIV application on 
thoracoabdominal volume regulation, respiratory muscle kinematics and circulatory 
responses in patients with COPD. It was found that acute application of pNIV, during 
recovery periods interspersing exercise bouts of high-intensity, increased both end-
expiratory and end-inspiratory thoracoabdominal volumes in COPD patients. 
Thoracoabdominal hyperinflation was mainly attributed to greater rib cage inflation 
with the pNIV device and in the majority of cases reduced expiratory abdominal 
recruitment. In fact, the  different patterns of dynamic hyperinflation observed in the 
present dissertation when pNIV was applied suggest that some patients exhibited an 
evolumic breathing pattern, whilst others exhibited a hyperinflator pattern during 
application of pNIV [123]. Moreover, although all patients hyperinflated during 
exercise, the different patterns of respiratory muscle kinematic response recorded when 
the pNIV device was applied indicate that a subset of patients exhibited greater 
recruitment of the expiratory abdominal muscles combating end-expiratory dynamic 
hyperinflation just like the evolumic pattern described by Aliverti and colleagues [123]. 
It has been postulated that such a contraction is beneficial because of lengthening of the 
diaphragm resulting in greater generation of negative pleural pressure (better position of 
the length-tension relationship) [64, 65]. Thus, adopting such a breathing pattern could 
assist the patient to fight against the provided by pNIV high expiratory pressures. 
However in contrast to the existing literature, acute application of pNIV was not 
associated with any adverse circulatory effects in COPD patients [198, 200], most likely 
due to the brief duration of pNIV application. In addition, using OEP technology 
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confirmed the different patterns of response to dynamic hyperinflation in COPD 
patients that was evident from the original studies namely: there were patients who 
reduced dynamic hyperinflation acutely with the use of pNIV (DH responders) and 
patients who worsened dynamic hyperinflation with pNIV (DH non-responders). Small 
improvements in dynamic hyperinflation with pNIV or in some cases worsening of 
dynamic hyperinflation with pNIV were attributed to the high fixed IPAP and EPAP 
applied by this specific pNIV device. 
Besides the acute effects of intermittent pNIV application on exercise tolerance, this 
dissertation investigated the acceptability, comfort and usability of the pNIV method 
during activities of daily living in those 24 patients that retained the device for three 
months following the completion of the laboratory exercise assessment. It was shown 
that with the pNIV device the majority of patients felt less anxious about becoming 
breathless and felt that their breathlessness recovered faster when using the device at 
home (Table 7.4). Interestingly, those patients demonstrating worse breathlessness 
when using the pNIV device during exercise testing (DH non-responders) also reported 
less benefit from using the device at home in terms of anxiety around breathlessness and 
recovery time from breathlessness (Table 7.4). This was the first study investigating the 
effects of a pNIV device on anxiety and recovery of breathlessness during activities of 
daily life in patients with COPD. In addition, the results of this dissertation confirm the 
results of previous studies [338, 339], showing that the use of smaller ventilators that 
are easier to operate are also easier to use during activities of daily living in patients 
with COPD. Devices such as the VitaBreath and NIOV can increase the adherence to 
domiciliary NIV application, mainly due to the simplicity of their operation. 
Accordingly, this dissertation makes the following two important recommendations: 
first, the individual COPD patient response to any given pNIV method should be 
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investigated prior to prescribing pNIV during exercise or daily physical activities, and 
second, research should focus on developing pNIV methods that automatically adjust 
IPAP and EPAP according to the individual patient breathing pattern and degree of 
expiratory flow limitation during exercise. Thus, further studies in auto-adjusted 
ventilators are warranted. 
Importantly, the findings of the present dissertation provide evidence that patients 
who cannot tolerate continuous NIV methods during exercise, may use the NIV 
apparatus in recovery from exercise when an intermittent mode of exercise is 
undertaken. This approach will facilitate the majority of patients to recover from 
breathlessness faster, thereby increasing the number of intermittent exercise bouts that 
they can endure in the setting of pulmonary rehabilitation. 
Future Research 
Future research may act upon the study limitations presented in this dissertation to 
complete a trial with sufficient number of participants to detect statistically significant 
differences in thoracoabdominal volumes between ‘DH responders’ and ‘DH non-
responders’. This would provide greater clarity into reasons why some COPD patients 
do not improve thoracoabdominal dynamic hyperinflation when using a pNIV device. 
Furthermore, future research should investigate how best to identify those patients who 
may benefit from any pNIV device in everyday life. Additionally, research into new 
portable NIV devices that allow the adjustment of IPAP and EPAP to the individual 
should be carried out, to examine the scope of their practical application for those 
exhibiting severe COPD. Given that there are important developments in auto-adjusted 
ventilators, future studies may focus on investigating the effects of such ventilators on 
daily physical tasks in patients with COPD. This is turn may encourage the 
development of suitable pNIV devices for patients with COPD. 
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Appendix A 
Table 1. Effect of Pressure Support Ventilation (PSV) compared to spontaneous breathing on the work of breathing at rest 
Study n NIV method 
ΔPes 
(cmH2O) 
ΔPdi 
(cmH2O) 
ΔPga 
(cmH2O) 
WoB 
(J/L) 
ΔPEEPi 
(cmH2O) 
EMGdi 
ΔEELV 
(ml) 
Nava 1993 [178] 7 COPD patients PSV (IPAP: 10 cmH2O) -4.29 -4.51 -0.14   
-40% 97 
Nava 1993 [178] 7 COPD patients 
PSV+ PEEP (IPAP: 10 
cmH2O / PEEP: 5 cmH2O) 
-5.80 -6.06 -0.23 
   
222 
Nava 1993 [178] 7 COPD patients PSV (IPAP: 20 cmH2O) -6.02 -5.84 0.16    
109 
Nava 1993 [178] 7 COPD patients 
PSV+ PEEP (IPAP: 20 
cmH2O / PEEP: 5 cmH2O) 
-7.84 -7.91 -0.06 
   
327 
Appendini 1994 
[184] 
7 COPD patients PSV (IPAP: 10 cmH2O)  
-4.50 
  
-0.20 
 
-30 
Appendini 1994 
[184] 
7 COPD patients 
PSV+ PEEP (IPAP: 10 
cmH2O / EPAP: 5 cmH2O)  
-8.90 
  
-2.50 
 
115 
Girault 1997 [177] 15 COPD patients PSV (IPAP: 15 cmH2O) -11.59   
-0.33 0.81 -33% 
 
Porta 1999 [180] 12 COPD patients 
PSV (IPAP: 15 cmH2O / 
EPAP: 4 cmH2O) 
-7.80 
   
-1.30 
  
Wysocki 2002 
[182] 
12 COPD patients 
PSV (IPAP: 17 cmH2O / 
EPAP: 5 cmH2O) 
-8.00 
  
-0.65 0 
  
Porta 2002 [179] 
11 COPD patients / 7 
patients with chronic 
ventilatory failure 
PSV (IPAP: 12 cmH2O) -5.80 -6.70   
-0.30 
  
Lellouche 2002 
[185] 
9 patients with acute 
respiratory failure 
Intermittent PSV (PEEP: 5 
cmH2O)  
-8.85 
 
-0.60 0.050 
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Study n NIV method ΔPes 
(cmH2O) 
ΔPdi 
(cmH2O) 
ΔPga 
(cmH2O) 
WoB 
(J/L) 
ΔPEEPi 
(cmH2O) 
EMGdi ΔEELV 
(ml) 
L'Her 2005 [188] 
10 patients with acute 
lung injury 
PSV (IPAP: 10 cmH2O / 
EPAP: 10 cmH2O)  
-6.20 
 
-0.48 -0.50 
  
L'Her 2005 [188] 
10 patients with acute 
lung injury 
PSV (IPAP: 15 cmH2O / 
EPAP: 5 cmH2O)  
-6.60 
 
-0.49 -0.30 
  
Prinianakis 2004 
[186] 
15 COPD patients 
PSV (IPAP: 14.2 cmH2O / 
EPAP: 3.5 cmH2O) 
Pressurisation 30 cmH2O 
 
-2.30 0.04 
 
-0.44 
  
Prinianakis 2004 
[186] 
15 COPD patients 
PSV (IPAP: 14.2 cmH2O / 
EPAP: 3.5 cmH2O) 
Pressurisation 80 cmH2O 
 
-3.40 -0.46 
 
-0.27 
  
Prinianakis 2004 
[186] 
15 COPD patients 
PSV (IPAP: 14.2 cmH2O / 
EPAP: 3.5 cmH2O) 
Pressurisation 120 cmH2O 
 
-3.60 0.04 
 
-0.71 
  
Prinianakis 2004 
[186] 
15 COPD patients 
PSV (IPAP: 14.2 cmH2O / 
EPAP: 3.5 cmH2O) 
Pressurisation 200 cmH2O 
 
-4.90 -0.36 
 
-0.71 
  
Wysocki 2004 
[43] 
7 patients following 
external thoracic 
restriction 
PSV (IPAP: 9 cmH2O) -2.00   
-0.34 
   
Poggi 2006 [48] 8 COPD patients 
PSV (IPAP: 15 cmH2O / 
EPAP: 4 cmH2O)     
-1.30 
  
Average 
 
IPAP: 13cmH2O / EPAP: 
4.5 cmH2O 
-6.57 -5.73 -0.13 -0.48 -0.55 -0.37 140 
PSV: pressure support ventilation; IPAP: inspiratory positive airway pressure; EPAP: expiratory positive airway pressure 
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Table 2. Effect of Continuous Positive Airway Pressure, Proportional Assist Ventilation, Inspiratory Positive Airway Pressure and Bi-level 
Positive Airway Pressure compared to spontaneous breathing on the work of breathing at rest 
Study n NIV method 
ΔPes 
(cmH2O) 
ΔPdi 
(cmH2O) 
ΔPga 
(cmH2O) 
WoB 
(J/L) 
ΔPEEPi 
(cmH2O) 
EMGdi 
ΔEELV 
(ml) 
CPAP 
         
Appendini 1994 
[184] 
7 COPD patients CPAP: 5 cmH2O  
-2.80 
  
-3.40 
 
110 
Elliott 1994 
[176] 
11 COPD patients CPAP: 7 cmH2O -2.50  
0.60 
    
L'Her 2005 
[188] 
10 patients with 
acute lung injury 
CPAP: 10 cmH2O  
-0.70 
 
-0.23 -0.50 
  
Average 
 
CPAP: 7 cmH2O -2.50 -1.75 0.60 -0.23 -1.95  
110 
PAV 
         
Polese 2000 
[183] 
15 COPD patients 
PAV (Flow assist: 4 
cmH2O/L/s, Volume 
assist: 14 cmH2O/L) 
+ CPAP: 2 cmH2O 
-4.00 -6.00 
  
-0.30 -28% 
 
Polese 2000 
[183] 
15 COPD patients 
PAV (Flow assist: 4 
cmH2O/L/s, Volume 
assist: 14 cmH2O/L) 
+ CPAP: 5 cmH2O 
-7.00 -8.00 
  
-1.00 -28% 
 
Wysocki 2002 
[182] 
12 COPD patients 
PAV (no details 
provided) 
-10.00 
  
-0.71 1.00 
  
Porta 2002 
[179] 
11 COPD / 7 chronic 
ventilatory failure 
PAV (Flow assist: 5 
cmH2O/L/s, Volume 
assist: 12 cmH2O/L) 
-4.30 -4.60 
  
-0.10 
  
Wysocki 2004 
[43] 
7 patients following 
external thoracic 
restriction 
PAV (Flow assist: 4 
cmH2O/L/s, Volume 
assist: 9 cmH2O/L) 
-3.00 
  
-0.40 
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Study n NIV method 
ΔPes 
(cmH2O) 
ΔPdi 
(cmH2O) 
ΔPga 
(cmH2O) 
WoB 
(J/L) 
ΔPEEPi 
(cmH2O) 
EMGdi 
ΔEELV 
(ml) 
Poggi 2006 [48] 8 COPD patients 
PAV (Flow assist: 5 
cmH2OL/s, Volume 
assist: 12 cmH2O/L) 
    
-0.90 
  
Average 
 
Flow assist: 4.4 
cmH2O/L/s, Volume 
assist: 12 cmH2O/L 
-5.66 -6.20 
 
-0.56 -0.26 -28%  
IPAP 
        
 
Brochard 1990 
[187] 
13 COPD patients IPAP: 20 cmH2O  
-11.20 
  
-0.20 -43%  
Elliott 1994 
[176] 
11 COPD patients IPAP: 20 cmH2O -8.8  
0.70 
   
 
Average 
 
IPAP: 20 cmH2O -8.8 -11.2 0.7  
-0.2 -0.43  
Bi-level PAP 
         
Renston 1994 
[191] 
17 COPD patients 
Bi-level PAP (IPAP 
18 cmH2O, EPAP 2 
cmH2O) 
     
-66% 
 
Thys 2002 
[192] 
12 COPD patients /  
8 patients with acute 
pulmonary oedema 
Bi-level PAP (IPAP: 
10 cmH2O and 
EPAP: 4 cmH2O) 
   
0.006 
   
Elliott 1994 
[176] 
11 COPD patients 
Bi-level PAP (IPAP 
20 cmH2O / EPAP 7 
cmH2O) 
-9.3 
 
0.30 
   
 
Average 
 
IPAP: 16 cmH2O, 
EPAP: 4 cmH2O 
-9.3  0.30 0.006 
 
-66%  
CPAP: Continuous Positive Airway Pressure; PAV: Proportional Assist Ventilation; IPAP: Inspiratory Positive Airway Pressure; BiPAP: Bi-
level Positive Airway Pressure; EPAP: expiratory positive airway pressure
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Table 3. Effect of Pressure Support Ventilation compared to spontaneous breathing on breathing pattern at rest 
Study n NIV method VE (L/min) 
bf 
(breaths/min) 
VT 
(ml) 
Ti 
(sec) 
Te 
(sec) 
Ttot 
(sec) 
Ti/Ttot 
(%) 
VT/Ti 
(L/sec) 
Nava 1993 
[178] 
7 COPD patients PSV (IPAP: 10 cmH2O) 0.9 -6 111  0.7  -0.02 0.032 
Nava 1993 
[178] 
7 COPD patients 
PSV+ PEEP (IPAP: 10 
cmH2O / PEEP: 5 cm 
H2O) 
1.5 -6 212  0.7  0.01 0.027 
Nava 1993 
[178] 
7 COPD patients PSV (IPAP: 20 cmH2O) 2.0 -7 321  0.8  0.01 0.09 
Nava 1993 
[178] 
7 COPD patients 
PSV+ PEEP (IPAP: 20 
cmH2O / PEEP: 5 cm 
H2O) 
1.9 -8 380  1.0  -0.01 0.145 
Appendini 
1994 [184] 
7 COPD patients PSV (IPAP: 10 cmH2O) 1.2 -2 180 0.20 0.87 1.07 -0.05 0.09 
Appendini 
1994 [184] 
7 COPD patients 
PSV+ PEEP (IPAP: 10 /  
EPAP: 5 cmH2O) 
1.9 -2 180 0.26 0.43 0.69 -0.01 0.09 
Girault 1997 
[177] 
15 COPD patients PSV (IPAP: 15 cmH2O) 1.6 -3 150 0.16 0.42 0.58 -0.01 0.09 
Porta 1999 
[180] 
12 COPD patients 
PSV (IPAP: 15 cmH2O / 
EPAP: 4 cmH2O) 
2.0 -2 189 
   
-0.01 0.1 
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Study n NIV method VE (L/min) 
bf 
(breaths/min) 
VT 
(ml) 
Ti 
(sec) 
Te 
(sec) 
Ttot 
(sec) 
Ti/Ttot 
(%) 
VT/Ti 
(L/sec) 
Wysocki 
2002 [182] 
12 COPD patients 
PSV (IPAP: 17 cmH2O / 
EPAP: 5 cmH2O)  
-3 261 
   
0.05 
 
Porta 2002 
[179] 
11 COPD patients / 7 
patients with chronic 
ventilatory failure 
PSV (IPAP: 12 cmH2O) 2.8 -1 169 
   
-0.04 0.19 
Lellouche 
2002 [185] 
9 patients following 
acute respiratory 
failure 
Intermittent PSV (PEEP: 
5 cmH2O) 
2.8 
 
59 0.04 
   
0.15 
L'Her 2005 
[188] 
10 patients with acute 
lung injury 
PSV (IPAP: 10 cmH2O / 
EPAP: 10 cmH2O) 
-1.0 -2 -52 
    
 
L'Her 2005 
[188] 
10 patients with acute 
lung injury 
PSV (IPAP: 15 cmH2O / 
EPAP: 5 cmH2O) 
2.0 -4 56 
    
 
Prinianakis 
2004 [186] 
15 COPD patients 
PSV (IPAP: 14.2 cmH2O 
/ EPAP: 3.5 cmH2O) 
Pressurisation 30 cmH2O  
-3 99 0.19 0.16 0.34 
 
 
Prinianakis 
2004 [186] 
15 COPD patients 
PSV (IPAP: 14.2 cmH2O 
/ EPAP: 3.5 cmH2O) 
Pressurisation 80 cmH2O  
-3 91 0.20 0.14 0.33 
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Study n NIV method VE (L/min) 
bf 
(breaths/min) 
VT 
(ml) 
Ti 
(sec) 
Te 
(sec) 
Ttot 
(sec) 
Ti/Ttot 
(%) 
VT/Ti 
(L/sec) 
Prinianakis 
2004 [186] 
15 COPD patients 
PSV (IPAP: 14.2 cmH2O 
/ EPAP: 3.5 cmH2O) 
Pressurisation 120 cmH2O  
2 120 0.11 0.12 0.22 
 
 
Prinianakis 
2004 [186] 
15 COPD patients 
PSV (IPAP: 14.2 cmH2O 
/ EPAP: 3.5 cmH2O) 
Pressurisation 200 cmH2O  
-3 103 0.07 0.37 0.43 
 
 
Wysocki 
2004 [43] 
7 patients following 
external thoracic 
restriction 
PSV (IPAP: 9 cmH2O) 
 
2 249 
   
-0.05 
 
Poggi 2006 
[48] 
8 COPD patients 
PSV (IPAP: 15 cmH2O / 
EPAP: 4 cmH2O) 
1.8 -4 200 0 0.60 
 
-0.07 
 
Average 
 
IPAP: 13cmH2O / EPAP: 
4.5 cmH2O 
1.7 -3 162 0.14 0.53 0.52 -0.02 0.10 
PSV: pressure support ventilation; IPAP: inspiratory positive airway pressure; EPAP: expiratory positive airway pressure 
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Table 4. Effect of Continuous Positive Airway Pressure, Proportional Assist Ventilation, Inspiratory Positive Airway Pressure and Bi-level 
Positive Airway Pressure compared to spontaneous breathing on breathing pattern at rest 
Study n NIV method 
VE 
(Litres/min) 
bf 
(breaths/min) 
VT 
(ml) 
Ti 
(sec) 
Te 
(sec) 
Ttot 
(sec) 
Ti/Ttot 
(%) 
VT/Ti 
(L/sec) 
CPAP 
  
        
Appendini 1994 
[184] 
7 COPD patients CPAP: 5 cmH2O 0.5 2 -10 -0.14 -0.16 -0.3 -0.01 0.03 
Elliott 1994 
[176] 
11 COPD patients CPAP: 7 cmH2O -0.5 -1 -10 
     
L'Her 2005 
[188] 
10 patients with 
acute lung injury 
CPAP: 10 cmH2O -3.3 -2 -141 
     
Average 
 
CPAP: 7 cmH2O -1.1 0 -54 -0.14 -0.16 -0.30 -0.01 0.03 
PAV 
  
        
Polese 2000 
[183] 
15 COPD patients 
PAV (Flow assist: 4 
cmH2O/L/s, Volume 
assist: 14 cmH2O/L) + 
CPAP: 2 cmH2O 
2.2 0 160    -0.01  
Polese 2000 
[183] 
15 COPD patients 
PAV (Flow assist: 4 
cmH2O/L/s, Volume 
assist: 14 cmH2O/L) + 
CPAP: 5 cmH2O 
1.7 0 110    0  
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Study n NIV method 
VE 
(Litres/min) 
bf 
(breaths/min) 
VT 
(ml) 
Ti 
(sec) 
Te 
(sec) 
Ttot 
(sec) 
Ti/Ttot 
(%) 
VT/Ti 
(L/sec) 
Wysocki 2002 
[182] 
12 COPD patients 
PAV (no details 
provided)  
-4 208 
   
-0.01 
 
Porta 2002 
[179] 
11 COPD patients / 
7 patients with 
chronic ventilatory 
failure 
PAV (Flow assist: 5 
cmH2O/L/s, Volume 
assist: 12 cmH2O/L) 
2.8 0 127    -0.02 0.12 
Wysocki 2004 
[43] 
7 patients following 
external thoracic 
restriction 
PAV (Flow assist: 4 
cmH2O/L/s, Volume 
assist: 9 cmH2O/L)  
2 180 
   
-0.04 
 
Poggi 2006 [48] 8 COPD patients 
PAV (Flow assist: 5 
cmH2O/L/s, Volume 
assist: 12 cmH2O/L) 
1.7 -1 110 -0.1 0.33  -0.06  
Average 
 
Flow assist: 4.4 
cmH2O/L/s, Volume 
assist: 12 cmH2O/L 
2.10 -1 149 -0.10 0.33 
 
 
 
-0.02 0.12 
IPAP 
  
        
Brochard 1990 
[187] 
13 COPD patients IPAP: 20 cmH2O 3.0 -16 300     
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Study n NIV method 
VE 
(Litres/min) 
bf 
(breaths/min) 
VT 
(ml) 
Ti 
(sec) 
Te 
(sec) 
Ttot 
(sec) 
Ti/Ttot 
(%) 
VT/Ti 
(L/sec) 
Elliott 1994 
[176] 
11 COPD patients IPAP: 20 cmH2O 2.0 -7 310     
 
Average 
 
IPAP: 20 cmH2O 2.50 -11 305      
Bi-level PAP 
  
        
Renston 1994 
[191] 
17 COPD patients 
Bi-level PAP (IPAP: 18 
cmH2O, EPAP: 2 
cmH2O)  
0 270     
 
Thys 2002 
[192] 
12 COPD patients /  
8 patients with 
acute pulmonary 
oedema 
Bi-level PPV (IPAP: 10 
cmH2O and EPAP: 4 
cmH2O) 
 
-15 
 
     
Elliott 1994 
[176] 
11 COPD patients 
Bi-level PAP (IPAP 20 
cmH2O / EPAP 7 
cmH2O) 
1.5 -5 180      
Average  
IPAP: 16 cmH2O, 
EPAP: 4 cmH2O 
1.5 -6 225      
CPAP: Continuous Positive Airway Pressure; PAV: Proportional Assist Ventilation; IPAP: Inspiratory Positive Airway Pressure; BiPAP: Bi-
level Positive Airway Pressure; EPAP: expiratory positive airway pressure 
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Table 5. Studies investigating the effect of the application of non-invasive ventilation on exercise tolerance and dynamic hyperinflation in 
patients with COPD. 
Author/Year Population Study protocol NIV Method 
Cyclo-ergometer 
   
O'Donnell 1988 [35] 
6 COPD patients 
(FEV1: 35%) 
2 Constant load exercise tests at 50% 
WRpeak 
Control                                                                       
CPAP: 4-5 cmH2O 
Petrof 1990 [36] 
8 COPD patients 
(FEV1: 25%) 
2 Constant load exercise tests lasting 
approximately 3 minutes each 
Control                                                                       
CPAP: 7.5-10 cmH2O 
Dolmage 1997 [46] 
10 COPD patients 
(FEV1: 29%) 
5 Constant load exercise tests at 60-70% of 
WRpeak at different days 
Sham: CPAP: 0 cmH2O, PAV: 0                                           
CPAP: 5 cmH2O                                                                         
PAV: Volume Assist: 6 cmH2O/L, Flow 
Assist: 3 cmH2O/L                                                           
CPAP+PAV: 5 cmH2O, Volume Assist: 6 
cmH2O/L, Flow Assist: 3 cmH2O/L/s 
Bianchi 1998 [44] 
15 COPR patients 
(FEV1: 32%) 
4 endurance tests at 80% peak in two 
consecutive days 
Control                                                                                  
Sham: 1 cmH2O                                                           
CPAP: 6 cmH2O                                                          
PSV: IPAP: 12-16 cmH2O, EPAP: 1 cmH2O 
PAV: Volume Assist: 8.6 cmH2O/L, Flow 
Assist: 3 cmH2O/L/s 
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Author/Year Population Study protocol NIV Method 
Hernandez 2001 [47] 
8 COPD patients 
(FEV1: 25%) 
2 Constant load exercise tests at 80% 
WRpeak 
Sham: 1-2 cmH2O                                                                       
PAV: Volume Assist: 9.8 cmH2O/L Flow 
Assist: 3.3 cmH2O/L/s 
van't Hul 2004 [42] 
45 COPD patients 
(FEV1: 39%) 
Visit 1: pulmonary function test and CPET                                                           
Visit 2: Constant load exercise test at 75% 
peak and familiarization with IPS                                                                   
Visit 3: 2 Constant load exercise tests with 
IPS5 and IPS10 
Control                                                                         
Sham: IPS5 cmH2O                                                     
IPS: 10 cmH2O 
Borghi-Silva 2008 
[209] 
16 COPD patients 
(FEV1: 42%) 
2 Constant load exercise tests at 70-80% 
WRpeak 
Sham: IPS: 5 cmH2O, PEEP: 2 cmH2O                                                    
PAV: Volume Assist: 5.8 cmH2O/L. Flow 
Assist 3.5 cmH2O/L/s 
Carrascossa 2010 [45] 
20 COPD patients 
(FEV1: 39%) 
2 Constant load exercise tests at 70-80% of 
WRpeak at the same day with 30 minutes 
break between the tests 
PAV: Volume Assist: 5.1 cmH2O/L, Flow 
Assist: 3.4 cmH2O/L/s 
Hussain 2011 [210] 
10 COPD patients 
(FEV1: 28%) 
3 Constant load exercise tests at 80% of 
WRpeak 
O2: 30%                                                                                                
O2: 30%  + Helium: 70%  (Heliox)                                                  
O2: 30% + IPS: IPAP: 9-19 cmH2O 
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Author/Year Population Study protocol NIV Method 
Treadmill 
   
Keilty 1994* [37] 
8 COPD patients 
(FEV1: 0.73 litres) 
3 endurance tests on 3 separate days on a 
treadmill (5 dyspnoea limit) 
Control                                                                                                                                                    
IPS: 12-15 cmH2O                                                       
CPAP-BiPAP: 6 cmH2O                                                 
O2: 2L 
Kyroussis 2000
$
 [38] 
5 COPD patients 
(FEV1: 27%) 
6 out of 12 iso distance with PPV                                              
5 out of 6 to the tolerance with PPV                                                                                       
Constant speed to exhaustion on treadmill 
Control                                                                                     
PPV: no details provided 
 
 
 
 
 
 
197 
 
Table 6. Effect of the application of non-invasive ventilation on exercise tolerance and dynamic hyperinflation in patients with COPD. 
Author/Year Exercise tolerance (min) ΔIC (litres) ΔIC (litres) 
 
Control Sham CPAP PSV PAV IPS CPAP+PAV PPV Iso-time 
Limit of 
tolerance 
O'Donnell 1988 [35] 6.0 
 
8.8 
     
-0.08 -0.02 
Petrof 1990 [36] 
        
0.04 
 
Dolmage 1997 [46] 4.9 6.6 8.3 
 
7.1 
 
12.9 
   
Bianchi 1998 [44] 7.1 7.2 9.6 10.5 12.5 
     
Hernandez 2001 [47] 5.4 
   
8.5 
     
van't Hul 2004 [42] 4.3 4.4 
   
6.3 
    
Borghi-Silva 2008 [209] 4.6 4.6 
  
5.6 
     
Carrascossa 2010 [45] 3.7 
   
4.2 
     
Hussain 2011 [210] 6.9 
    
11.2 
  
0.20 
 
Average 5.4 5.7 8.9 10.5 7.6 8.8 12.9 
 
0.05 -0.02 
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Treadmill 
          
Keilty 1994* [37] 137 
 
121 
  
336 
    
Kyroussis 2000
$
 [38] 6.8 
      
13.2 
  
FEV1: forced expiratory flow at the first second; CPAP: continuous positive airway pressure; PSV: pressure support ventilation; PAV: 
proportional assist ventilation; IPS: inspiratory pressure support; PPV: positive pressure ventilation; Δ: change; IC: inspiratory capacity; IPAP: 
inspiratory positive airway pressure; BiPAP: Bi-level Positive Airway Pressure; IPAP: inspiratory positive airway pressure; EPAP: expiratory 
positive airway pressure; WRpeak: peak work rate *: data presented as distance covered in metres; 
$
: data presented in minutes 
Appendix B 
Consent form for studies presented in chapters 4, 5 and 7. 
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Participant information sheet of the study presented in Chapters 4, 5, and 7 
Title:  Influence of the VitaBreath device on exercise tolerance in patients with 
chronic obstructive pulmonary disease. 
You are being invited to take part in a research study that will assess whether a 
new device can help people with chronic obstructive pulmonary disease (COPD) 
recover from a bout of exercise more quickly, reducing breathlessness, and allow 
them to exercise for longer. Before you decide if you would like to take part, 
please take time to read the information, and discuss it with others if you wish. If 
you would like someone to read through the information with you, please ask. 
What is the purpose of the study? 
People with COPD have more air in their lungs than other people (this problem 
with high lung volumes is called “hyperinflation”). Unfortunately this is unhelpful 
as breathing at higher lung volumes requires more effort and contributes to 
breathlessness. When anyone exercises, they breathe more quickly. People with 
COPD have narrowed airways, which makes breathing out difficult. When they 
breathe more quickly they may not be able to breathe out fully before they need to 
take the next breath in. This means that the volume of air in their lungs tends to 
increase further during exercise, which makes breathing even more difficult. This 
problem is called “dynamic hyperinflation”.  
Pulmonary rehabilitation is one of the most helpful interventions for people with 
COPD and most of the benefit gained is from exercise. Anything that helps people 
increase the amount of exercise they can perform should lead to further 
improvements. 
Non-invasive positive pressure ventilation is a method of supporting a person’s 
normal breathing. The ventilator delivers a flow of air at low pressure as you 
breathe out, which helps you to breathe out more completely. The device also 
detects when you start to breathe in and delivers a stronger flow of air at a higher 
pressure, helping you to take a deeper breath in. Previous research studies have 
shown that when people with COPD use non-invasive ventilation during exercise 
they are able to exercise for longer and are less breathless. The purpose of this 
study is to assess whether a new portable non-invasive ventilation device, called 
the VitaBreath, helps people with COPD recover from breathlessness during the 
exercise breaks more quickly (by reducing “dynamic hyperinflation”, described 
above) and to exercise for longer overall. The VitaBreath device is small and 
light, weighing 0.5 kilograms (just over one pound). It is handheld and battery 
powered. 
Why have you been chosen?  
You have been chosen because you have COPD and are keen to improve your 
ability to exercise by taking part in a pulmonary rehabilitation program. If you 
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agree to be assessed for the trial, we will verify that you do develop “dynamic 
hyperinflation” (breathing at progressively higher lung volumes) during exercise.  
Do I have to take part?  
No, it is your free choice to take part. If you decide to take part you will be asked 
to sign a consent form. You are free at any time to withdraw from the study, and 
do not have to give a reason. If you decide to withdraw from the study, we will 
use the information we have gathered up to that point, but we will not include 
your personal information unless you give us permission to do so.  
If you decide not to take part you will continue to receive the same standard of 
pulmonary rehabilitation and usual care. 
What is the VitaBreath device? 
The VitaBreath device is a non-invasive portable ventilator which provides 
different levels of positive air pressure during inspiration and expiration. This 
assists normal breathing efforts in a similar way to a conventional non-invasive 
ventilator. In comparison to conventional noninvasive ventilators, the VitaBreath 
device is compact, light, battery powered and inexpensive. Consequently it is 
suitable to use anywhere, including away from your home. 
What does it mean if I take part in the study?  
If you choose to take part you will attend North Tyneside General Hospital on 
three occasions over 10 days. You will perform some simple breathing tests in the 
lung function department, which will take about 30 minutes on your first visit, and 
undergo an exercise test. The exercise test is called a cardiopulmonary exercise 
test, and allows us to measure how your breathing, heart and muscles respond to 
exercise. This will take about 60 minutes. 
You should wear cool, comfortable clothing suitable for exercise. You can eat a 
light meal a few hours before the exercise test, but you should avoid eating a large 
heavy meal. Adhesive pads will be attached to your skin to monitor your heart and 
you will wear a blood pressure cuff and oxygen saturation probe. During the test 
you will breathe through a mouth piece, initially at rest and then while cycling on 
a fixed bike. After three minutes of measurements at rest, followed by three 
minutes of pedalling freely without resistance at a steady rate, the amount of 
resistance you have to pedal against will be increased every minute until it 
becomes too difficult to continue. This will determine your maximum exercise 
capacity. During the next two visits you will perform an exercise test with the 
resistance you have to pedal against will be set between 60% and 80% of this 
maximum value. You will be asked to cycle for a short period of time (either two 
or six minutes) followed by a two minute rest period, and repeat this sequence of 
exercise and rest as often as you can.  On one visit you will use the VitaBreath 
device during rest periods and on the other visit you will perform a simple 
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technique called pursed lip breathing (similar to blowing out a candle) to aid 
recovery. A computer will decide how long you exercise for during each cycling 
bout (two or six minutes) and whether you use the VitaBreath device or pursed lip 
breathing first; you will not be able to choose. This is avoid any potential bias 
favouring one technique over the other as there may be a “learning effect”, and 
you may perform better on the second exercise test.  
After the tests you will receive information about your exercise capacity and the 
factors limiting your exercise tolerance. 
What are the possible disadvantages and risks to taking part?  
You should expect to feel breathless and/or muscle discomfort during and after 
the exercise test. This is not harmful, but rather a normal part of exercise. You 
will soon return to your original state. The risks are no different to similar levels 
of exercise in other settings, and overall exercise is beneficial. About 1 in 1000 
patients develops complications such as abnormal blood pressure, fainting, 
problems with heart rate or rhythm. In exceptional circumstances there can be 
more serious complications such as angina (chest pain) or a heart attack. 
What are the advantages to taking part? 
You will have the chance to experience the effect of using the device following 
exercise. This may help you recover more quickly. You will be allowed to keep 
the device, which will be supplied with a charger. Your results will help us 
determine whether routine use of this device during pulmonary rehabilitation is 
helpful, and thus will be of benefit to other people with COPD.  
Payment  
Travel expenses will be reimbursed. 
Will my personal information be kept confidential?  
During the study we will collect information from you about your health and well-
being. Your personal information such as your name and date of birth will be kept 
confidential and only available to the research team. The information given will 
only be used in a way that cannot be traced back to you, and any personal 
information will be stored securely. With your permission, we will write to your 
GP to let him/her know that you are taking part in the study. No one outside the 
research team will know if you decide not to take part. 
What if there is a problem or I need more information?  
If you wish to complain, or have any concerns about the study, please ask to speak 
to the researcher who will do their best to answer your questions. If you are still 
unhappy, you can complain formally using the normal NHS complaints channels. 
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What will happen with the results of the study?  
The results will be discussed at scientific medical meetings, and also will be 
published in medical journals so that others can learn from our findings. You can 
receive a copy of the results by contacting Dr Stephen Bourke (whose details are 
at the end of this document). 
 
Contact details: 
Dr. Stephen Bourke 
Consultant Respiratory Physician 
North Tyneside General Hospital 
Rake Lane 
North Shields 
NE29 8NH 
Tel: 0191 2934026 
Email: stephen.bourke@NHCT.nhs.uk 
 
Ioannis Vogiatzis 
Professor of Rehabilitation Sciences 
Faculty of Health and Life Sciences 
Department of Sport, Exercise and Rehabilitation 
Northumbria University 
Contact Number: 01913395446 
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Letter to GP for studies presented in chapters 4, 5 and 7. 
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Letter of support from Philips Respironics 
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Appendix C 
Consent form of the study presented in Chapter 6. 
Effect of the VitaBreath device on chest wall dynamic hyperinflation and 
respiratory muscle activation during recovery from exercise in patients with 
Chronic Obstructive Pulmonary Disease. 
 
 
 
 
Please initial boxes 
1) I have read the information sheet for the above study, version 1.5 dated 
24
th
 of August 2019, and have had the opportunity to ask questions. 
 
 
2) I understand that I do not have to take part, and I am free to withdraw at 
any time, without giving any reason if I do not want to, without my legal 
rights or the care I receive being affected. 
 
 
3) I understand that if I withdraw, the information I have provided will still 
be used up to when I withdraw, but with my personal information removed 
so I cannot be identified, unless I state otherwise. 
 
 
 4) I understand that relevant sections of my medical records and data collected 
during the study may be looked at by responsible individuals from the NHS 
Trust or regulatory authorities where it is relevant to taking part in this 
research. I give permission for these individuals to have access to my records 
 
5) I understand that the information will be used in future reports, articles or 
presentations by the research team. 
 
 
6) I understand my personal information will not appear in any future 
reports, articles or presentations by the research team. 
 
 
7) I give permission for information to be sent to the GP about my being 
involved in the study. 
 
 
  8) I agree to participate to the study  
  DD 
 
MM YYYY 
Participant name (PRINT) Signature Date 
       DD 
 
MM YYYY 
Researcher taking consent (PRINT) Signature Date 
 
 
 
PARTICIPANT NAME: 
  
Year of birth: 
 
IRAS No: 259201 
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Participant information sheet of the study presented in Chapter 6. 
Title: Effect of the VitaBreath device on chest wall dynamic hyperinflation and 
respiratory muscle activation during recovery from exercise in patients with 
Chronic Obstructive Pulmonary Disease. 
IRAS No: 259201 
 
You are being invited to take part in a research study that will assess the effect of 
a CE marked device which has been used since 2015 (VitaBreath) on your 
breathing pattern and its effect on the operation of your respiratory muscles. The 
study is part of a Ph.D. project. Before you decide if you would like to take part, 
please take time to read the information, and discuss it with others if you wish. If 
you would like someone to read through the information with you, please ask. 
What is the purpose of the study? 
People with COPD have more air in their lungs than other people (this problem 
with high lung volumes is called “hyperinflation”). Unfortunately this is unhelpful 
as breathing at higher lung volumes requires more effort and contributes to 
breathlessness. When anyone exercises, they breathe more quickly. People with 
COPD have narrowed airways, which makes breathing out difficult. When they 
breathe more quickly they may not be able to breathe out fully before they need to 
take the next breath in. This means that the volume of air in their lungs tends to 
increase further during exercise, which makes breathing even more difficult. This 
problem is called “dynamic hyperinflation”. Today there are available ventilation 
assist devices that can help people with COPD to breathe easier even during 
exercise or activities of daily living such as the VitaBreath device.  
Data from a previous study we conducted comparing use of the VitaBreath device 
during recovery periods between bouts of exercise to pursed lip breathing (normal 
breathing strategy recommended to COPD patients) showed that patients using the 
VitaBreath device were able to exercise longer and also reported less 
breathlessness. However, during the first study we weren’t able to investigate the 
actual mechanism by which the device impacts on your breathing capacity 
because specialised technology to monitor your breathing pattern was not 
available.  
The purpose of this study is to investigate the mechanism by which the VitaBreath 
device influences your breathing patter and better understand how breathing 
through the device influences the activation of your respiratory muscles and your 
sensation of breathlessness. 
Why have you been chosen?  
You have been chosen because you have COPD and you have experienced 
breathlessness during moderate exercise. If you agree to be assessed for the trial, 
you will attend North Tyneside General Hospital to ensure that you meet all of the 
criteria required to participate, including that you are clinically stable and safe to 
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exercise. If you are suitable for the trial and agree to take part you will attend 
Northumbria University and perform two exercise tests each lasting for 20 
minutes each on the same day.  
Do I have to take part?  
No, it is your free choice to take part. If you decide to take part you will be asked 
to sign a consent form. You are free at any time to withdraw from the study, and 
do not have to give a reason. If you decide to withdraw from the study, we will 
use the information we have gathered up to that point, but we will not include 
your personal information unless you give us permission to do so.  
If you decide not to take part you will continue to receive the same standard usual 
care. 
What is the VitaBreath device? 
The VitaBreath device is a non-invasive portable ventilator which provides 
different levels of positive air pressure during inspiration and expiration. This 
assists normal breathing efforts in a similar way to a conventional non-invasive 
ventilator. In comparison to conventional non-invasive ventilators, the VitaBreath 
device is compact, light, battery powered and inexpensive. Consequently it is 
suitable to use anywhere, including away from your home. If you participated in 
the previous study you will have experience using the VitaBreath device, if not 
you will be trained how to use the device properly. 
What does it mean if I take part in the study?  
If you choose to take part you will attend North Tyneside General Hospital once 
to perform some simple breathing tests, including spirometry, lung volumes and 
diffusion capacity assessment, in the lung function department, and have an ECG 
(tracing of your heart rhythm). One of the respiratory doctors will speak to you 
about your COPD and any other problems, and perform a physical examination. 
This will take about 90 minutes in total. If you have not your exercise capacity 
assessed before you will undergo an exercise test on a bicycle ergometer. The 
exercise test is called cardiopulmonary exercise test, and allows us to measure 
how your breathing, heart and muscles respond to exercise. This will take about 
60 minutes. On your second visit (which will be conducted within a period of 5 
days following the first visit) you will attend Northumbria University for 
approximately 2 hours. Adhesive skin markers and optodes (simple sensors) will 
be attached on the skin of your chest to record chest wall volumes, activation and 
oxygenation requirements of the respiratory muscles. This will take about 20 
minutes. Following your preparation you will perform two exercise tests lasting 
20 minutes each. Between the two tests there will be a break in order to allow 
complete recovery from exercise.  
You should wear cool, comfortable clothing suitable for exercise. You can eat 
a light meal a few hours before the exercise test, but you should avoid eating 
a large heavy meal. Adhesive pads will be attached to your skin to monitor your 
heart and you will wear a blood pressure cuff and oxygen saturation probe. After 
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three minutes of measurements at rest, followed by three minutes of pedalling 
freely without resistance at a steady rate, you will be asked to cycle for two 
minutes followed by a two minute recovery period, and repeat this sequence of 
exercise and recovery for 20 minutes in total. During the first minute of each 
recovery you will breathe either through the VitaBreath device or using the pursed 
lip breathing technique. 
After the tests you will receive information about the effect of the VitaBreath 
device on the way you breathe. 
What are the possible disadvantages and risks to taking part?  
You should expect to feel breathless and/or muscle discomfort during and after 
the exercise test. This is not harmful, but rather a normal part of exercise. You 
will soon return to your original state. The risks are no different to similar levels 
of exercise in other settings, and overall exercise is beneficial. About 1 in 1000 
patients develops complications such as abnormal blood pressure, fainting, 
problems with heart rate or rhythm. In exceptional circumstances there can be 
more serious complications such as angina (chest pain) or a heart attack. 
What are the advantages to taking part? 
One of the conclusions of the original study is that patients retaining the device 
for use at home found the device helpful to their breathing, so it is likely that they 
would like to test their breathing capacity again during exercise and compare their 
old results with the ones of this study. The results of the trial will inform clinical 
services in the future. This may be of benefit to participants during future 
pulmonary rehabilitation courses, as well as other patients. If you do not have 
your own device we will provide you with a new device to use during the study, 
which you can keep after you have completed the study. 
Payment  
Travel expenses to Northumbria University will be reimbursed. 
Will my personal information be kept confidential?  
During the study we will collect information from you about your health and well-
being. Your personal information such as your name and date of birth will be kept 
confidential and only available to the research team. The information given will 
only be used in a way that cannot be traced back to you, and any personal 
information will be stored securely. With your permission, we will write to your 
GP to let him/her know that you are taking part in the study. No one outside the 
research team will know if you decide not to take part. 
What if there is a problem or I need more information?  
If you wish to complain, or have any concerns about the study, please ask to speak 
to the researchers who will do their best to answer your questions. If you are still 
unhappy, you can complain formally using the normal NHS complaints channels. 
What will happen with the results of the study?  
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The results will be discussed at scientific medical meetings, and also will be 
published in medical journals so that others can learn from our findings. You can 
receive a copy of the results by contacting Dr Stephen Bourke (whose details are 
at the end of this document). 
This study has been reviewed and approved by REC. 
Northumbria Healthcare trust is the sponsor for this study based in the United 
Kingdom / England. We will be using information from you and your medical 
records in order to undertake this study and will act as the data controller for this 
study. This means that we are responsible for looking after your information and 
using it properly. Northumbria Healthcare trust will keep identifiable information 
about you for 12 months after the study has finished. 
Your rights to access change or move your information are limited, as we need to 
manage your information in specific ways in order for the research to be reliable 
and accurate. If you withdraw from the study, we will keep the information about 
you that we have already obtained. To safeguard your rights, we will use the 
minimum personally-identifiable information possible. 
You can find out more about how we use your information by contacting 
Professor Stephen Bourke. 
North Tyneside General Hospital will collect information from you and your 
medical records for this research study in accordance with our instructions. North 
Tyneside General Hospital will use your name, and contact details to contact you 
about the research study, and make sure that relevant information about the study 
is recorded for your care, and to oversee the quality of the study. Individuals from 
Northumbria Healthcare trust and regulatory organisations may look at your 
medical and research records to check the accuracy of the research study. North 
Tyneside General Hospital will pass these details to Northumbria Healthcare 
trust along with the information collected from you and/or your medical records. 
The only people in Northumbria Healthcare trust who will have access to 
information that identifies you will be people who need to contact you to about the 
research study or audit the data collection process. The people who analyse the 
information will not be able to identify you and will not be able to find out your 
name or contact details. 
Northumbria Healthcare trust will collect information about you for this research 
study from your medical records. This information will include your name, NHS 
number, contact details and health information, which is regarded as a special 
category of information. We will use this information to contact you in regards to 
your involvement to the study. 
You can find out more about how we use your information by contacting the 
Respiratory Nurse Consultant in charge of this study, who’s contact details can be 
found below; 
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Contact details: 
Prof. Stephen Bourke 
Consultant Respiratory Physician 
North Tyneside General Hospital 
Rake Lane 
North Shields 
NE29 8NH 
Tel: 0191 2934026 
Email: stephen.bourke@nhct.nhs.uk  
 
Ioannis Vogiatzis 
Professor of Rehabilitation Sciences 
Faculty of Health and Life Sciences 
Department of Sport, Exercise and Rehabilitation 
Northumbria University 
Contact Number: 01913395446 
 
Independent contact: 
Dr. John Steer 
Consultant Respiratory Physician 
North Tyneside General Hospital 
Rake Lane 
North Shields 
NE29 8NH 
Email: john.steer@nhct.nhs.uk 
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Appendix D 
Assessment of inspiratory and expiratory pressures provided by the 
VitaBreath device 
 
Breathing through the VitaBreath device whilst connected to a pressure transducer 
to record inspiratory and expiratory positive airway pressures. 
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Appendix E 
Questionnaire 
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